Document:

<PAGE>   1
                                                                   EXHIBIT 10.11

[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

                             RESEARCH COLLABORATION

                                       AND

                             CROSS-LICENSE AGREEMENT

                                      AMONG

                             F.HOFFMANN-LA ROCHE LTD

                                       AND

                             HOFFMANN-LA ROCHE INC.

                                       AND

                              DECODE GENETICS, INC.

                          DATED AS OF FEBRUARY 1, 1998

<PAGE>   2

                               TABLE OF CONTENTS

                                                                            Page

1.       DEFINITIONS ......................................................    2

2.       REPRESENTATIONS AND WARRANTIES ...................................   17
    2.1  Representations and Warranties of Both Parties ...................   17
    2.2  Representations of deCODE ........................................   18

3.       STEERING COMMITTEE ...............................................   18
    3.1  Members ..........................................................   18
    3.2  Responsibilities .................................................   18
    3.3  Meetings .........................................................   20
    3.4  Decisions ........................................................   21
    3.5  Minutes ..........................................................   21
    3.6  Expenses .........................................................   22

4.       DISCLOSURE OF KNOW-HOW ...........................................   22
    4.1  Disclosure of deCODE Know-How ....................................   22
    4.2  Disclosure of Roche Know-How .....................................   22
    4.3  Mechanism for Exchange of Know-How ...............................   22

5.       COLLABORATIVE RESEARCH PROGRAM ...................................   23
    5.1  Exclusivity ......................................................   23
    5.2  Diseases .........................................................   23
    5.3  Research Programs ................................................   26
    5.4  Research Funding .................................................   27
    5.5  Use of Funds .....................................................   32
    5.6  Roche Review Right ...............................................   32
    5.7  Conduct ..........................................................   33
    5.8  Records ..........................................................   34
    5.9  Plasma Samples ...................................................   34
    5.10 Cell Lines and Tissue Samples ....................................   35
    5.11 Biological Materials Transfer ....................................   35
    5.12 Research Term ....................................................   36
    5.13 Post-Research Term Developments Proposal .........................   37
    5.14 Validation of Targets ............................................   39

6.       DEVELOPMENT AND COMMERCIALIZATION ................................   39

    6.1  Commercialization Efforts by Roche for Selected Diseases .........   39
    6.2  Notice of Failure by Roche to Use Efforts for a Selected Disease .   40
    6.3  Abandonment Of a Selected Disease ................................   42
    6.4  Sale After Registration ..........................................   43

                                      -i-
<PAGE>   3
                         TABLE OF CONTENTS (continued)

    6.5 Commercialization Efforts by deCODE and its Sublicensees ..........   44
    6.6 Reports ...........................................................   45
    6.7 Ownership of Regulatory Filings ...................................   45

7.      GRANT OF LICENSES .................................................   46
    7.1 Grants ............................................................   46
    7.2 Rights of First Negotiation .......................................   47

8.      EQUITY, PAYMENTS AND ROYALTIES ....................................   47
    8.1 Equity ............................................................   47
    8.2 Payments ..........................................................   48
    8.3 Royalties .........................................................   51
    8.4 Royalty Reductions ................................................   54
    8.5 Obligation to Pay Royalties .......................................   56
    8.6 Roche Supply Obligation ...........................................   56
    8.7 Barred Royalties ..................................................   56

9.      PAYMENTS AND REPORTS ..............................................   56
    9.1 Payment ...........................................................   56
    9.2 Mode of Payment ...................................................   57
    9.3 Records Retention .................................................   58
    9.4 Audit Request .....................................................   58
    9.5 Taxes .............................................................   60
    9.6 Blocked Currency ..................................................   60
    9.7 Interest on Late Payments .........................................   60
    9.8 Mechanism for Adjustment to Royalties .............................   60

10.     OWNERSHIP; PATENTS ................................................   60
   10.1 Ownership .........................................................   60
   10.2 Patent Filing, Maintenance and Prosecution Regarding Inventions ...   61

11.     PATENT ENFORCEMENT AND INFRINGEMENT ...............................   64
   11.1 Patent Enforcement ................................................   64
   11.2 Notice of Certification ...........................................   66
   11.3 Infringement Actions by Third Parties .............................   66

12.     INDEMNIFICATION ...................................................   67
   12.1 Research Activities ...............................................   67
   12.2 Product Liability .................................................   67

                                      -ii-
<PAGE>   4
                         TABLE OF CONTENTS (continued)

   12.3  Notice ...........................................................   67

13.      PUBLICATION; NON-DISCLOSURE ......................................   68
   13.1  Publication ......................................................   68
   13.2  Non-Disclosure and Non-use; Exceptions ...........................   69
   13.3  Authorized Disclosure ............................................   70
   13.4  Injunctive Relief ................................................   70
   13.5  Third Parties ....................................................   70

14.      TERM; TERMINATION ................................................   70
   14.1  Term; Expiration .................................................   70
   14.2  Effect of Expiration .............................................   71
   14.3  Termination Without Cause ........................................   71
   14.4  Effect of Abandonment ............................................   72
   14.5  Breach by Roche Other than Under Section 6.2 or 6.4 ..............   75
   14.6  Breach of Efforts Obligation by Roche ............................   76
   14.7  No Sales After Registration ......................................   79
   14.8  Breach by deCODE .................................................   79
   14.9  Obligations ......................................................   80
   14.10 Termination of Sublicenses .......................................   80
   14.11 Surviving Obligations ............................................   81
   14.12 No Waiver ........................................................   81
   14.13 Dispute ..........................................................   81

15.      FORCE MAJEURE ....................................................   81
   15.1  Events of Force Majeure ..........................................   81

16.      MISCELLANEOUS ....................................................   82
   16.1  Relationship of Parties ..........................................   82
   16.2  Assignment .......................................................   82
   16.3  Disclaimer of Warranties .........................................   82
   16.4  Further Actions ..................................................   82
   16.5  Notice ...........................................................   82
   16.6  Use of Name ......................................................   83
   16.7  Public Announcements .............................................   83
   16.8  Waiver ...........................................................   84
   16.9  Compliance with Law ..............................................   84
   16.10 Severability .....................................................   84
   16.11 Amendment ........................................................   85

                                     -iii-

<PAGE>   5
                         TABLE OF CONTENTS (continued)

     16.12 Governing Law ..................................................   85
     16.13 Arbitration ....................................................   85
     16.14 Entire Agreement ...............................................   86
     16.15 Parties in Interest and Bankruptcy .............................   86
     16.16 Descriptive Headings ...........................................   86
     16.17 Counterparts ...................................................   86
     16.18 Interpretation .................................................   87

                                    EXHIBITS

           Exhibit A             Primary Diseases

           Exhibit B             Secondary Diseases

           Exhibit C             English Translation of Informed Consent Form

           Exhibit D             Initial Steering Committee

           Exhibit E             Form of Public Announcement

                                      -iv-
<PAGE>   6

                             RESEARCH COLLABORATION
                                       AND
                             CROSS-LICENSE AGREEMENT

         THIS RESEARCH COLLABORATION AND CROSS-LICENSE AGREEMENT (this
"Agreement") dated as of February 1, 1998 is by and among Hoffmann-La Roche
Inc., a corporation duly organized and existing under the laws of the state of
New Jersey and having offices at 340 Kingsland Street, Nutley, New Jersey 07110
("Roche-Nutley") and F.Hoffmann-La Roche Ltd, a corporation duly organized and
existing under the laws of Switzerland and having offices at Grenzacherstrasse
124, CH-4070 Basel, Switzerland ("Roche-Basel"), and deCODE genetics, Inc., a
corporation duly organized and existing under the laws of the state of Delaware,
for and on behalf of itself and Islensk erfdagreining ehf., a wholly-owned
subsidiary of deCODE genetics, Inc., duly organized and existing under the laws
of Iceland, both having offices at Lynghalsi 1, IS-110 Reykjavik, Iceland
(individually and collectively "deCODE").

                             PRELIMINARY STATEMENTS

         A. deCODE has developed an expertise in conducting research in the
field of human genetics and human genomics, an objective of which is to discover
potential targets and assays for use in drug discovery.

         B. deCODE has research facilities, experienced personnel and other
capabilities conducive to conducting such research.

         C. Roche-Nutley and Roche Basel (individually and collectively "Roche")
has expertise in drug discovery, and in developing, manufacturing and marketing
diagnostic and pharmaceutical products.

         D. Roche and deCODE wish to collaborate to discover genetic variations
that affect the pathogenesis of diseases. The purpose of this collaboration is
to develop new methods to diagnose diseases and to obtain validated targets
useful in drug discovery.

         E. The Parties recognize the importance of making the results of
research into the genetics of human diseases publicly available. They also
recognize the interest of participants in genetic studies of human disease to
have the results of such studies made publicly available. deCODE and Roche do,
however, consider it the most important interest of the participants to have the
results of genetic studies turned into methods to prevent, treat and/or diagnose
diseases.

         NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual covenants and agreements of the Parties contained in this Agreement, and
in a Series C

                                      -1-
<PAGE>   7

Preferred Stock and Warrant Purchase Agreement between Roche Finance Ltd and
deCODE ("Equity Agreement"), the Parties agree as follows:

1.       DEFINITIONS.

         As used in this Agreement, the following terms will have those meanings
set forth in this Section 1 unless the context dictates otherwise.

         1.1      "Abandoned Products" shall mean:

                  (a) all Therapeutic Products for a Selected Disease for which
Roche terminates this Agreement pursuant to Section 6.3(a)(i) prior to the first
Registration in any Major Country of a Therapeutic Product for such Selected
Disease;

                  (b) all Therapeutic Products in a given Major Country for a
Selected Disease for which Roche terminates this Agreement in the Major Country
pursuant to Section 6.3(a)(ii) after the first Registration in any Major Country
of a Therapeutic Product for such Selected Disease;

                  (c) all Diagnostic Products for a Selected Disease for which
Roche terminates this Agreement pursuant to Section 6.3(b)(i) prior to the first
Registration in any Major Country of a Diagnostic Product for such Selected
Disease;

                  (d) all Diagnostic Products in a given Major Country for a
Selected Disease for which Roche terminates this Agreement in the Major Country
pursuant to Section 6.3(b)(ii) after the first Registration in any Major Country
of a Diagnostic Product for such Selected Disease;

                  (e) a given Roche Product in a given country for which Roche
terminates this Agreement pursuant to Section 6.4(c) after Registration in such
country of such Roche Product;

                  (f) all Therapeutic Products for a Selected Disease for which
a Validated Target was obtained as of the effective date of termination of this
Agreement by Roche pursuant to Section 14.3(b)(i); and

                  (g) all Diagnostic Products for diagnosing a Disease that was
a Selected Disease as of the effective date of termination of this Agreement by
Roche pursuant to Section 14.3(b)(i).

                  Notwithstanding the foregoing, an Abandoned Product shall not
include a Roche Product which comprises a Roche Compound that, at the effective
date of such termination, is being marketed, prepared for commercial launch or
in clinical

                                      -2-
<PAGE>   8

development or for which Roche, its Affiliate or sublicensee can document a
substantial plan to clinically develop (provided that such Roche Compound is a
Clinical Candidate), for an indication in a Selected Disease if Roche, its
Affiliate or sublicensee, at the effective date of such termination, is then
marketing, preparing for commercial launch, clinically developing, or can
document a substantial plan for clinically developing a given product for the
same indication; provided, that such given product, at the Effective Date, was
not being marketed in any country by Roche, an Affiliate or sublicensee.

         1.2 "Affiliate", with respect to any Party, shall mean (a) an
organization at least fifty percent (50%) of which is owned and/or controlled
directly or indirectly, by stock ownership or otherwise, by a Party, (b) an
organization which directly or indirectly owns and/or controls a Party, by stock
ownership or otherwise; or [CONFIDENTIAL TREATMENT REQUESTED].

         1.3 "Annual Research Plan" shall mean, for each Research Program, a
reasonably detailed description of (i) the annual goals and scope of such
Research Program, and (ii) the annual activities, including without limitation
scientific work assigned to, and to be conducted by, each Party to discover
Candidate Genes and develop Validated Targets for the Disease that is the
subject of such Research Program.

         1.4 "Antisense Agent" shall mean any pharmaceutically active agent
which (a) [CONFIDENTIAL TREATMENT REQUESTED] and (e) is conceived and reduced to
practice as a result of a Research Program by a Party, its Affiliate or its
Collaborator at any time during a period commencing on the Effective Date and
ending [CONFIDENTIAL TREATMENT REQUESTED]

         1.5 "Biological Materials" shall mean [CONFIDENTIAL TREATMENT
REQUESTED]

         1.6 "Biological Pathway" shall have that meaning as determined by a
Decision, made as necessary for the purposes of this Agreement and consistent
with the criteria set forth in Section 3.2(r).

                                      -3-
<PAGE>   9

         1.7 "Candidate Gene" shall mean a Novel Gene which is the subject of a
Candidate Gene

Identification.

         1.8 "Candidate Gene Confirmation" shall mean the Decision, as reflected
in a Minutes, that a Candidate Gene is Confirmed.

         1.9 "Candidate Gene Identification" shall mean the Decision, as
reflected in a Minutes, that a Novel Gene affects the pathogenesis of a Disease
in Iceland and that the knowledge of such affect is novel.

         1.10 "Clinical Candidate" shall mean a Roche Compound or product that
Roche, its Affiliate or sublicensee has subjected to formal toxicology and
absorption, distribution, metabolism and excretion testing in non-human animals.

         1.11 "Collaborator" shall mean, (i) for Roche, a Third Party with whom
Roche has agreed jointly to research and/or develop one or more Roche Products
who agrees to be bound by the terms and conditions of this Agreement, and (ii)
for deCODE, a Third Party with whom deCODE has agreed jointly to research and/or
develop one or more deCODE Products who agrees to be bound by the terms and
conditions of this Agreement.

         1.12     "Combination Product" shall mean:
                   -

                  (a) For a Product other than a Diagnostic Product, a Product
containing both (i) at least one pharmaceutically active agent that is a
Compound and (ii) one or more pharmaceutically active agents that are not
Compounds.

                  (b) For a Diagnostic Product other than a Plasma Diagnostic
Product, a Product (i) useful in diagnosis, prognosis, prediction or disease
management of a Selected Disease and at least one other disease that is not a
Selected Disease, or (ii) containing (1) a component which causes such
Combination Product to be a Diagnostic Product, and (2) at least one other
component that is able to detect and/or quantify the presence or amount of (A) a
gene other than a Disease Gene, or (B) a product of a gene other than a Disease
Gene, or (C) a product of a gene that is not a member of the Biological Pathway
of which a product of a Disease Gene is a member.

                  (c) For a Plasma Diagnostic Product, a Product containing a
component which causes such Product to be a Plasma Diagnostic Product and at
least one other component that is able to detect and/or quantify the presence or
amount of (i) a product of a gene other than a Disease Gene, or (ii) a product
of a gene that is not a member of the Biological Pathway of which a product of a
Disease Gene is a member.

         1.13     "Compound" shall mean a deCODE Compound or a Roche Compound.

                                      -4-

<PAGE>   10

         1.14 "Confidential Information" shall mean any and all Technical
Information that is (i) disclosed by one Party ("Disclosing Party") to the other
Party ("Receiving Party") under this Agreement or the Secrecy Agreement between
the Parties dated September 5, 1997, and which at the time of disclosure is
clearly marked as "Confidential," but not Technical Information which is orally
or visually disclosed to a Receiving Party unless such oral or visual disclosure
is described or summarized in a writing, marked as "Confidential" and provided
to the Receiving Party within forty-five (45) days after such oral or visual
disclosure, or (ii) Program Know-How.

         1.15 "Confirm" or "Confirmed" shall mean a Decision that a Candidate
Gene has been confirmed as affecting the pathogenesis of a Disease. In any
event, a demonstration by deCODE [CONFIDENTIAL TREATMENT REQUESTED] shall be the
subject of a Decision that a Candidate Gene has been confirmed as affecting the
pathogenesis of the Selected Disease.

         1.16 "Decision" shall mean a decision pursuant to Section 3.4 and shall
be effective as of the date the Minutes reflecting the decision are finalized as
provided in Section 3.5.

         1.17 "deCODE Compound" shall mean an Antisense Agent or a Gene Therapy
Agent.

         1.18 "deCODE Generalized Technology" shall mean any Technical
Information relating to generalized methods for conducting genomics research and
characterizing the function of genes which deCODE or its Affiliates, prior to or
during the Research Term, owns or controls (provided that deCODE or its
Affiliates has the right to license or otherwise make available such Technical
Information to Roche).

         1.19 "deCODE Invention" shall mean an Invention conceived and reduced
to practice solely by one or more Representatives of deCODE.

         1.20 "deCODE Know-How" shall mean (i) any Technical Information,
excluding deCODE Generalized Technology, which deCODE or its Affiliates, prior
to or during the Research Term, owns or controls (provided that deCODE or its
Affiliates has the right to license or otherwise make available such Technical
Information to Roche) which relates to the Research Programs or is necessary to
make, have made, use, offer for sale, sell or import Roche Products, or (ii) any
Program Know-How which deCODE or its Affiliates owns or controls, either solely
or jointly with Roche.

         1.21 "deCODE Patents" shall mean (i) any Patents, excluding Patents
claiming deCODE Generalized Technology, which deCODE or its Affiliates, prior to
or during the Research Term, owns or controls (provided that deCODE or its
Affiliates has the right

                                      -5-
<PAGE>   11

to license or otherwise make available such Patents to Roche) which relate to
the Research Programs or are necessary to make, have made, use, offer for sale,
sell or import Products, or (ii) any Program Patent which deCODE or its
Affiliates owns or controls, either solely or jointly with Roche.

         1.22 "deCODE Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired deCODE Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a deCODE Patent
that has not been on file in a given country with the applicable patent office
for more than five (5) years from the earliest date from which the patent
application was filed or claims priority in the given country.

         1.23 "deCODE Product" shall mean any (i) pharmaceutical product which
comprises, in whole or as a component thereof, as its pharmaceutically active
agent, a deCODE Compound, or (ii) Abandoned Product, or (iii) Reverted Product.

         1.24 "Development Program" shall mean the drug discovery and
development activities performed by a Party in accordance with Section 6 to
discover and/or develop Products.

         1.25 "Diagnostic Product" shall mean any product in the form of a
device, compound, kit or service useful for the diagnosis, prognosis, prediction
or disease management of a Selected Disease which device, compound, kit or
service contains a component which is (a) able to detect and/or quantify the
presence or amount of [CONFIDENTIAL TREATMENT REQUESTED] such component being
conceived and reduced to practice as a result of a Research Program by a Party,
its Affiliate or its Collaborator, at any time during a period commencing on the
Effective Date and ending [CONFIDENTIAL TREATMENT REQUESTED]

                  Diagnostic Product shall also mean any product in the form of
a device, compound, kit or service [CONFIDENTIAL TREATMENT REQUESTED], such
component being conceived and reduced to practice as a result of a Research
Program by a Party, its Affiliates or its Collaborator at any time during a
period commencing on the Effective Date and ending [CONFIDENTIAL TREATMENT
REQUESTED].

                                      -6-
<PAGE>   12

         1.26 "Direct Gene Expression Agent Type 1" shall mean any
pharmaceutically active agent which is (a) [CONFIDENTIAL TREATMENT REQUESTED]
and (b) conceived and reduced to practice as a result of a Research Program by a
Party, its Affiliate or its Collaborator at any time during a period commencing
on the Effective Date and ending [CONFIDENTIAL TREATMENT REQUESTED].

         1.27 "Direct Gene Expression Agent Type 2" shall mean any
pharmaceutically active agent which agent is (a) [CONFIDENTIAL TREATMENT
REQUESTED] and (b) conceived and reduced to practice as a result of a Research
Program by a Party, its Affiliate or its Collaborator at any time during a
period commencing on the Effective Date and ending [CONFIDENTIAL TREATMENT
REQUESTED]

         1.28 "Direct Gene Expression Product Type 1" shall mean any
pharmaceutical product which comprises, in whole or as a component thereof, as
its pharmaceutically active agent, a Direct Gene Expression Agent Type 1.

         1.29 "Direct Gene Expression Product Type 2" shall mean any
pharmaceutical product which comprises, in whole or as a component thereof, as
its pharmaceutically active agent, a Direct Gene Expression Agent Type 2.

         1.30 "Disease Gene" shall mean a Candidate Gene that is the subject of
a Candidate Gene Confirmation.

         1.31 "Diseases" shall mean the Primary Diseases, Secondary Diseases,
and Selected Diseases, collectively.

         1.32 "Dollar" or "$" shall mean USA Dollars.

         1.33 "Drug Type 1" shall mean any pharmaceutically active agent which
(a) [CONFIDENTIAL TREATMENT REQUESTED] and (b) is conceived and reduced to
practice as a result of a Research Program by a Party, its Affiliate or its
Collaborator at any time during a period commencing on the Effective Date and
ending [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that a Drug Type 1
is not an Antisense Agent, a Gene Therapy Agent, a Direct Gene Expression Agent
Type 1 or a Direct Expression Agent Type 2.

         1.34 "Drug Type 2" shall mean any pharmaceutically active agent which
(a) [CONFIDENTIAL TREATMENT REQUESTED]

                                      -7-
<PAGE>   13

[CONFIDENTIAL TREATMENT REQUESTED], and (b) is conceived and reduced to practice
as a result of a Research Program by a Party, its Affiliate or its Collaborator
at any time during a period commencing on the Effective Date and ending
[CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that a Drug Type 2 is not
an Antisense Agent, a Gene Therapy Agent, a Direct Gene Expression Agent Type 1,
a Direct Expression Agent Type 2 or a Drug Type 1.

         1.35 "Drug Product Type 1" shall mean any pharmaceutical product which
comprises, in whole or as a component thereof, as its pharmaceutically active
agent, a Drug Type 1.

         1.36 "Drug Product Type 2" shall mean any pharmaceutical product which
comprises, in whole or as a component thereof, as its pharmaceutically active
agent, a Drug Type 2.

         1.37 "Effective Date" shall mean February 1, 1998; provided that the
Parties have executed the Equity Agreement on or before February 1, 1998.
Execution of the Equity Agreement shall be a condition precedent to this
Agreement.

         1.38 "Europe" shall mean the United Kingdom, France, Germany, Italy,
and Spain.

         1.39 "FDA" shall mean the USA Food and Drug Administration, or the
successor thereto, or any corresponding foreign registration or regulatory
authority.

         1.40 "First Commercial Sale" shall mean, with respect to a Product in a
country of the Territory, the first commercial sale to a Third Party (other than
a sublicensee) by a Party, its Affiliates or sublicensees, as the case may be,
of the Product in the country, after obtaining Registration for the Product in
the given country or, if for a country where no Registration for the Product is
required, the date of first commercial sale of such Product by the Party, its
Affiliates or sublicensees to a Third Party (other than a sublicensee) in the
country. "First Commercial Sale" shall not mean the sale of a Product for use in
a clinical trial or for compassionate use.

         1.41 "FTE" shall mean a full time equivalent scientific person year of
scientific work on or in direct connection with a Research Program, carried out
by a Representative of deCODE. Scientific work on or in direct connection with
the Research Programs includes, but is not limited to, experimental laboratory
work, recording and writing of results, reviewing literature and references,
holding scientific discussions, managing and leading scientific staff and
carrying out project management duties.

                                      -8-
<PAGE>   14

         1.42 "FTE Rate" shall mean [CONFIDENTIAL TREATMENT REQUESTED] per FTE.
The FTE Rate shall include all personnel, equipment, reagents and all other
expenses including support staff and overhead for or associated with an FTE.

         1.43 "Gene Therapy Agent" shall mean any pharmaceutically active agent
which (a) consists of nucleic acid or a functional analog, derivative or homolog
thereof [CONFIDENTIAL TREATMENT REQUESTED], and (b) upon delivery by any means,
compensates, either completely or partially, for the genetic defect that
underlies the Selected Disease the pathogenesis of which is affected by the
Disease Gene, and (c) is conceived and reduced to practice as a result a
Research Program by a Party, its Affiliate or its Collaborator at any time
during a period commencing on the Effective Date and ending [CONFIDENTIAL
TREATMENT REQUESTED].

         1.44 "IND" shall mean an Investigational New Drug application, as
defined in the Federal Food, Drug and Cosmetic Act and the regulations
promulgated thereunder, conducted or sponsored by Roche, its Affiliates or
sublicensees, for initiating in the USA human clinical testing for prevention or
treatment of a Selected Disease using a Roche Product, or any corresponding
foreign application, registration or certification in [CONFIDENTIAL TREATMENT
REQUESTED].

         1.45 "IND Filing" shall mean the filing of an IND based upon which
human clinical testing commences in [CONFIDENTIAL TREATMENT REQUESTED].

         1.46 "Invention" shall mean Program Know-How which is conceived or
reduced to practice by one or more Representatives of a Party or jointly by
Representatives of the Parties as a result of a Research Program.

         1.47 "Joint Invention" shall mean an Invention conceived or reduced to
practice jointly by Representatives of the Parties.

         1.48 "Major Country" shall mean [CONFIDENTIAL TREATMENT REQUESTED].

         1.49 "Major Research Program" shall mean a research program directed to
discovering genetic variations that affect the pathogenesis of a Primary Disease
and obtaining validated targets useful in drug discovery for the Primary
Disease.

         1.50 "Minor Research Program" shall mean a research program directed to
discovering genetic variations that affect the pathogenesis of a Secondary
Disease and obtaining validated targets useful in drug discovery for the
Secondary Disease.

                                      -9-
<PAGE>   15

         1.51 "Minutes" shall mean the final minutes of a Steering Committee
meeting, as finalized under Section 3.5.

         1.52 "NDA" shall mean a New Drug Application or a Product License
Application, as the case may be, for a Roche Product, for prevention or
treatment of a Selected Disease, filed with the FDA in the USA or any
corresponding foreign application, registration or certification in
[CONFIDENTIAL TREATMENT REQUESTED].

         1.53 "NDA Filing" shall mean, for a given NDA for a given Roche
Product, a communication from the FDA that the NDA for the given product is
accepted for review by the FDA in [CONFIDENTIAL TREATMENT REQUESTED], as the
case may be.

         1.54 "Net Sales" and the related term "Adjusted Gross Sales" shall have
the following meanings: -

         (a) As to Roche:

         (i) "Adjusted Gross Sales" shall mean, with respect to any Roche
Product, the amount of gross sales invoiced by Roche, its Affiliates or
sublicensees to Third Parties for such Roche Product, commencing with the First
Commercial Sale of such Roche Product, less deductions for the following items
which are included in the invoiced amounts and do not exceed reasonable and
customary amounts in the country in which such sale occurred: (1) returns
(including withdrawals and recalls), (2) rebates (price reductions including
Medicaid and similar types of rebates, e.g., chargebacks), (3) volume (quantity)
discounts granted at the time of invoicing, (4) sales taxes and other taxes
directly linked and included in the gross sales amount, as computed in the
Roche's Sales Statistics for the countries concerned. Adjusted Gross Sales shall
also include the amount or fair market value of all other consideration received
by Roche, its Affiliates or sublicensees with respect to Roche Products, whether
such consideration is in cash, payment in kind, exchange or another form.

         (ii) "Net Sales" shall mean the amount calculated by subtracting from
Adjusted Gross Sales a lump sum deduction of [CONFIDENTIAL TREATMENT REQUESTED]
of Adjusted Gross Sales for those sales related deductions which are not
accounted for on a product-by-product basis (e.g. outward freights, postage,
transportation insurance, packing materials for dispatch of goods, custom
duties, discounts granted later than at the time of invoicing, cash discounts
and other direct expenses).

         (b) As to deCODE:

         (i) "Adjusted Gross Sales" shall mean, with respect to any deCODE
Product, the amount of gross sales invoiced by deCODE or its Affiliates to

                                      -10-
<PAGE>   16

Third Parties for such deCODE Product, commencing with the First Commercial Sale
of such deCODE Product, less deductions for the following items which are
included in the invoiced amounts and do not exceed reasonable and customary
amounts in the country in which such sale occurred: (1) returns (including
withdrawals and recalls), (2) rebates (price reductions including Medicaid and
similar types of rebates, e.g., chargebacks), (3) volume (quantity) discounts
granted at the time of invoicing, and (4) sales taxes and other taxes directly
linked and included in the gross sales amount. Net Sales shall also include the
amount or fair market value of all other consideration received by deCODE or its
Affiliates with respect to deCODE Products, whether such consideration is in
cash, payment in kind, exchange or another form.

         (ii) "Net Sales" shall mean the amount calculated by subtracting from
Adjusted Gross Sales a lump sum deduction of [CONFIDENTIAL TREATMENT REQUESTED]
for those sales related deductions which are not accounted for on a
product-by-product basis (e.g. outward freights, postage, transportation
insurance, packing materials for dispatch of goods, custom duties, discounts
granted later than at the time of invoicing, cash discounts and other direct
expenses).

         (c) In the event the price of a Diagnostic Product (including a
Diagnostic Product that becomes an Abandoned Product or a Reverted Product)
includes an amount to cover instrument system costs or amortisation recovery
under an Instrument System Rental Plan or similar plan, the Net Sales for such
Diagnostic Product shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED]of Net
Sales.

         (d) For a Combination Product that is not a Diagnostic Product, the
Parties shall meet approximately one (1) year prior to commercial launch of such
Combination Product to negotiate in good faith and agree to an appropriate
adjustment to Net Sales to reflect the relative significance of each Compound
contained in the Combination Product. If, after good faith negotiations (not to
exceed ninety (90) days, which can be extended by mutual agreement), the Parties
can not agree to an appropriate adjustment, Net Sales shall be equal to Net
Sales of the Combination Product multiplied by a fraction, the numerator of
which is the reasonable fair market value of the Compound(s) and the denominator
of which is the reasonable fair market value of all pharmaceutically active
agents contained in the Combination Product.

         (e) For a Combination Product that is a Diagnostic Product, the Parties
shall meet approximately three (3) months prior to commercial launch of such
Combination Product to negotiate in good faith and agree to an appropriate
adjustment to Net Sales to reflect the relative significance of each component
of the Combination Product that causes such Combination Product to be a
Diagnostic Product. If, after good faith negotiations (not to exceed thirty (30)
days, which can be extended by mutual agreement), the Parties can not agree to
an appropriate adjustment, Net Sales shall be equal to Net Sales of the
Combination Product multiplied by a fraction, the numerator of which is the
reasonable fair market value of the component(s) of said Product which

                                      -11-
<PAGE>   17

cause said Product to be a Diagnostic Product, and the denominator of which is
the reasonable fair market value of the Combination Product.

         (f) With respect to Products sold in combination with other products by
Roche, its Affiliates or sublicensees with respect to Roche Products, and by
deCODE or its Affiliates, with respect to deCODE Products, in a capitation or
bundled transaction (each, a "Bundled Transaction"), the Parties agree to
negotiate in good faith and agree on a reasonable mechanism for fairly
calculating Net Sales resulting from such Bundled Transaction to reflect the
relative value of the Product to the other products included in the Bundles
Transaction.

         (g) For a Diagnostic Product that is a kit for nucleic acid
amplification, the Parties shall meet approximately three (3) months prior to
commercial launch of such Diagnostic Product to negotiate in good faith and
agree to an appropriate adjustment to Net Sales to reflect the relative
significance of each component (e.g., sample preparation, amplification and
detection) of the Diagnostic Product.

         1.55 "Novel Gene" shall mean a gene [CONFIDENTIAL TREATMENT REQUESTED]

         1.56 "Participants" shall mean those persons who enroll to participate
in harvesting programs or other studies being conducted as part of a Research
Program.

         1.57 "Party" shall mean deCODE or Roche and, when used in the plural,
shall mean deCODE and Roche.

         1.58 "Patents" shall mean all patents and patent applications
throughout the Territory, and any extensions, renewals, continuations,
continuations-in-part, divisions, patents-of-addition, reissues, reexaminations,
registrations, patents of confirmation, patents of importation, and
Supplementary Protection Certificates and foreign counterparts thereof.

         1.59 "Plasma Diagnostic Product" shall mean a Diagnostic Product
derived from Biological Materials.

         1.60 "Primary Diseases" shall mean the Diseases listed in Exhibit A, as
it may be modified from time to time.

         1.61 "Product" shall mean Roche Products and deCODE Products,
collectively.

         1.62 "Program Know-How" shall mean any and all Technical Information,
including any Invention, that is developed or conceived and reduced to practice
solely by a Party, or jointly by both Parties, as a result of a Research
Program; provided,

                                      -12-
<PAGE>   18

however, that any Technical Information that is developed or conceived and
reduced to practice as a result of a Research Program solely by one or more
Representatives of deCODE relating to generalized methods for conducting
genomics research and characterizing the function of genes shall be considered
deCODE Generalized Technology but not Program Know-How.

         1.63 "Program Patents" shall mean any and all Patents claiming an
Invention. -

         1.64 "Program Patent Valid Claim" shall mean: (i) a claim of any issued
and unexpired Program Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a Program Patent
that has not been on file in a given country with the applicable patent office
for more than [CONFIDENTIAL TREATMENT REQUESTED] from the earliest date from
which the patent application was filed or claims priority in the given country.

         1.65 "Registration" shall mean, for a given country and a given Product
for diagnosing, preventing or treating a Selected Disease, an official approval,
resulting from an application for such official approval in the given country
filed by Roche, its Affiliate or sublicensee, which is required by the
government or health authority of the given country for the Product to be
offered for sale in such country, including authorizations as may be required
for the production, importation, pricing, reimbursement and sale of such Product
in such country, and for subsequent regulatory filings for line extensions
and/or additional indications of such Product.

         1.66 "Representative of a Party" shall mean an employee of a Party or
any other person who is contractually required to assign or grant exclusive
rights in and to Program Know-How to a Party.

         1.67 "Research Programs" shall mean the Major Research Programs and
Minor Research Programs, collectively. A Research Program does not include steps
involved in drug discovery and development of Products, including without
limitation Development Programs.

         1.68 "Research Term" shall mean, subject to Sections 5.12 and 5.13, a
five (5) year period commencing on the Effective Date and ending on February 1,
2003, unless earlier terminated as otherwise provided in this Agreement.

         1.69 "Reverted Products" shall mean:

         (a) all Therapeutic Products for a Selected Disease for which deCODE
terminates this Agreement pursuant to Section 14.6(a)(i) prior to the first
Registration in any Major Country of a Therapeutic Product for such Selected
Disease;

                                      -13-

<PAGE>   19

         (b) all Therapeutic Products in a given Major Country for a Selected
Disease for which deCODE terminates this Agreement in the Major Country pursuant
to Section 14.6(a)(ii) after the first Registration in any Major Country of a
Therapeutic Product for such Selected Disease;

         (c) all Diagnostic Products for a Selected Disease for which deCODE
terminates this Agreement pursuant to Section 14.6(b)(i) prior to the first
Registration in any Major Country of a Diagnostic Product for such Selected
Disease;

         (d) all Diagnostic Products in a given Major Country for a Selected
Disease for which deCODE terminates this Agreement in the Major Country pursuant
to Section 14.6(b)(ii) after the first Registration in any Major Country of a
Diagnostic Product for such Selected Disease;

         (e) a given Roche Product in a given country for which deCODE
terminates this Agreement pursuant to Section 14.7 after Registration in such
country of such Roche Product;

         (f) all Therapeutic Products for a Selected Disease for which a
Validated Target was obtained as of the effective date of termination of this
Agreement by deCODE pursuant to Section 14.5(a)(iii)(2); and

         (g) all Diagnostic Products for diagnosing a Disease that was a
Selected Disease as of the effective date of termination of this Agreement by
deCODE pursuant to Section 14.5(a)(iii)(2).

         Notwithstanding the foregoing, a Reverted Product shall not include a
Roche Product which comprises a Roche Compound that, at the effective date of
such termination, is being marketed, prepared for commercial launch or in
clinical development or for which Roche, its Affiliate or sublicensee can
document a substantial plan to clinically develop (provided that such Roche
Compound is a Clinical Candidate), for an indication in a Selected Disease if
Roche, its Affiliate or sublicensee, at the effective date of such termination,
is then marketing, preparing for commercial launch, clinically developing, or
can document a substantial plan for clinically developing a given product for
the same indication; provided, that such given product, at the Effective Date,
was not being marketed in any country by Roche, an Affiliate or sublicensee.

         1.70 "Roche Compound" shall mean a Direct Gene Expression Agent Type 1,
a Direct Gene Expression Agent Type 2, a Drug Type 1, or a Drug Type 2.

         1.71 "Roche Invention" shall mean an Invention conceived and reduced to
practice solely by one or more Representatives of Roche.

                                      -14-
<PAGE>   20

1.72 "Roche Know-How" shall mean (i) any Technical Information which Roche or
its Affiliates, prior to or during the Research Term, owns or controls (provided
that Roche or its Affiliates has the right to license or otherwise make
available such Technical Information to deCODE) which relates to the Research
Programs or is necessary to make, have made, use, offer for sale, sell or import
deCODE Products (excluding [CONFIDENTIAL TREATMENT REQUESTED]), or (ii) any
Program Know-How which Roche or its Affiliates owns or controls either solely or
jointly with deCODE.

1.73 "Roche Patents" shall mean (i) any Patents which Roche or its Affiliates,
prior to or during the Research Term, owns or controls (provided that Roche or
its Affiliates has the right to license or otherwise make available such Patents
to deCODE) which relate to the Research Programs or are necessary to make, have
made, use, offer for sale, sell or import Products (excluding [CONFIDENTIAL
TREATMENT REQUESTED] or (ii) any Program Patent which Roche or its Affiliates
owns or controls, either solely or jointly with deCODE.

1.74 "Roche Patent Valid Claim" shall mean: (i) a claim of any issued and
unexpired Roche Patent which has not been disclaimed, revoked or held
unpatentable, invalid or unenforceable by final decision of a court or other
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed within the time allowed for appeal, and which claim is otherwise
enforceable, or (ii) a claim of a patent application that is a Roche Patent that
has not been on file in a given country with the applicable patent office for
more than [CONFIDENTIAL TREATMENT REQUESTED] from the earliest date from which
the patent application was filed or claims priority in the given country

1.75 "Roche Product" shall mean Diagnostic Products and Therapeutic Products,
collectively.

1.76 "Royalty Sublicensing Income" shall mean that portion of Sublicensing
Income directly attributable to royalties received by deCODE from its Third
Party licensees with respect to such Third Party licensees' sales of a given
deCODE Product in a given country.

1.77 "Royalty Term" shall mean:

         (a) As to Roche, for a given Roche Product in a given country in the
Territory, a period of time commencing on the First Commercial Sale of the given
Roche Product in the given country and ending on the later of: (i) [CONFIDENTIAL
TREATMENT REQUESTED] from the date of the First Commercial Sale of such Roche
Product in such country, or (ii) the last date on which the making, having made,
using, offering for sale, selling or importing of the

                                      -15-
<PAGE>   21

Roche Product in the given country by Roche, its Affiliates or sublicensees is
claimed by a deCODE Patent Valid Claim or a Program Patent Valid Claim.

         (b) As to deCODE, for a given deCODE Product in a given country in the
Territory, a period of time commencing (i) with respect to Net Sales, on the
First Commercial Sale of the given deCODE Product in the given country, and (ii)
with respect to Sublicensing Income, on the Effective Date, and ending on the
later of: (1) [CONFIDENTIAL TREATMENT REQUESTED] from the date of the First
Commercial Sale of such deCODE Product in such country, or (2) the last date on
which the making, having made, using, offering for sale, selling or importing of
the deCODE Product in the given country by deCODE, its Affiliates or
sublicensees is claimed by a Roche Patent Valid Claim or a Program Patent Valid
Claim.

         (c) If, in a country in the Territory, the above definition of Royalty
Term is unenforceable, then for such country, Royalty Term shall mean the
longest term as may be enforceable under the applicable laws of such country,
provided that in no event shall the Royalty Term in such country exceed the
maximum term above.

1.78 "Secondary Diseases" shall mean the Diseases listed in Exhibit B, as it may
be modified from time to time.

1.79 "Selected Disease" shall mean a Primary Disease or a Secondary Disease for
which a Candidate Gene is the subject of a Candidate Gene Confirmation.

1.80 "Steering Committee" shall mean the body organized and acting pursuant to
Section 3.

1.81 "Sublicensing Income" shall mean all monetary consideration, including, for
example, up-front payments, milestones, and royalties, received by deCODE from
its Third Party licensees with respect to a given deCODE Product, but excluding
any amounts received from Third Party licensees to reimburse deCODE for research
and development expenses of deCODE which deCODE can reasonably document.

1.82 "Technical Information" shall mean information, data or know-how (whether
patentable or not patentable), including without limitation, ideas, concepts,
formulas, manufacture, methods, procedures, designs, compositions of matter,
plans, applications, specifications, drawings, techniques, materials (including
without limitation biological materials such as Biological Materials, RNA, DNA,
DNA fragments, organisms, proteins, polypeptides, plasmids, vectors and the
like) compounds, products, processes, research, technical data, apparatus,
equipment, samples, inventions, discoveries, and the like, as well as
improvements related thereto.

1.83 "Territory" shall mean the entire world

                                      -16-
<PAGE>   22

1.84 "Therapeutic Products" shall mean any pharmaceutical product which
comprises, in whole or as a component thereof, as its pharmaceutically active
agent, a Roche Compound.

1.85 "Third Party" shall mean any party other than a Party, or an Affiliate of a
Party.

1.86 "USA" shall mean the United States of America. -

1.87 "Validated Target" shall mean a biological molecule which is the subject of
a Decision that such biological molecule is [CONFIDENTIAL TREATMENT REQUESTED].

2.       REPRESENTATIONS AND WARRANTIES.

2.1 Representations and Warranties of Both Parties. Each Party represents and
warrants to the other Party that, as of the Effective Date:

         (a) such Party is duly organized and validly existing under the laws of
the state or country of its incorporation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof;
and

         (b) such Party has taken all corporate action necessary to authorize
the execution and delivery of this Agreement and the fulfilling of its
obligations under this Agreement; and

         (c) such Party is not aware of any impediment which would inhibit its
ability to fulfill the terms and conditions imposed on it by this Agreement; and

         (d) such Party has disclosed all material information in its possession
or control requested by the other Party relating to the subject matter of this
Agreement and other material information in its possession or control, which, in
its reasonable opinion, would be material to the other Party entering into this
Agreement, and to its knowledge such information does not contain any untrue
statement of material fact or omit to state a material fact; and

         (e) such Party, without having conducted a formal investigation, is not
aware of any patent rights or other proprietary rights of any Third Party which
might be infringed by either Party carrying out its obligations under this
Agreement; and

         (f) such Party has the right to grant the other Party the rights and
licenses hereby granted under this Agreement.

                                      -17-
<PAGE>   23

2.2 Representations of deCODE. deCODE represents and warrants to Roche that:

         (a) As of the Effective Date, there are no patents or patent
applications that deCODE owns or controls in the Territory which could preclude
Roche from carrying out its obligations under this Agreement and which deCODE
does not have the right to license or otherwise make available to Roche; and

         (b) all Participants have signed, or will have signed before becoming a
Participant, an informed consent form in accordance with the English language
translation of an informed consent form in Exhibit C.

3.       STEERING COMMITTEE.

3.1 Members. The Parties shall establish a Steering Committee, which shall
consist of six (6) members, three (3) members from each Party. Two (2) members
from each Party must be both (i) a member of senior management and (ii) a
scientist. The initial members of the Steering Committee are set forth on
Exhibit D. Members of the Steering Committee may be represented at any meeting
by a designee appointed by such member for such meeting. The initial chairperson
shall be selected by deCODE and is designated on Exhibit D. The initial
chairperson shall serve as chairperson for the first contract year. Thereafter,
the chairperson of the Steering Committee for a given contract year shall be
selected within thirty (30) days of the beginning of such given contract year on
an alternating basis between the Parties, and shall serve as chairperson during
such given contract year. The initial secretary shall be selected by Roche and
is designated on Exhibit D. The initial secretary shall serve as secretary for
the first contract year. Thereafter, the secretary of the Steering Committee for
a given contract year shall be selected within thirty (30) days of the beginning
of such given contract year by the Party not designating the chairperson for the
same given contract year, and shall serve as secretary during such given
contract year. Each Party shall be free to change its members, on prior written
notice to the other Party. Each Party may, in its discretion, invite
non-Committee Representatives of such Party, provided that each Party approves
the other Party's invitee(s) in advance.

3.2 Responsibilities. The Steering Committee shall:

         (a) oversee all Research Programs;

         (b) evaluate and determine scientific criteria to be implemented under
all Research Programs;

                                      -18-
<PAGE>   24

         (c) establish a mechanism by which the Parties will exchange deCODE
Know-How and Roche Know-How, including Program Know-How, and oversee the
exchange of such Know-How;

         (d) commencing on the Effective Date, discuss and prepare an Annual
Research Plan for each Research Program for the first year of the Research Term
and, prior to thirty (30) days after the Effective Date, finalize an Annual
Research Plan for each Research Program for the first year of the Research Term
and have each such Annual Research Plan signed and dated by a representative of
each Party on the Steering Committee;

         (e) not less than three (3) months prior to each anniversary of the
Effective Date during the Research Term, discuss and prepare an Annual Research
Plan for each ongoing Research Program, and, prior to each anniversary of the
Effective Date during the Research Term, finalize an Annual Research Plan for
each Research Program for the next year of the Research Term and have each such
Annual Research Plan signed and dated by a representative of each Party on the
Steering Committee;

         (f) decide upon approval of proposed amendments or modifications to any
Annual Research Plan;

         (g) evaluate data from all Research Programs;

         (h) coordinate the activities of the Parties, and review and evaluate
progress, under the Research Programs, provided that the Steering Committee
shall not have authority to make any determination that either Party is in
breach of its obligations under the Research Programs;

         (i) discuss, prepare and finalize an Annual Research Plan for a
Research Program for any new Primary Disease or new Secondary Disease;

         (j) decide about: (1) whether any Novel Gene is a Candidate Gene, and
(2) whether any Candidate Gene is Confirmed;

         (k) monitor qualifications for Representatives of deCODE who will
perform deCODE's research obligations under the Research Programs contemplated
under this Agreement;

         (l) decide if there is a scientific need for plasma samples
[CONFIDENTIAL TREATMENT REQUESTED] each Research Program;

                                      -19-
<PAGE>   25

         (m) from time to time, if necessary, adjust the fee for plasma samples
under Section 5.9 to reflect the actual costs and expenses incurred by deCODE in
connection with providing such plasma samples to Roche;

         (n) decide if there may be a scientific need for cell lines and/or
tissue samples for each Disease and, if so, determine from time to time the
number of cell lines and/or tissue samples reasonably required for each Disease,
which shall not be more than from [CONFIDENTIAL TREATMENT REQUESTED]
Participants with a given Disease and [CONFIDENTIAL TREATMENT REQUESTED]
Participants acting as control subjects with respect to the given Disease;

         (o) if cell lines and/or tissue samples are determined to be required
from a Research Program by the Steering Committee, [CONFIDENTIAL TREATMENT
REQUESTED];

         (p) decide when a Disease has been mapped to a chromosomal location and
whether a mapping reveals that what was considered one (1) Disease by the
Parties as of the Effective Date is, instead, more than one (1) disease;

         (q) decide whether any Validated Targets have been obtained;

         (r) as and when necessary for purposes of this Agreement, decide
whether: [CONFIDENTIAL TREATMENT REQUESTED]; and

         (s) perform any other activities related to the Research Programs as
the Parties may request from time to time, other than deciding that a Party is
in breach of an obligation under this Agreement.

         3.3 Meetings. During the Research Term and until one (1) year after the
end of the Research Term the Steering Committee shall meet at least twice every
contract year, and more frequently as the Parties deem appropriate, on such
dates, places and at such times as the Parties shall agree. Thereafter, during
the term of this Agreement, the Steering Committee shall meet on an as needed
basis on such dates, places and at such times as the Parties shall agree. The
meetings shall alternate between the offices of the Parties unless the Parties
otherwise agree. The chairperson shall, if practicable, send notice of all
meetings to all members of the Steering Committee no less than twenty (20) days
before the date of the meeting. The Steering Committee may also convene

                                      -20-
<PAGE>   26

or be polled or consulted from time to time by means of telecommunications,
video conferences or correspondence, as deemed necessary or appropriate;
provided, however, that the Steering Committee meet in person at least twice
every contract year during the Research Term and until one (1) year after the
end of the Research Term.

         3.4 Decisions.

         (a) The Steering Committee may decide on any subject matter that is
subject to the Steering Committee's decision-making authority. All decisions of
the Steering Committee shall be made by consensus of the members (or their
designees) present at any meeting. Such consensus shall require that at least
two (2) members of each Party are present at such meeting.

         (b) In the event that consensus cannot be reached by the Steering
Committee after good faith discussions with respect to a matter that is subject
to its decision-making authority, then (except as set forth in Section
8.2(a)(i)), the matter shall be referred for further review and resolution to
the President of Global Pharma Research at Roche, or such other similar position
designated by Roche from time to time, and the Chief Executive Officer at
deCODE, or such other similar position designated by deCODE from time to time
(such officers, collectively, the "Executive Officers"). The Executive Officers
of each Party shall use reasonable efforts to resolve the matter within thirty
(30) days after the matter is referred to them. If the Executive Officers cannot
resolve the matter within thirty (30) days, then: (i) if the matter pertains to
relations with Participants, or research sites, consultants, investigators or
vendors in Iceland, or any governmental authority in Iceland, the matter shall
be decided by the Executive Officer of deCODE in good faith, giving appropriate
consideration to the reasonable business and scientific concerns of Roche; and
(ii) if the matter pertains to any other subject, the matter shall be decided by
the Executive Officer of Roche in good faith, giving appropriate consideration
to the reasonable business and scientific concerns of deCODE.

         (c) No decision, either by the Steering Committee or an Executive
Officer, on any matter that is subject to the Steering Committee's
decision-making authority, may have the effect of materially increasing the
economic burdens or the research responsibilities of a Party without the prior
written approval of such Party.

         3.5 Minutes. Promptly after each Steering Committee meeting, the
secretary of the Steering Committee shall prepare and distribute to the
chairperson draft minutes of the meeting, which shall provide a description in
reasonable detail of the discussions had at the meeting and a list of any
actions, decisions or determinations approved by the Steering Committee and a
list of any issues to be resolved by the Executive Officers. The chairperson may
then comment on the draft minutes. The secretary shall discuss with the
chairperson any comments of the chairperson and circulate a final draft of the
minutes to all members of the Steering Committee within fifteen (15) days of the

                                      -21-
<PAGE>   27

meeting. The members of the Steering Committee shall then have fifteen (15) days
after circulation of the final draft minutes to provide their comments thereon
to the secretary of the Steering Committee. If a member of the Steering
Committee does not comment to the secretary on the draft minutes within the
fifteen (15) day period after circulation, said member is deemed to have agreed
to the final draft minutes. Upon the expiration of the fifteen (15) day period
after circulation, the secretary and the chairperson of the Steering Committee
shall have an additional fifteen (15) days to discuss the other members'
comments and finalize the minutes. The secretary and chairperson shall each sign
and date the final minutes. The signature of the chairperson and the secretary
on the final minutes shall indicate each Party's assent to the minutes. With the
sole exception of specific items of the meeting minutes to which the chairperson
and the secretary cannot agree and which are escalated as provided below, final
minutes of all Steering Committee meetings shall be finalized no later than
forty five (45) days after the meeting to which the minutes pertain. If at any
time during the preparation and finalization of the Steering Committee meeting
minutes the secretary and the chairperson of the committee do not agree on any
issue with respect to the minutes, this issue shall be resolved by the
escalation process provided in Section 3.4(b). The decision resulting from the
escalation process shall be recorded by the secretary of the Steering Committee
in an amended finalized minutes for said meeting. All other issues in the
minutes which are not subject to such escalation shall be finalized within the
above-mention forty-five (45) days.

         3.6 Expenses. Each Party shall be responsible for all travel and
related costs and expenses for its members and non-Committee invitees to attend
meetings of, and otherwise participate on, the Steering Committee.

4.       DISCLOSURE OF KNOW-HOW

         4.1 Disclosure of deCODE Know-How. Promptly following the Effective
Date, deCODE shall disclose to Roche all existing deCODE Know-How and
thereafter. deCODE shall disclose to Roche on an ongoing basis during the
Research Term all additional deCODE Know-How .

         4.2 Disclosure of Roche Know-How. Promptly following the Effective
Date, Roche shall disclose to deCODE such Roche Know-How and thereafter Roche
shall disclose to deCODE on an ongoing basis during the Research Term all
additional Roche Know-How.

         4.3 Mechanism for Exchange of Know-How. The Steering Committee shall
establish a mechanism by which the Parties will exchange deCODE Know-How and
Roche Know-How, including Program Know-How, in accordance with this Agreement,
and oversee the exchange of such Know-How.

                                      -22-
<PAGE>   28

5.       COLLABORATIVE RESEARCH PROGRAM.

         5.1 Exclusivity. Nothing in this Agreement shall prohibit deCODE or its
Affiliates from using Program Know-How relating to Disease Genes, Validated
Targets or members of a Biological Pathway of which a Disease Gene is a member
for: (i) carrying out research relating to generalized methods for conducting
genomic research and relating to generalized methods for characterizing the
function of genes, or (ii) making, having made, using, offering for sale,
selling or importing deCODE Products. However, other than as provided in the
preceding sentence, for a Selected Disease, during the period commencing on the
Effective Date and ending [CONFIDENTIAL TREATMENT REQUESTED], neither deCODE nor
its Affiliates shall use, for the benefit of a Third Party, without the prior
written consent of Roche, Program Know-How relating to [CONFIDENTIAL TREATMENT
REQUESTED]. In not event shall Roche unreasonably withhold such consent.

         5.2 Diseases.

             (a) Primary Diseases. The Primary Diseases are set forth in
Exhibit A, as it may be amended from time to time. Each Primary Disease shall be
the subject of an independent and separate Major Research Program. For a period
commencing on the Effective Date and ending [CONFIDENTIAL TREATMENT REQUESTED],
Roche shall, at all times, fund [CONFIDENTIAL TREATMENT REQUESTED] to be
allocated among the Primary Diseases as set forth in this Agreement or as the
Parties may otherwise agree.

             (b) Secondary Diseases. The Secondary Diseases are set forth in
Exhibit B, as it may be amended from time to time. Each Secondary Disease shall
be the subject of an independent and separate Minor Research Program. For a
period commencing on the Effective Date and ending [CONFIDENTIAL TREATMENT
REQUESTED], Roche shall, at all times, fund [CONFIDENTIAL TREATMENT REQUESTED]
to be allocated among the Secondary Diseases as set forth in this Agreement or
as the Parties may otherwise agree.

             (c) Making a Disease a Selected Disease. -

                 (i) For a given Primary or Secondary Disease, during the
Research Term, should a Party in good faith believe that it has identified a
Novel Gene with respect to a Disease, such Party shall promptly provide written
notice to the Steering Committee identifying the Novel Gene, the Disease and the
basis for such Party's belief. The Steering Committee shall, as promptly as
practicable after receipt of such notification, meet to discuss whether such
Novel Gene is, in the opinion of the

                                      -23-
<PAGE>   29

Steering Committee, a Candidate Gene with respect to such Disease. The Steering
Committee shall record its Decision in the Minutes of such meeting pursuant to
Section 3.5. If the Steering Committee decides that the Novel Gene is a
Candidate Gene with respect to such Disease, the Minutes shall identify the
Disease and a detailed description of the Candidate Gene and the basis for the
Steering Committee Decision, and such Minutes shall be considered a Candidate
Gene Identification and such Novel Gene shall be considered a Candidate Gene. If
the Steering Committee determines that such Novel Gene is not a Candidate Gene
with respect to such Disease, the Minutes shall identify the Disease and a
detailed description of the Novel Gene and the basis for the Steering Committee
Decision, and such Minutes shall not be considered a Candidate Gene
Identification and such Novel Gene shall not be considered a Candidate Gene.

                 (ii) For a given Candidate Gene, should a Party in good faith
believe that such Candidate Gene has been or should be considered confirmed as
affecting the pathogenesis of a Disease, such Party shall promptly provide
written notice to the Steering Committee identifying such Candidate Gene, the
Disease and the basis for such Party's belief. The Steering Committee shall, as
promptly as practicable after receipt of such notification, meet to discuss
whether such Candidate Gene is in the opinion of the Steering Committee,
Confirmed. The Steering Committee shall record its Decision in the Minutes of
such meeting pursuant to Section 3.5. If the Steering Committee makes a Decision
that such Candidate Gene is Confirmed, the Minutes shall identify the Disease
and a detailed description of the Candidate Gene and the basis for the Steering
Committee Decision, and such Minutes shall be considered a Candidate Gene
Confirmation, and such Candidate Gene shall be considered a Disease Gene, and
the Disease shall be considered a Selected Disease. If the Steering Committee
makes a Decision that such Candidate Gene is not Confirmed, the Minutes shall
identify the Disease and a detailed description of the Candidate Gene and the
basis for the Steering Committee Decision, and such Minutes shall not be
considered a Candidate Gene Confirmation, and the Candidate Gene shall not be
considered a Disease Gene.

             (d) Abandonment for a Disease. Subject to the terms and conditions
of this Agreement, commencing [CONFIDENTIAL TREATMENT REQUESTED] after the
Effective Date, at any time during the Research Term, Roche may, for any reason,
terminate this Agreement with respect to all Roche Products for a Disease other
than a Selected Disease by giving [CONFIDENTIAL TREATMENT REQUESTED] prior
written notice to deCODE. In such event, the effective date of termination shall
be the date [CONFIDENTIAL TREATMENT REQUESTED] after Roche provides such written
notice to deCODE. Following a termination of this Agreement by Roche with
respect to all Roche Products for a Disease other than a Selected Disease
pursuant to this Section 5.2(d), all licenses granted by deCODE to Roche under
Section 7 and any other applicable Section of this Agreement shall terminate
with respect to Roche Products for such Disease. In addition, at deCODE's
request, within sixty (60) days after the date of such termination, Roche shall
transmit to deCODE all reports, information and data in the possession or
control of Roche, its Affiliates or its sublicensees for such Disease generated
or developed as result of the relevant Research Program (provided that Roche

                                      -24-
<PAGE>   30

has the right to make available such information to deCODE). After the
effective date of such termination, in no event shall Roche, its Affiliates
or sublicensees make, have made, use, offer for sale, sell or import Roche
Products for such Disease. If Roche terminates this Agreement pursuant to this
Section 5.2(d) with respect to Roche Products for a Disease, such Disease shall
no longer be considered a Disease under this Agreement.

             (e) Switching Diseases.

                 (i) Making a Secondary Disease a Primary Disease. Subject to
the terms and conditions of this Agreement, Roche may, at any time during the
Research Term, provide written notice to deCODE that Roche wishes to make a
Secondary Disease a Primary Disease. Upon deCODE's receiving such notice, the
Steering Committee shall, within sixty (60) days of such notice discuss, prepare
and finalize an Annual Research Plan for the new Primary Disease. deCODE shall,
within thirty (30) days of finalization by the Steering Committee of such Annual
Research Plan, commence a separate and independent Major Research Program for
such new Primary Disease and conduct such Major Research Program as described in
such Annual Research Plan.

                 (ii) Making a Primary Disease a Secondary Disease. Subject to
the terms and conditions of this Agreement, Roche may, at any time during the
Research Term, provide written notice to deCODE that Roche wishes to make a
Primary Disease a Secondary Disease. Upon deCODE's receiving such notice, the
Steering Committee shall, within sixty (60) days of such notice discuss, prepare
and finalize an Annual Research Plan for the new Secondary Disease. deCODE
shall, within thirty (30) days of finalization by the Steering Committee of such
Annual Research Plan, commence a separate and independent Minor Research Program
for such new Secondary Disease and conduct such Minor Research Program as
described in such Annual Research Plan.

             (f) Adding a New Disease. Roche may, at any time during the
Research Term, request in writing that the Parties discuss the selection of a
new disease to be a Primary Disease or Secondary Disease. The parties shall then
discuss whether or not to conduct a Research Program for such new disease. In
the event that the Parties agree to conduct a Research Program for such new
disease (a "New Disease"), such New Disease shall be deemed to be a Primary
Disease or a Secondary Disease, as the case may be. The Steering Committee
shall, within sixty (60) days thereafter, discuss, prepare and finalize an
Annual Research Plan for such New Disease. deCODE shall, within thirty (30) days
of finalization by the Steering Committee of such Annual Research Plan, commence
a Major Research Program or a Minor Research Program, as the case may be, for
such New Disease and conduct such Research Program as described in such Annual
Research Plan. Nothing in this Section 5.2(f) shall obligate either Party to
agree to any New Diseases.

                                      -25-
<PAGE>   31

         5.3 Research Programs.

             (a) Scope.

                (i)  Major Research Programs.

                     (1) Each Major Research Program shall have as its subject
an independent and separate Primary Disease. For each Major Research Program,
deCODE shall conduct, at its cost except as provided in Section 5.4(a), those
activities that are assigned to deCODE in the Annual Research Plan for such
Major Research Program. Unless otherwise mutually agreed in writing by Roche and
deCODE, deCODE shall assign [CONFIDENTIAL TREATMENT REQUESTED] per Major
Research Program per contract year during the Research Term.

                      (2) For a period commencing on the Effective Date and
ending [CONFIDENTIAL TREATMENT REQUESTED], there shall, at all times, be
[CONFIDENTIAL TREATMENT REQUESTED] independent and separate Major Research
Programs.

                 (ii) Minor Research Programs.

                      (1) During the Research Term, the Parties shall undertake
each Minor Research Program to maintain sufficient Technical Information related
to the Secondary Disease that is the subject of such Minor Research Program so
that such Secondary Disease could become the subject of a Major Research Program
within ninety (90) days of notice from Roche of its wish to make such Secondary
Disease a Primary Disease. For each Minor Research Program, deCODE shall
conduct, at its cost except as provided in Section 5.4(b), those activities that
are assigned to deCODE in the Annual Research Plan for such Minor Research
Program. Unless otherwise mutually agreed in writing by Roche and deCODE, deCODE
shall assign [CONFIDENTIAL TREATMENT REQUESTED] per Minor Research Program per
contract year during the Research Term.

                      (2) For a period commencing on the Effective Date and
ending [CONFIDENTIAL TREATMENT REQUESTED], there shall, at all times, be
[CONFIDENTIAL TREATMENT REQUESTED] independent and separate Minor Research
Programs. At any time during the Research Term, Roche shall not be required to
provide funding for more than [CONFIDENTIAL TREATMENT REQUESTED] per contract
year for all Minor Research Programs.

             (b) Oversight. The Steering Committee shall oversee each Research
Program.

             (c) Annual Research Plan. For the first year of the Research Term,
commencing on the Effective Date, the Steering Committee will discuss and
prepare an Annual Research Plan for each Research Program and will finalize an
Annual Research Plan for each Research Program on or prior to thirty (30) days
after the Effective Date.

                                      -26-
<PAGE>   32

Thereafter, during the Research Term, the Steering Committee shall
(i) commencing not less than three (3) months prior to each anniversary of the
Effective Date, discuss and prepare an Annual Research Plan for each Research
Program for the upcoming contract year, and (ii) prior to each anniversary of
the Effective Date during the Research Term, finalize an Annual Research Plan
for each Research Program for the upcoming year of the Research Term. Each
Annual Research Plan may be amended from time to time upon Steering Committee
approval. Each Annual Research Plan, and any amendment thereto, shall be signed
and dated by a representative of each Party on the Steering Committee.

            (d) FTE Rate Adjustment. For a period commencing on the Effective
Date and until [CONFIDENTIAL TREATMENT REQUESTED], the FTE Rate shall be
[CONFIDENTIAL TREATMENT REQUESTED]. Beginning on February 1, 2001, the FTE Rate
shall be adjusted at the beginning of each contract year during the Research
Term. The adjustment for the payments due on [CONFIDENTIAL TREATMENT REQUESTED]
under Section 5.4 shall reflect the average of: (i) the difference between
December [CONFIDENTIAL TREATMENT REQUESTED] and December 1997 in the Consumer
Price Index for All Urban Consumers ("CPI-U") for All Items as reported in the
CPI Detailed Report published by the U.S. Department of Labor Bureau of Labor
Statistics, and (ii) the difference between December [CONFIDENTIAL TREATMENT
REQUESTED] and December 1997 in the Product Price Index ("PPI") for All Products
as reported in the PPI Detailed Report published by the U.S. Department of Labor
Bureau of Labor Statistics. The adjustment for the payments due on [CONFIDENTIAL
TREATMENT REQUESTED] under Section 5.4 shall reflect the average difference
between the CPI-U between December [CONFIDENTIAL TREATMENT REQUESTED] and
December [CONFIDENTIAL TREATMENT REQUESTED] and the PPI between December
[CONFIDENTIAL TREATMENT REQUESTED] and December [CONFIDENTIAL TREATMENT
REQUESTED]. With respect to any additional contract year during the Research
Term, the adjustment to the FTE Rate shall be made in like manner.

            (e) Use of FTEs. The Parties acknowledge that deCODE's utilization
of Representatives of deCODE during the course of each Research Program may
fluctuate during the Research Term and that deCODE's obligation to allocate a
certain number of FTEs to a Research Program, and satisfaction of such
obligation, will be based on such allocation calculated over the course of a
given year of the Research Term.

         5.4 Research Funding.

             (a) Major Research Programs. Subject to the terms and conditions of
this Agreement, for each Major Research Program then in effect on the relevant
due date, Roche shall pay to deCODE the following amounts, which shall be due
and payable as follows:

                                      -27-
<PAGE>   33

                           [CONFIDENTIAL TREATMENT REQUESTED]

                                      -28-
<PAGE>   34

                           [CONFIDENTIAL TREATMENT REQUESTED]

                                      -29-
<PAGE>   35

                  (b) Minor Research Programs. Subject to the terms and
conditions of this Agreement, for each Minor Research Program then in effect on
the relevant due date, Roche shall pay to deCODE the following amounts, which
shall be due and payable as follows:

                           [CONFIDENTIAL TREATMENT REQUESTED]

                                      -30-
<PAGE>   36

                           [CONFIDENTIAL TREATMENT REQUESTED]

                                      -31-
<PAGE>   37

[CONFIDENTIAL TREATMENT REQUESTED]

         (c) Adjustment to Amount of Payment. The Parties acknowledge and agree
that the amount of each quarterly payment set forth in Sections 5.4(a) and
5.4(b) are determined based on [CONFIDENTIAL TREATMENT REQUESTED] of the number
of FTEs to be allocated to such Research Program by deCODE for an contract year
[CONFIDENTIAL TREATMENT REQUESTED], multiplied by the FTE Rate.

         (d) Other Expenses. Subject to Sections 5.4(a) and 5.4(b), each Party
shall be - responsible for its own costs and expenses related to each Research
Program.

         (e) Method of Payment. Payments under this Section 5.4 shall be made by
Roche to deCODE by wire transfer to:

                           State Street Bank and Trust Co.
                           225 Franklin Street
                           Boston, MA 02110-2804
                           Account No. 94262524
                           ABA No. 011000028

or such other account as deCODE may, from time to time, designate to Roche in
writing.

                  (f) FTE Support. At any time during the Research Term, Roche
shall not be required to provide funding for more than [CONFIDENTIAL TREATMENT
REQUESTED] per contract year for all Major Research Programs. At any time during
the Research Term, Roche shall not be required to provide funding for more than
[CONFIDENTIAL TREATMENT REQUESTED] per contract year for all Minor Research
Programs.

         5.5 Use of Funds. deCODE will use funding provided by Roche under this
Section 5 only in support of the Research Programs. deCODE will not use any
Third Party funding in direct support of a Research Program. The use of any
Third Party funding by deCODE in indirect support of a Research Program shall
not adversely impact Roche's rights and licenses under this Agreement.

         5.6      Roche Review Right.

                  (a) Within thirty (30) days following the end of each quarter
of the Research Term, deCODE shall prepare and submit to Roche a statement
setting forth for each Research Program the number of deCODE scientists who
actually worked on

                                      -32-
<PAGE>   38

such Research Program during the previous quarter and the portion of an FTE that
each such deCODE scientist worked on such Research Program.

                  (b) deCODE shall keep full, true and accurate books of account
containing all information necessary to determine the correctness of the number
of deCODE scientists who actually worked on any Research Program during any
period of the Research Term and the portion of an FTE that each such deCODE
scientist worked on any such Research Program. Such books of account shall be
kept at deCODE's principal place of business. Not more than once per contract
year during the Research Term, Roche or its authorized independent public
accountant shall have the right to engage deCODE's independent public
accountant, at reasonable times and upon reasonable notice, to examine on
deCODE's premises, such records of deCODE. Results of any such examination shall
be made available to both Parties. Roche shall bear the cost of such audit,
unless such audit indicates an overstatement of the number of FTEs that worked
on any Research Program by five percent (5%) or more, in which event deCODE
shall bear the costs of such audit.

         5.7 Conduct.

         (a) Each Party. Each Party shall for each Research Program:

         (i) conduct such Research Program as described in each Annual Research
Plan for such Research Program;

         (ii) use reasonable diligence to (1) perform the activities assigned to
such Party under the Annual Research Plan for such Research Program and (2)
complete such activities on a timely basis;

         (iii) conduct such Research Program in good scientific manner, and in
compliance in all material respects with all requirements of applicable laws,
rules and regulations, and all other requirements of any applicable good
laboratory practices to attempt to achieve its objectives efficiently and
expeditiously;

         (iv) within thirty (30) days following the end of each calendar quarter
during the Research Term, furnish the other Party with written reports
summarizing (1) all scientific work performed by such Party and (2) Program
Know-How developed by such Party (including without limitation a summary of
Inventions and results and data generated), in the conduct of such Research
Program during such calendar quarter;

         (v) within sixty (60) days after the end of a given Research Program
or, as otherwise requested by the Steering Committee, furnish to the other Party
a detailed written report relating to (1) all scientific work performed by such
Party and (2) Program Know-How developed by such Party (including without
limitation a

                                      -33-
<PAGE>   39

summary of Inventions and results and data generated), in the conduct of such
Research Program during such Research Program;

         (vi) promptly disclose Inventions to the other Party in accordance with
Section 10; and

         (vii) during the Research Term, allow Representatives of the other
Party, during normal business hours and with reasonable frequency, to visit the
offices and laboratories of such Party where such Research Program is being
conducted, and consult informally, during such visits or by telephone, with such
Party's Representatives performing scientific work on or in direct connection
with such Research Program; provided, however, that (1) such Representatives of
the other Party are under an agreement binding such Representatives to protect
Confidential Information to at least the same extent or greater as is required
of such other Party under this Agreement and (2) the Party allowing any such
visit approves in writing prior to such visit the other Party's Representatives,
which approval shall not be unreasonably withheld. Any such visit shall not
unreasonably interrupt the operations of the Party that is visited.

         (b) Of Roche. To the extent that validation of a target is not part of
an Annual Research Plan for a Selected Disease, Roche shall use reasonable
efforts to obtain a Validated Target for such Selected Disease.

         5.8 Records.

         (a) During the Research Term and for each Research Program, deCODE and
Roche each shall maintain records in sufficient detail and in such good
scientific manner as to, in all material aspects, completely and accurately
reflect all scientific work performed and results achieved in the conduct of
such Research Program (including all Inventions and results and data generated
in the conduct of such Research Program). Such records shall be maintained in
separate, bound laboratory notebooks for each Research Program. The Parties
shall maintain such records in a form required under all applicable laws and
regulations of the Major Countries.

         (b) During the Research Term and for each Research Program, deCODE and
Roche each shall have the right, during normal business hours and upon
reasonable notice, and subject to such reasonable procedures as the other Party
may require, to inspect all such records of the other Party relating to the
Research Programs. deCODE and Roche each shall maintain such records of the
other Party contained therein as Confidential Information in accordance with
Section 13 and shall not use such records except to the extent otherwise
permitted by this Agreement.

         5.9 Plasma Samples. deCODE shall (i) harvest plasma samples from
Participants and (ii) preserve - such harvested plasma samples. The Steering
Committee shall determine if there is a scientific need for plasma samples
[CONFIDENTIAL TREATMENT REQUESTED]

                                      -34-
<PAGE>   40

[CONFIDENTIAL TREATMENT REQUESTED]. If the Steering Committee determines that
there is a scientific need for plasma samples [CONFIDENTIAL TREATMENT REQUESTED]

         5.10 Cell Lines and Tissue Samples. If the Steering Committee
determines that there may be a - scientific need for cell lines and/or tissue
samples for any Disease, [CONFIDENTIAL TREATMENT REQUESTED]

         5.11 Biological Materials Transfer.

         (a) For any Biological Material, deCODE shall provide Roche with all
related deCODE Know-How and shall inform Roche of any hazards or precautions
which need to be taken with respect to the Biological Material that deCODE is
aware of, or becomes aware of, during the term of this Agreement. deCODE shall
properly label, package, and transport the Biological Material in accordance
with all applicable laws and regulations and as reasonably requested by Roche.
Nothing herein shall be construed as giving Roche any title or ownership to any
Biological Materials. Roche may not use any Biological Material except in the
conduct of a Research Program or a Development Program without the prior written
consent of deCODE. Roche shall not supply any Biological Material to any Third
Party, other than Collaborators, without the prior written consent of deCODE. In
no event shall Roche use any Biological Materials to harvest DNA. Upon deCODE's
written request during the Research Term or one (1) year thereafter, Roche shall
destroy all unused Biological Materials.

         (b) THE BIOLOGICAL MATERIALS ARE PROVIDED "AS IS" AND WITHOUT ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,

                                      -35-
<PAGE>   41

INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF
FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE
BIOLOGICAL MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER
PROPRIETARY RIGHTS OF ANY THIRD PARTY.

         5.12 Research Term.

         (a) End of Research Term. Subject to Sections 5.12(b), 5.12(c),
5.12(d), 5.12(e) and 5.13, the Research Term shall end on February 1, 2003.
Subject to Section 5.13, at the end of the Research Term, any Disease that was
the subject of an ongoing Research Program shall no longer be considered a
Disease provided such Disease is not otherwise a Selected Disease.

         (b) Continuation. If Roche wishes to maintain [CONFIDENTIAL TREATMENT
REQUESTED] independent and separate Major Research Programs for [CONFIDENTIAL
TREATMENT REQUESTED] different Primary Diseases for the contract year commencing
[CONFIDENTIAL TREATMENT REQUESTED], then Roche shall notify deCODE in writing no
later than [CONFIDENTIAL TREATMENT REQUESTED] of Roche's intention to continue
the Research Term for the one (1) year period commencing [CONFIDENTIAL TREATMENT
REQUESTED]. If so continued, and if Roche wishes to maintain [CONFIDENTIAL
TREATMENT REQUESTED] independent and separate Major Research Programs for
[CONFIDENTIAL TREATMENT REQUESTED] different Primary Diseases for the contract
year commencing [CONFIDENTIAL TREATMENT REQUESTED], then Roche shall notify
deCODE in writing no later than [CONFIDENTIAL TREATMENT REQUESTED] of Roche's
intention to continue the Research Term for the one (1) year period commencing
[CONFIDENTIAL TREATMENT REQUESTED]. In any such notice, Roche shall list all
Diseases for which Roche, at that time, is then interested in maintaining Major
Research Programs and Minor Research Programs. The Research Term shall continue
for such one (1) year period commencing [CONFIDENTIAL TREATMENT REQUESTED] or
[CONFIDENTIAL TREATMENT REQUESTED], as the case may be, provided that Roche
maintains [CONFIDENTIAL TREATMENT REQUESTED] independent and separate Major
Research Programs for [CONFIDENTIAL TREATMENT REQUESTED] different Primary
Diseases during each such year. In the event that any Primary Disease becomes a
Selected Disease during any such year, Roche shall continue to fund
[CONFIDENTIAL TREATMENT REQUESTED] FTEs during such year, which shall be
allocated to the remaining Major Research Programs as the parties may agree. If
Roche does not send a notice pursuant to this Section 5.12(b) by [CONFIDENTIAL
TREATMENT REQUESTED], or if the Research Term is not otherwise continued
pursuant to Section 5.12(c), then the Research Term shall end on [CONFIDENTIAL
TREATMENT REQUESTED]. If Roche does not send a notice pursuant to this Section
5.12(b) by [CONFIDENTIAL TREATMENT REQUESTED], or if the Research Term is not
otherwise continued pursuant to Section 5.12(c), then the [CONFIDENTIAL
TREATMENT REQUESTED].

         (c) Mutual Continuation. If Roche wishes to maintain less than
[CONFIDENTIAL TREATMENT REQUESTED], but at least [CONFIDENTIAL TREATMENT
REQUESTED], independent and separate Major Research Programs for less than
[CONFIDENTIAL TREATMENT REQUESTED], but at least [CONFIDENTIAL TREATMENT
REQUESTED], different Primary Diseases for the contract year commencing
[CONFIDENTIAL TREATMENT REQUESTED], then Roche shall notify deCODE in writing no
later than [CONFIDENTIAL TREATMENT REQUESTED] of Roche's desire to continue the
Research Term for the one (1) year period commencing [CONFIDENTIAL TREATMENT
REQUESTED]. If so continued or if continued for the contract year

                                      -36-
<PAGE>   42

commencing [CONFIDENTIAL TREATMENT REQUESTED] pursuant to Section 5.12(b), and
if Roche wishes to maintain less than [CONFIDENTIAL TREATMENT REQUESTED], but at
least [CONFIDENTIAL TREATMENT REQUESTED], independent and separate Major
Research Programs for less than [CONFIDENTIAL TREATMENT REQUESTED], but at least
[CONFIDENTIAL TREATMENT REQUESTED], different Primary Diseases for the contract
year commencing [CONFIDENTIAL TREATMENT REQUESTED], then Roche shall notify
deCODE in writing no later than [CONFIDENTIAL TREATMENT REQUESTED] of Roche's
desire to continue the Research Term for the one (1) year period commencing
[CONFIDENTIAL TREATMENT REQUESTED]. In any such notice, Roche shall list all
Diseases for which Roche, at that time, is then interested in maintaining Major
Research Programs and Minor Research Programs. Upon consent of deCODE, the
Research Term shall continue for such one (1) year period commencing
[CONFIDENTIAL TREATMENT REQUESTED] or [CONFIDENTIAL TREATMENT REQUESTED], as the
case may be, provided that Roche maintains such number of independent and
separate Major Research Programs for such number of different Primary Diseases
as the Parties have initially agreed upon during each such year. In the event
that any Primary Disease becomes a Selected Disease during any such year, Roche
shall continue to fund the same number of FTEs initially agreed upon by the
parties during such year, which shall be allocated to the remaining Major
Research Programs as the parties may agree. If Roche does not send a notice
pursuant to this Section 5.12(c) by [CONFIDENTIAL TREATMENT REQUESTED], or if
the Research Term is not otherwise continued pursuant to Section 5.12(b), then
the Research Term shall end on [CONFIDENTIAL TREATMENT REQUESTED]. If Roche does
not send a notice pursuant to this Section 5.12(c) by [CONFIDENTIAL TREATMENT
REQUESTED], or if the Research Term is not otherwise continued pursuant to
Section 5.12(b), then the Research Term shall end on [CONFIDENTIAL TREATMENT
REQUESTED].

         (d) Funding and FTE Commitment during Continuation Years. The level of
funding provided by Roche to deCODE under Section 5.4 and the number of FTEs
provided by deCODE under Section 5.3 for each such Research Program shall remain
unchanged by any continuation of the Research Term under Section 5.12(b) or
5.12(c) (except for adjustments to reflect any adjustments to the FTE Rate
pursuant to Section 5.3(d)), unless otherwise agreed in writing by the Parties.

         (e) Extensions. Provided the Research Term has continued under Sections
5.12(b) and/or (c) until [CONFIDENTIAL TREATMENT REQUESTED], the Parties may
mutually agree to extend the Research Term beyond [CONFIDENTIAL TREATMENT
REQUESTED]for such number of Diseases, and on such terms, as the Parties may
mutually agree. In the event that Roche is interested in such an extension,
Roche shall so notify deCODE in writing no later than [CONFIDENTIAL TREATMENT
REQUESTED]. The level of funding to be provided by Roche to deCODE, the number
of FTEs to be provided by deCODE shall be determined by the Parties at such time
of any such mutual agreement of extension. Such extensions shall be deemed to be
included in the Research Term for all purposes under this Agreement except as
certain terms may be modified by the mutual agreement of the Parties.

         5.13 Post-Research Term Developments Proposal.

         (a) After the Research Term, deCODE shall have no further obligations
to conduct research activities. However, deCODE shall advise Roche, if during
the six

                                      -37-
<PAGE>   43

(6) month period after the end of the Research Term (without giving effect to
any extension of the Research Term pursuant to this Section 5.13(a)), it obtains
mapping data or other significant information with respect to a disease that at
the end of the Research Term was a Disease (for example, new information that a
gene affects the pathogenesis of a Disease or confirming a Candidate Gene).
Then, Roche, in its sole discretion, may elect to provide funding to deCODE to
continue a Major Research Program with respect to such Disease for one (1)
additional six (6) month period. The funding for such Major Research Program
will be at the level provided during the last contract year of the Research
Term, either as provided in Section 5.4(a) (as adjusted due to any adjustment of
the FTE Rate pursuant to Section 5.3(d)) or at the level agreed upon pursuant to
Section 5.12(e), as the case may be, such work shall be deemed to be a part of a
Major Research Program, and the Research Term shall be extended with respect to
such Major Research Program. In addition, Roche shall reimburse deCODE for the
work performed by deCODE with respect to such Disease for the period from the
end of the original Research Term through the date that Roche elects to fund the
additional six (6) month period. Such reimbursement shall be at the same level
of funding that would have been provided for a Major Research Program during the
last contract year of the Research Term, either as provided in Section 5.4(a)
(as adjusted due to any adjustment of the FTE Rate pursuant to Section 5.3(d))
or at the level agreed upon pursuant to Section 5.12(e), as the case may be.

         (b) Notwithstanding anything to the contrary, for any disease that at
the end of the Research Term was a Disease but was not a Selected Disease, the
following shall apply:

         (i) If deCODE believes, at any time during the six (6) month period
following the six (6) month period after the end of the Research Term (without
giving effect to any extension of the Research Term pursuant to Section
5.13(a)), that a gene is either a Novel Gene, a Candidate Gene or a Disease Gene
(collectively, "Proposed Gene") for the Disease, it shall so notify Roche in
writing ("deCODE Notice").

         (ii) If Roche, at any time within the sixty (60) day period following
receipt of a deCODE Notice, notifies deCODE in writing that Roche is interested
in negotiating for the rights to such Proposed Gene (a "Roche Notice"), then the
Parties shall conduct good faith negotiations on an exclusive basis directed to
Roche acquiring such rights. In the event that Roche does not provide a Roche
Notice to deCODE during such sixty (60) day period, then deCODE shall be free to
offer such rights to any Third Party under any terms and conditions without any
obligations to Roche.

         (iii) In the event that, within six (6) months after the Roche Notice
is provided, the Parties fail to execute an agreement related to Roche acquiring
such rights, then deCODE shall be free to offer such rights to any Third Party
on terms and conditions no more favorable, taken as a whole, than the most
favorable terms last offered by Roche to deCODE for such rights. Within ten (10)
days after the expiration

                                      -38-
<PAGE>   44

of such six (6) month period, Roche shall provide deCODE with a written document
setting forth such terms.

         5.14 Validation of Targets. For a given Selected Disease, at any time
during the term of the Agreement, [CONFIDENTIAL TREATMENT REQUESTED], such Party
shall promptly provide written notice to the Steering Committee [CONFIDENTIAL
TREATMENT REQUESTED]. The Steering Committee shall, as promptly as practicable
after receipt of such notification, meet to discuss whether [CONFIDENTIAL
TREATMENT REQUESTED]. The Steering Committee shall record its Decision in the
Minutes of such meeting pursuant to Section 3.5. If the Steering Committee makes
a Decision that [CONFIDENTIAL TREATMENT REQUESTED]. If the Steering Committee
makes a Decision that [CONFIDENTIAL TREATMENT REQUESTED]

6. DEVELOPMENT AND COMMERCIALIZATION. -

         6.1 Commercialization Efforts by Roche for Selected Diseases.

         (a) For a Selected Disease, once a first Validated Target is obtained,
during the term of this Agreement, Roche, directly or through an Affiliate or
sublicensee, will use reasonable commercial efforts [CONFIDENTIAL TREATMENT
REQUESTED].

         (b) Once a first Candidate Gene is Confirmed for a Selected Disease,
during the term of this Agreement, Roche, directly or through an Affiliate or
sublicensee, will use reasonable commercial efforts [CONFIDENTIAL TREATMENT
REQUESTED].

         (c) Therapeutic Efforts and Diagnostic Efforts, as the case may be, for
a given Roche Product for a Selected Disease shall mean reasonable commercial
efforts, consistent with sound and reasonable business practices and judgment,
comparable to efforts exerted by Roche for its own products of a like kind and
at a like stage of development and having similar potential, taking into account
scientific, business and marketing considerations.

         (d) For a given Selected Disease, prior to the first Registration of a
Therapeutic Product for such Selected Disease in any Major Country, Roche's
exercise

                                      -39-
<PAGE>   45

of Therapeutic Efforts is to be determined by judging Roche's Efforts taken as a
whole in the Major Countries. For a given Selected Disease, prior to the first
Registration of a Diagnostic Product for such Selected Disease in any Major
Country, Roche's exercise of Diagnostic Efforts is to be determined by judging
Roche's Efforts taken as a whole in the Major Countries.

         (e) For a given Selected Disease, after the first Registration of a
Therapeutic Product for such Selected Disease in any Major Country, Roche's
exercise of Therapeutic Efforts is to be determined by judging Roche's Efforts
taken on a Major Country-by-Major Country basis. For a given Selected Disease,
after the first Registration of a Diagnostic Product for such Selected Disease
in any Major Country, Roche's exercise of Diagnostic Efforts is to be determined
by judging Roche's Efforts taken as a whole taken on a Major Country-by-Major
Country basis.

         6.2 Notice of Failure by Roche to Use Efforts for a Selected Disease.

         (a) Therapeutic Products for a Disease.

         (i) For a given Selected Disease, prior to the first Registration in
any Major Country of a Therapeutic Product for such Selected Disease, if deCODE
reasonably believes that Roche is not using Therapeutic Efforts, [CONFIDENTIAL
TREATMENT REQUESTED].

         (ii) For a given Selected Disease, after the first Registration in any
Major Country of a Therapeutic Product for such Selected Disease, if deCODE
reasonably believes that Roche is not using Therapeutic Efforts in any Major
Country,

                                      -40-
<PAGE>   46

[CONFIDENTIAL TREATMENT REQUESTED], then deCODE shall be entitled to proceed
under of Section 14.6(a)(ii) of this Agreement.

         (b) Diagnostic Products for a Disease.

         (i) For a given Selected Disease, prior to the first Registration in
any Major Country of a Diagnostic Product for such Selected Disease, if deCODE
reasonably believes that Roche is not using Diagnostic Efforts, [CONFIDENTIAL
TREATMENT REQUESTED]

                                      -41-
<PAGE>   47

[CONFIDENTIAL TREATMENT REQUESTED], then deCODE shall be entitled to proceed
under Section 14.6(b)(i) of this Agreement.

         (ii) For a given Selected Disease, after the first Registration in any
Major Country of a Diagnostic Product for such Selected Disease, if deCODE
reasonably believes that Roche is not using Diagnostic Efforts in any Major
Country, [CONFIDENTIAL TREATMENT REQUESTED], then deCODE shall be entitled to
proceed under Section 14.6(b)(ii) of this Agreement.

         6.3 Abandonment Of a Selected Disease.

         (a) For Therapeutic Products.

         (i) For a given Selected Disease, commencing [CONFIDENTIAL TREATMENT
REQUESTED] Effective Date, at any time during the term of this Agreement prior
to the first Registration in any Major Country of a Therapeutic Product for such
Selected Disease, Roche may, for any reason, terminate this Agreement with
respect to all Therapeutic Products for the Selected Disease by giving
[CONFIDENTIAL TREATMENT REQUESTED] prior written notice to deCODE. In such
event, the effective date of termination shall be the date [CONFIDENTIAL
TREATMENT REQUESTED] after Roche provides such written notice to deCODE. The
effects of such termination shall be governed by Section 14.4(a)(ii). After the
effective date of such termination, in no event shall Roche, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import Therapeutic
Products for such Selected Disease.

         (ii) For a given Selected Disease, commencing [CONFIDENTIAL TREATMENT
REQUESTED]after the Effective Date, at any time during the term of this
Agreement after the first

                                      -42-
<PAGE>   48

Registration in any Major Country of a Therapeutic Product for such Selected
Disease, Roche may, for any reason, terminate this Agreement in a given Major
Country with respect to all Therapeutic Products for the Selected Disease by
giving six (6) months' prior written notice to deCODE. In such event, the
effective date of termination shall be the date six (6) months after Roche
provides such written notice to deCODE. The effects of such termination shall be
governed by Section 14.4(a)(iii). After the effective date of such termination,
in no event shall Roche, its Affiliates or sublicensees make, have made, use,
offer for sale, sell or import Therapeutic Products for such Selected Disease in
such given Major Country.

         (b) For Diagnostic Products.

         (i) For a given Selected Disease, commencing nine (9) months after the
Effective Date, at any time during the term of this Agreement prior to the first
Registration in any Major Country of a Diagnostic Product for such Selected
Disease, Roche may, for any reason, terminate this Agreement with respect to all
Diagnostic Products for the Selected Disease by giving six (6) months' prior
written notice to deCODE. In such event, the effective date of termination shall
be the date six (6) months after Roche provides such written notice to deCODE.
The effects of such termination shall be governed by Section 14.4(b)(ii). After
the effective date of such termination, in no event shall Roche, its Affiliates
or sublicensees make, have made, use, offer for sale, sell or import Diagnostic
Products for such Selected Disease.

         (ii) For a given Selected Disease, commencing nine (9) months after the
Effective Date, at any time during the term of this Agreement after the first
Registration in any Major Country of a Diagnostic Product for such Selected
Disease, Roche may, for any reason, terminate this Agreement in a given Major
Country with respect to all Diagnostic Products for the Selected Disease by
giving six (6) months' prior written notice to deCODE. In such event, the
effective date of termination shall be the date six (6) months after Roche
provides such written notice to deCODE. The effects of such termination shall be
governed by Section 14.4(b)(iii). After the effective date of such termination,
in no event shall Roche, its Affiliates or sublicensees make, have made, use,
offer for sale, sell or import Diagnostic Products for such Selected Disease in
such given Major Country.

         (c) If Roche terminates this Agreement pursuant to this Section 6.3(a)
and (b) with respect to all Therapeutic Products and all Diagnostic Products for
a Disease, such Disease shall no longer be considered a Disease under this
Agreement.

         6.4 Sale After Registration.

         (a) Time Period. For a given Roche Product which is the subject of a
Registration in a given country, Roche, its Affiliate or sublicensee shall,
within one (1)

                                   -43-
<PAGE>   49

year after such Registration, make a First Commercial Sale of the given Roche
Product in the given country.

         (b) Notice of Failure. If Roche, its Affiliate or sublicensee has not,
within one (1) year after Registration of a Roche Product in a given country,
made a First Commercial Sale of the given Roche Product in the given country,
deCODE may provide Roche written notice to Roche specifying the same.
[CONFIDENTIAL TREATMENT REQUESTED], then deCODE shall be entitled to proceed
under Section 14.7 of this Agreement.

         (c) Abandonment of a Roche Product after Registration. Notwithstanding
anything to the contrary herein, at any time during the term of this Agreement,
Roche may, for any reason, terminate this Agreement in a given country with
respect to a given Roche Product that was the subject of a Registration in the
given country by giving [CONFIDENTIAL TREATMENT REQUESTED] prior written notice
to deCODE. In such event, the effective date of such termination shall be the
date [CONFIDENTIAL TREATMENT REQUESTED] after Roche provides such written notice
to deCODE. The effects of such termination shall be governed by Section 14.4(c).
After the effective date of such termination, in no event shall Roche, its
Affiliates or sublicensees make, have made, use, offer for sale, sell or import
the given Roche Product in the given country.

         6.5 Commercialization Efforts by deCODE and its Sublicensees. During
the term of this Agreement, deCODE shall have no diligence obligation with
respect to deCODE Products for a Selected Disease other than using reasonable
efforts to identify

                                      -44-
<PAGE>   50

and obtain a licensee for such deCODE Products in the event deCODE determines
not to develop deCODE Products for the Selected Disease directly or through an
Affiliate. In the event that deCODE grants rights to any deCODE Products for a
Selected Disease to a licensee, deCODE shall require such licensee to use
reasonable commercial efforts, in the Major Countries as a whole, directed to
the commercialization of at least one (1) deCODE Product for such Selected
Disease ("Sublicensee's Required Efforts").

         6.6 Reports.

         (a) By Roche.

         (i) At least once per year during the term of this Agreement, Roche
will inform deCODE as to the goals and scope of each Roche Development Program.

         (ii) For a Selected Disease, commencing at the end of the Research
Program for such Selected Disease, and until the Registration of a Diagnostic or
Therapeutic Product in a given Major Country for such Selected Disease, within
sixty (60) days after the end of each calendar year, Roche shall provide to
deCODE a written summary of Roche's, its Affiliates and sublicensees Therapeutic
Efforts and Diagnostic Efforts during such previous calendar year, provided that
Roche is permitted by any such sublicensee to share such information with
deCODE. The written summary shall also include information relating to the plan
for pursuing regulatory approvals, the estimated date for making any IND Filing
or NDA Filing, the expected date of receipt of approval of any IND or an NDA,
and the anticipated launch date with respect to each Roche Product in each Major
Country, to the extent such information is available. All such summaries shall
be treated by deCODE as Confidential Information under Section 13.

         (b) By deCODE. For a Selected Disease, commencing at the end of the
Research Program for such Selected Disease, and until the first registration of
a deCODE Product in any Major Country, within sixty (60) days after the end of
each calendar year, provided deCODE determines not to develop deCODE Products
for the Selected Disease directly or through an Affiliate, deCODE shall provide
to Roche a written summary of: (i) deCODE's and its Affiliates' efforts to
identify and obtain a licensee for deCODE Products for the Selected Disease, and
(ii) the Sublicensee's Required Efforts of deCODE's licensees in the Major
Countries during such previous year; provided that deCODE is permitted by such
sublicensee to share such information with Roche. All such summaries shall be
treated by Roche as Confidential Information under Section 13.

         6.7 Ownership of Regulatory Filings. Other than as explicitly provided
for in this Agreement, nothing herein shall be construed as giving deCODE any
title or ownership to any IND, NDA or other regulatory filings related to a
Roche Product. Other than as explicitly provided for in this Agreement, nothing
herein shall be construed as

                                      -45-
<PAGE>   51

giving Roche any title or ownership to any IND, NDA or other regulatory filings
related to a deCODE Product.

         7. GRANT OF LICENSES.

         7.1 Grants.

         (a) To Roche. Subject to the terms and conditions of this Agreement,
deCODE grants to Roche and its Affiliates (i) the sole and exclusive worldwide
right and license under deCODE Know-How and deCODE Patents, and (ii) a
non-exclusive right and license to use deCODE Generalized Technology, to make,
have made, use, offer for sale, sell and import Roche Products in the Territory.
The Parties acknowledge that the above rights and licenses includes, without
limitation, the right and license to make, have made and use Disease Genes and
Validated Targets in the Territory to research and develop Roche Products. The
rights and licenses granted to Roche pursuant to this Section 7.1(a) shall
include the right to grant sublicenses thereto. Roche shall advise deCODE of all
sublicenses granted under this Agreement. If Roche grants a sublicense, all of
the terms and conditions of this Agreement shall apply to the sublicensee to the
same extent as they apply to Roche for all purposes. Roche guarantees and
assumes responsibility for the performance of all obligations so imposed on such
sublicensee by reason of operation of any such sublicense.

         (b) To deCODE. Subject to the terms and conditions of this Agreement,
Roche grants to deCODE and its Affiliates the sole and exclusive worldwide right
and license, with the right to sublicense (subject to Section 7.2), under Roche
Know-How and Roche Patents, to make, have made, use, offer for sale, sell and
import deCODE Products in the Territory. The Parties acknowledge that the above
right and license includes, without limitation, the right and license to make,
have made and use Disease Genes and Validated Targets in the Territory to
research and develop deCODE Products. The rights and licenses granted to deCODE
pursuant to this Section 7.1(b) shall include the right to grant sublicenses
thereto. deCODE shall advise Roche of all sublicenses granted under this
Agreement. If deCODE grants a sublicense, all of the terms and conditions of
this Agreement shall apply to the sublicensee to the same extent as they apply
to deCODE for all purposes.

         (c) Research Programs. Each Party grants to the other Party and its
Affiliates a fully paid-up, non-royalty bearing non-exclusive right and license,
without the right to grant sublicenses, under such Party's respective Know-How
and Patents, for the sole and exclusive purpose of the other Party fulfilling
its research obligations under any and all Research Programs under this
Agreement.

                                      -46-
<PAGE>   52

         7.2 Rights of First Negotiation.

         (a) deCODE Notice. If, at any time during the term of this Agreement,
deCODE is interested in offering rights to a deCODE Product to a Third Party,
deCODE shall give written notice ("deCODE Notice") to Roche of its interest.
Such deCODE Notice shall include sufficient information regarding such deCODE
Product as deCODE, in good faith, deems reasonably necessary for Roche to make a
reasonably informed decision regarding whether or not Roche wishes to pursue
negotiations for such rights.

         (b) Decision Period. Roche shall have a period of sixty (60) days,
extendible by mutual agreement of the Parties, said period to commence on the
receipt by Roche of the deCODE Notice ("Decision Period"), to decide whether or
not it wishes to pursue negotiations for such rights.

         (c) Negotiations. In the event that Roche, within such Decision Period,
provides written notice to deCODE that it is interested in pursuing negotiations
for such rights, then the Parties shall conduct good faith negotiations on an
exclusive basis directed to Roche acquiring such rights.

         (d) Third Party Terms. In the event that, within six (6) months after
Roche provides written notice to deCODE that it is interested in pursuing
negotiations for such rights, the Parties fail to execute an agreement related
to Roche acquiring such rights, then deCODE shall be free to offer such rights
to any Third Party on terms and conditions no more favorable, taken as a whole,
than the most favorable terms last offered by Roche to deCODE for such rights.
Within ten (10) days after the expiration of such six (6) month period, Roche
shall provide deCODE with a written document setting forth such terms.

         (e) New Opportunity. In the event that Roche, within such Decision
Period, does not provide written notice to deCODE that it is interested in
pursuing negotiations for such rights, (i) deCODE shall be free to offer such
rights to any Third Party under any terms and conditions, and (ii) in the event
additional material new findings not yet presented to Roche are developed during
a two (2) year period commencing on the date that is the end of the Decision
Period, and unless prohibited by agreement or ongoing negotiations with a Third
Party, deCODE shall give Roche the opportunity to review such additional data
and to reconsider its interest in such negotiation.

         8. EQUITY, PAYMENTS AND ROYALTIES.

         8.1 Equity. Either prior to or contemporaneously with the execution of
this Agreement, the Parties shall enter the Equity Agreement, upon such terms
and conditions as are set forth in such Equity Agreement.

                                      -47-
<PAGE>   53

         8.2 Payments.

         (a) Discovery Payments.

         (i) Roche shall pay to deCODE a non-refundable payment of [CONFIDENTIAL
TREATMENT REQUESTED] within thirty (30) days after [CONFIDENTIAL TREATMENT
REQUESTED] and receipt by Roche of an invoice for such sum. The Steering
Committee shall pursuant to Section 3.4(a) decide [CONFIDENTIAL TREATMENT
REQUESTED]. In any event, only one (1) payment under this Section 8.2(a)(i)
shall be due for each Disease, regardless of the [CONFIDENTIAL TREATMENT
REQUESTED]

         (ii) Roche shall pay deCODE the following nonrefundable payments within
thirty (30) days after the occurrence of the following events with respect to
each Disease and receipt by Roche of an invoice for such sum:

                       [CONFIDENTIAL TREATMENT REQUESTED]

         (b) Development Payments - Therapeutic Products. For a given
Therapeutic Product, Roche shall pay to deCODE the following nonrefundable
payments

                                      -48-
<PAGE>   54

within thirty (30) days after the occurrence of the following events ("Events")
as set forth below in Table I:

[CONFIDENTIAL TREATMENT REQUESTED]

         (c) Payment Limitations. For a given Therapeutic Product, Roche will
make each of such payments under Section 8.2(b) only once, for the first
occurrence of an Event for the Therapeutic Product, independent of the number of
occurrences of the Event for the Therapeutic Product. In the event that Roche's
clinical development of any Therapeutic Product for a Selected Disease (an
"Original Product") terminates and, at or after the time of such termination,
Roche is engaged or subsequently becomes engaged in clinical development of any
other Therapeutic Product for such Selected Disease (a "Replacement Product")
and both the Original Product and the Replacement Product treat or prevent the
Selected Disease through the same Biological Pathway, then Roche shall be
entitled to a credit against milestone payments due pursuant to Section 8.2(b)
with respect to the Replacement Product in the amount equal to all milestone
payments actually paid with respect to the Original Product prior to termination
of development thereof.

         By way of illustration, assume that for a given Selected Disease, where
each Therapeutic Product treats or prevents the Selected Disease through the
same Biological Pathway:

         (i) In Year 1:

         (1) Therapeutic Product 1, a Direct Gene Expression Product Type 1,
reaches Event 1,

                                      -49-
<PAGE>   55

         (2) Therapeutic Product 2, a Direct Gene Expression Product Type 2,
reaches Event 1, and

         (3) Therapeutic Product 3, a Drug Product Type 2, reaches Events 1 and
2.

                       [CONFIDENTIAL TREATMENT REQUESTED]

         (ii) In Year 2:

         (1) Roche terminates the development of Therapeutic Product 1,

         (2) Therapeutic Product 2 reaches Event 2,

         (3) Therapeutic Product 3 reaches Event 3, and

         (4) Therapeutic Product 4, a Direct Gene Expression Product Type 1,
reaches Events 1 and 4.

                       [CONFIDENTIAL TREATMENT REQUESTED]

         (iii) In Year 3:

         (1) Roche terminates the development of Therapeutic Product 2,

         (2) Therapeutic Product 3 reaches Events 4 and 5, and

         (3) Therapeutic Product 4 reaches Event 5.

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                      -50-
<PAGE>   56

[CONFIDENTIAL TREATMENT REQUESTED]

         (d) Diagnostic Product. Roche shall pay to deCODE the following
nonrefundable payments within thirty (30) days after the occurrence of the
following events ("Event") with respect to Diagnostic Products for each Selected
Disease:

[CONFIDENTIAL TREATMENT REQUESTED]

         Roche will make each of such payments under this Section 8.2(d) only
once with respect to each Selected Disease, for the first occurrence of a
respective Event with the first Diagnostic Product to reach such Event with
respect to such Selected Disease.

         8.3 Royalties.

         (a) Royalty Rates Paid by Roche. For a given Roche Product, during the
Royalty Term for the Roche Product, Roche shall pay to deCODE a royalty on Net
Sales of the given Roche Product, on a country-by-country basis, at the
following rates as set forth in Table II:

                                      -51-
<PAGE>   57

[CONFIDENTIAL TREATMENT REQUESTED]

         (b) Royalty Rates Paid by deCODE.

         (i) For a given deCODE Product other than an Abandoned Product or a
Reverted Product, during the Royalty Term for the deCODE Product, deCODE shall
pay to Roche a royalty of [CONFIDENTIAL TREATMENT REQUESTED] on Net Sales of the
given deCODE Product, on a country-by-country basis, [CONFIDENTIAL TREATMENT
REQUESTED] of the Sublicensing Income received by deCODE from its sublicensees
with respect to the given deCODE Product.

         (ii) For a given deCODE Product that is an Abandoned Product, during
the Royalty Term for the Abandoned Product, deCODE shall pay to Roche a royalty
on Net Sales of the given Abandoned Product, on a country-by-country basis, at
the following rates as set forth in Table III:

[CONFIDENTIAL TREATMENT REQUESTED]

         If for a given deCODE Product that is an Abandoned Product, deCODE
licenses rights to such Abandoned Product to a Third Party in a given country,
then during the Royalty Term for the Abandoned Product deCODE shall pay to
Roche:

                                      -52-
<PAGE>   58

(1) [CONFIDENTIAL TREATMENT REQUESTED] of the Sublicensing Income received by
deCODE from its sublicensees in the given country with respect to the given
Abandoned Product that is a Drug Product Type 1 or Type 2, (2) [CONFIDENTIAL
TREATMENT REQUESTED] of the Sublicensing Income received by deCODE from its
sublicensees in the given country with respect to the a given Abandoned Product
that is a Direct Gene Expression Product Type 1 or Type 2, and (3) [CONFIDENTIAL
TREATMENT REQUESTED] of the Sublicensing Income received by deCODE from its
sublicensees in the given country with respect to the given Abandoned Product
that is a Diagnostic Product.

         Notwithstanding the above, the royalties otherwise due under this
Section 8.3(b)(ii) to Roche for Abandoned Products other than a Diagnostic
Product shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED] if such Abandoned
Product was not the subject of an IND Filing by Roche, its Affiliate or
sublicensee prior to the date Roche gives notice of such abandonment.

         (iii) For a given deCODE Product that is a Reverted Product, if such
Reverted Product is (1) a Therapeutic Product which, at the time of the
effective date of termination was the subject of an IND Filing by Roche, its
Affiliate or sublicensee, or (2) a Diagnostic Product, then during the Royalty
Term for the Reverted Product, deCODE shall pay to Roche a royalty on Net Sales
of the given Reverted Product, on a country-by-country basis, at the following
rates as set forth in Table IV:

[CONFIDENTIAL TREATMENT REQUESTED]

         If for a given deCODE Product that is a Reverted Product, where such
Reverted Product is (1) a Therapeutic Product which, at the time of the
effective date of termination was the subject of an IND Filing by Roche, its
Affiliate or sublicensee, or (2) a Diagnostic Product, deCODE licenses rights to
such Reverted Product to a Third Party in a given country, then during the
Royalty Term for the Reverted Product deCODE shall pay to Roche: (1)
[CONFIDENTIAL TREATMENT REQUESTED] of the Sublicensing Income received by deCODE
from its sublicensees in the given country with respect to the given Reverted
Product that is a Drug Product Type I or Type II, and (2) [CONFIDENTIAL
TREATMENT REQUESTED] of the Sublicensing Income received by deCODE from its

                                      -53-
<PAGE>   59

sublicensees in the given country with respect to the given Reverted Product
that is a Diagnostic Product.

         8.4 Royalty Reductions.

         (a) Reductions for no Valid Claim.

         (i) Reduction for Roche. The royalties otherwise due under Section
8.3(a) shall be reduced, on a country-by-country basis, by [CONFIDENTIAL
TREATMENT REQUESTED] with respect to a given Roche Product in a given country if
Roche's (i) making, having made or using Disease Genes and Validated Targets to
make, have made, use, offer for sale, sell and import the Roche Product, or (ii)
making, having made, using, offering for sale, selling or importing the Roche
Product, is not claimed by a deCODE Patent Valid Claim or a Roche Patent Valid
Claim in such country.

         (ii) Reduction for deCODE. The royalties or percentage of Royalty
Sublicensing Income otherwise due under Section 8.3(b) shall be reduced, on a
country-by-country basis, by [CONFIDENTIAL TREATMENT REQUESTED] with respect to
a given deCODE Product in a given country if, deCODE's (i) making, having made
or using Disease Genes and Validated Targets to make, have made, use, offer for
sale, sell and import the deCODE Product, and (ii) making, having made, using,
offering for sale, selling or importing the deCODE Product is not claimed by a
Roche Patent Valid Claim of a Roche Patent solely owned by Roche in such
country.

         (b) Reduction for Generic Competition.

         (i) By Roche. Roche may reduce the royalties otherwise due under
Section 8.3(a), on a country-by-country basis, by [CONFIDENTIAL TREATMENT
REQUESTED] with respect to a given Roche Product in a given country if, in such
country, in any calendar quarter, one or more Third Parties markets a product
("Third Party Product") having as a pharmaceutically active ingredient the same
Compound as the Roche Product, or its salt, where (1) the manufacture, use or
sale of such Third Party Product is not claimed by a deCODE Patent Valid Claim
of an issued deCODE Patent or a Roche Patent Valid Claim of an issued Roche
Patent in such country, and (2) such Third Party Product(s), in aggregate, have
at least [CONFIDENTIAL TREATMENT REQUESTED] of the aggregate unit volume of
sales for such Roche Product and such Third Party Product in any calendar year
in such country, as measured by IMS published data or such other index as the
Parties may agree upon.

         (ii) By deCODE. deCODE may reduce the royalties or percentage of
Royalty Sublicensing Income otherwise due under Section 8.3(b), on a
country-by-country basis, by [CONFIDENTIAL TREATMENT REQUESTED] with respect to
a given deCODE Product in a given country if, in such country, in any calendar
quarter, one or more Third Parties markets a Third Party Product having as a
pharmaceutically active ingredient the same

                                      -54-
<PAGE>   60

Compound as the deCODE Compound, or its salt, where (1) the manufacture, use or
sale of such Third Party Product is not claimed by a in a deCODE Patent Valid
Claim of an issued deCODE Patent or a Roche Patent Valid Claim of an issued
Roche Patent in such country, and (2) such Third Party Product(s), in aggregate,
have at least [CONFIDENTIAL TREATMENT REQUESTED] of the aggregate unit volume of
sales for such deCODE Product and such Third Party Product in any calendar year
in such country, as measured by IMS published data or such other index as the
Parties may agree upon.

         (c) Third Party Royalties. If, for a given Product in a given country,
a Party believes that the making, having made, using, offering for sale, selling
or importing the given Product in the given country would represent a
significant risk of infringement of a Third Party Patent, the Party shall notify
the other Party in writing, and the Parties will in good faith discuss the need
to obtain a license from the Third Party ("Third Party License"). If the Parties
fail to agree as to the need for such Third Party License, the Parties will
submit the matter to patent counsel acceptable to both Parties for a legal
opinion about the need to obtain such Third Party License. The Parties will
[CONFIDENTIAL TREATMENT REQUESTED] the costs associated with such legal opinion.

         If the Parties agree on the need for the Third Party License, or if
patent counsel provides reasons as to why the making, having made, offering for
sale, selling or importing of the given Product in the given country would
represent a significant risk of infringement of the Third Party Patent, the
Party may reduce the royalties or percentage of Royalty Sublicensing Income
otherwise due under Section 8.3 for the given Product by an amount equal to
[CONFIDENTIAL TREATMENT REQUESTED] of the royalties and payments paid by the
Party to such Third Party under the Third Party License.

         Notwithstanding the above, for a given Product, in no event shall such
reduction apply to a Third Party License from a Collaborator where the Third
Party License results from a collaboration having as its subject the Product.

         (d) Limit of Reductions to Royalties. Notwithstanding anything to the
contrary, a Party may not reduce the royalties or percentage of Royalty
Sublicensing Income due to the other Party for any calendar quarter on account
of any reductions in royalties or percentage of Royalty Sublicensing Income
provided for in this Section 8.4 by an amount which would reduce the amount of
royalties or the amount of Royalty Sublicensing Income, as the case may be,
otherwise due under Section 8.3 by more than [CONFIDENTIAL TREATMENT REQUESTED].
Any amount of reductions in royalties or percentage of Royalty Sublicensing
Income which exceed the foregoing limits for a given calendar quarter may be
applied by the Party in subsequent calendar quarters, subject again to the
foregoing limitations. The limitations to the royalty and Royalty Sublicensing
Income reductions provided in this Section 8.4 shall not apply against
additional credits or reductions or deductions under any other Sections of this
Agreement.

                                      -55-

<PAGE>   61

         8.5 Obligation to Pay Royalties.

         (a) Sales among Roche and its Affiliates and Sublicensees. The
obligation to pay royalties to deCODE under Section 8.3 is imposed only once
with respect to the same unit of Roche Product, regardless of the number of
deCODE Patents pertaining thereto. There shall be no obligation to pay royalties
to deCODE under Section 8.3 on sales of Roche Products among Roche and its
Affiliates and its sublicensees, but in such instances the obligation to pay
royalties shall arise only upon the sale by Roche, its Affiliates or its
sublicensees to Third Parties (other than sublicensees of Roche).

         (b) Sales among deCODE and its Affiliates. The obligation to pay
royalties to Roche under Section 8.3 is imposed only once with respect to the
same unit of deCODE Product, regardless of the number of Roche Patents
pertaining thereto. There shall be no obligation to pay royalties on Net Sales
or a percentage of Royalty Sublicensing Income to Roche under Section 8.3 on
sales of deCODE Products among deCODE and its Affiliates and its sublicensees,
but in such instances the obligation to pay royalties on Net Sales shall arise
only upon the sale by deCODE or its Affiliates to Third Parties (other than
sublicensees of deCODE) and the obligation to pay a percentage of Royalty
Sublicensing Income shall arise only upon the sale by deCODE's sublicensees to
Third Parties.

         8.6 Roche Supply Obligation. During the Royalty Term, Roche shall
provide quantities of Roche Products necessary or required by the persons who
are both citizens and residents of Iceland for the prevention, diagnosis and/or
treatment of the Diseases at no charge.

         8.7 Barred Royalties. If the royalties set out in this Section 8, after
giving effect to all reductions and credits to such royalties allowable under
this Agreement, are higher than the maximum royalties permitted by the law or
regulations of a given country, the royalty payable for such country shall be
equal to the maximum permitted under such law or regulations.

         9. PAYMENTS AND REPORTS.

         9.1 Payment. Except as otherwise provided in this Agreement, all
royalties on Net Sales of Roche Products shall be calculated quarterly as of
[CONFIDENTIAL TREATMENT REQUESTED] (each as being the last day of a
[CONFIDENTIAL TREATMENT REQUESTED]) and shall be paid by Roche within sixty (60)
days after the end of each [CONFIDENTIAL TREATMENT REQUESTED] for which such Net
Sales are calculated. Each such payment shall be accompanied by a statement,
Product-by-Product and country-by-country, of the amount of Net Sales during
such calendar quarter and the amount of royalties due on such Net Sales.

                                      -56-
<PAGE>   62

Except as otherwise provided in this Agreement, all royalties on Net Sales of
deCODE Products and the amount of Sublicensing Income due shall be calculated
quarterly as of March 31, June 30, September 30 and December 31 (each as being
the last day of a calendar quarter) and shall be paid by deCODE within sixty
(60) days after the end of each calendar quarter for which such Net Sales or
Sublicensing Income are calculated. Each such payment shall be accompanied by a
statement, Product-by-Product and country-by-country, of the amount of Net
Sales, the amount of royalties due on such Net Sales, or the amount of
Sublicensing Income due, as the case may be.

         9.2 Mode of Payment. A Party shall make all payments required under
this Agreement as directed by the other Party from time to time in United States
Dollars or such other currency as the Parties may mutually agree.

         (a) For Roche and its Affiliates. For Roche and its Affiliates,
whenever for the purpose of calculating royalty conversion from any foreign
currency shall be required, such conversion shall be made as follows: when
calculating the Adjusted Gross Sales, the amount of such sales in foreign
currencies shall be converted into Swiss Francs as computed in the central
Roche's Swiss Francs Sales Statistics for the countries concerned, using the
average monthly rate of exchange at the time for such currencies as retrieved
from the Reuters System; and when calculating the royalties on Net Sales, such
conversion shall be at the average rate of the Swiss Franc to the Dollar, as
retrieved from the Reuters System for the applicable [CONFIDENTIAL TREATMENT
REQUESTED].

         (b) For a Sublicensee of Roche in a Country. For a sublicensee of
Roche, whenever for the purpose of calculating royalty conversion from any
foreign currency shall be required, such conversion shall be made as follows:
when calculating the Adjusted Gross Sales, the amount of such sales shall be
reported by the sublicensee to Roche within thirty (30) days from the end of the
[CONFIDENTIAL TREATMENT REQUESTED], after having converted each applicable
monthly sales in foreign currency into the Dollar using the average rates of
exchange published in The Wall Street Journal (or some other source agreed upon
in writing by the Parties for the country) for each respective month of the
applicable [CONFIDENTIAL TREATMENT REQUESTED].

         (c) For deCODE and its Affiliates. For deCODE and its Affiliates,
whenever for the purpose of calculating royalty conversion from any foreign
currency shall be required, such conversion shall be made as follows: when
calculating the Adjusted Gross Sales and Net Sales, the amount of such sales in
foreign currencies shall be converted into Dollars, as computed for the country
concerned using the average monthly rate of exchange listed in The Wall Street
Journal (or some other source agreed upon in writing by the Parties for the
country) for each applicable month of the applicable calendar quarter.

         (d) For a Sublicensee of deCODE in a Country. For a sublicensee of
deCODE, the Sublicensing Income shall be calculated by conversion of such
amount

                                      -57-
<PAGE>   63

from the currency in which it was paid to deCODE into Dollars as computed for
the country concerned using the average monthly rate of exchange listed in The
Wall Street Journal (or some other source agreed upon in writing by the Parties
for the country) for each applicable month of the applicable calendar quarter.

         9.3 Records Retention. Each Party shall keep, and require its
Affiliates and sublicensees to keep, full, true and accurate books of account in
accordance with generally accepted accounting principles, consistently applied
("Books of Account") containing all particulars that may be necessary for the
purpose of calculating all royalties and Sublicensing Income payable to the
other Party under this Agreement for a period of three calendar (3) years after
the end of the calendar year in which such sales occurred. Such Books of Account
shall be kept at the principal place of business of the Party, its Affiliates or
its sublicensees, as the case may be.

         9.4 Audit Request.

         (a) By deCODE. At deCODE's expense, deCODE or its authorized
independent public accountant has the right to engage Roche's independent public
accountant to perform, on behalf of deCODE or its independent public accountant,
an audit, conducted in accordance with generally accepted auditing standards in
the USA, of such Books of Account of Roche, its Affiliates and sublicensees that
are deemed necessary by Roche's independent public accountants to report on
Adjusted Gross Sales and Net Sales of the Roche Products for the period or
periods requested by deCODE. Results of any such examination shall be made
available to both Parties. deCODE or its authorized independent public
accountant shall have the right to review the reports prepared by Roche's
independent public accountant and make inquiries of Roche's independent public
accountant regarding such reports.

         Such audit shall not be performed more frequently than once per
calendar year nor more frequently than once with respect to Books of Account
covering any specific period of time, upon at least thirty (30) working days'
prior written notice, and shall be conducted during regular business hours in
such a manner as to not unnecessarily interfere with Roche's normal business
activities.

         All Books of Account referred to under this Section 9.4(a) shall be
used only for the purpose of verifying royalty statements or compliance with
this Agreement and (ii) shall be treated by deCODE as Confidential Information
under Section 13.

         The failure of deCODE to request verification of any royalty
calculation during the period under Section 9.3 when Books of Account have to be
retained shall be considered acceptance of the accuracy of such reporting.

         In the event that such audit shall indicate that in any calendar year
the royalties which should have been paid by Roche are greater than those which
were

                                      -58-
<PAGE>   64

actually paid by Roche, then Roche shall promptly pay the underpaid amount to
deCODE and, if the royalties which should have been paid by Roche are at least
five percent (5%) greater than those which were actually paid by Roche, then
Roche shall also reimburse deCODE for the reasonable cost of such audit. In the
event that such audit shall indicate that in any calendar year the royalties
which were actually paid by Roche are greater than those which should have been
paid, then, at Roche's option, deCODE shall promptly reimburse to Roche the
overpaid amount or Roche shall deduct the overpaid amount from the next royalty
payment to be paid deCODE.

         (b) By Roche. At Roche's expense, Roche or its authorized independent
public accountant has the right to engage deCODE's independent public accountant
to perform, on behalf of Roche or its independent public accountant, an audit,
conducted in accordance with generally accepted auditing standards in the USA,
of such Books of Account of deCODE, its Affiliates and sublicensees that are
deemed necessary by deCODE's independent public accountants to report on
Adjusted Gross Sales, Net Sales and Sublicensing Income of the deCODE Products
for the period or periods requested by Roche. Results of any such examination
shall be made available to both Parties. Roche or its authorized independent
public accountant shall have the right to review the reports prepared by
deCODE's independent public accountant and make inquiries of deCODE's
independent public accountant regarding such reports.

         Such audit shall not be performed more frequently than once per
calendar year nor more frequently than once with respect to Books of Account
covering any specific period of time, upon at least thirty (30) working days'
prior written notice, and shall be conducted during regular business hours in
such a manner as to not unnecessarily interfere with deCODE's normal business
activities.

         All Books of Account referred to under this Section 9.4(b) shall be
used only for the purpose of verifying royalty statements or compliance with
this Agreement and (ii) shall be treated by Roche as Confidential Information
under Section 13.

         The failure of Roche to request verification of any royalty calculation
during the period under Section 9.3 when Books of Account have to be retained
shall be considered acceptance of the accuracy of such reporting.

         In the event that such audit shall indicate that in any calendar year
the royalties which should have been paid by deCODE are greater than those which
were actually paid by deCODE, then deCODE shall promptly pay the underpaid
amount to Roche and, if the royalties which should have been paid by deCODE are
at least five percent (5%) greater than those which were actually paid by
deCODE, then deCODE shall also reimburse Roche for the reasonable cost of such
audit. In the event that such audit shall indicate that in any calendar year the
royalties which were actually paid by deCODE are greater than those which should
have been paid, then, at deCODE's option,

                                      -59-
<PAGE>   65

Roche shall promptly reimburse to deCODE the overpaid amount or deCODE shall
deduct the overpaid amount from the next royalty payment to be paid Roche.

         9.5 Taxes. All amounts owing to a Party ("owed Party") specified in
this Agreement shall be paid by the other Party ("paying Party") net of all
applicable taxes, fees, and other charges excluding only taxes on the paying
Party's income. In particular, any tax required to be withheld by a paying Party
under the laws of any country for the account of the Owed Party ("Withholding
Taxes"), shall be promptly paid by the paying Party for and on behalf of the
owed Party to the appropriate governmental authority, and the paying Party shall
furnish the owed Party with proof of payment of such tax. Any such tax actually
paid on the owed Party's behalf shall be deducted from royalty payments due the
owed Party. The Paying Party will reasonably assist the owed Party in minimizing
the Withholding Taxes applicable to any payment made by the paying Party and in
claiming tax refund at the owed Party's request.

         9.6 Blocked Currency. In each country where the local currency is
blocked by applicable law and cannot be removed from such country, royalties
accrued in that country shall be paid to the owed Party in such country in local
currency by deposit in a local bank designated by the owed Party.

         9.7 Interest on Late Payments. Any payment under this Agreement that is
not paid on or before the date such payment is due shall bear interest, to the
extent permitted by applicable law, at the [CONFIDENTIAL TREATMENT REQUESTED]
from time to time, or such other index as the Parties may agree in writing,
[CONFIDENTIAL TREATMENT REQUESTED], calculated in the number of days such a
payment is overdue.

         9.8 Mechanism for Adjustment to Royalties. For the first calendar
quarter of each calendar year during the term of this Agreement, a Party shall
be entitled to deduct from the royalties owed to the other Party for that
quarter any reductions, deductions or credits on royalties allowed under this
Agreement during the previous calendar year provided the Party did not otherwise
previously take such reductions or credits. In the event that any reductions,
deductions or credits otherwise allowable to a Party in the last calendar year
during the term of the Agreement have not been fully utilized by such Party upon
the expiration of this Agreement, then the other Party shall reimburse such
Party for the allowable amount.

                                      -60-
<PAGE>   66

         10.  OWNERSHIP; PATENTS.

         10.1 Ownership.

         (a) Technical Information. Except as otherwise provided in this
Agreement, this Agreement does not grant either Party any rights in or to
Technical Information, or any Patents related thereto, owned or controlled by
the other Party.

         (b) Inventions. deCODE shall solely own deCODE Inventions and resulting
Patents. Roche shall solely own Roche Inventions and resulting Patents. The
Parties shall jointly own Joint Inventions and resulting Patents. The
determination of inventorship shall be made in accordance with the patent laws
of the relevant countries of the Territory.

         10.2 Patent Filing, Maintenance and Prosecution Regarding Inventions.

         (a) Disclosure. As soon as a Party concludes that an Invention has been
made, it shall promptly inform the Steering Committee, and provide a summary of
the Invention. Should a Party be faced with a possible loss of rights in a Major
Country, such communication may take place promptly after filing a priority
patent application for the Invention.

         (b) Filing.

         (i) deCODE Inventions and Roche Inventions. For deCODE Inventions and
Roche Inventions, the Party owning the Invention shall have the first right of
election to prepare and file a priority patent application for the Invention, at
its own cost. Should the Party owning the Invention elect not to prepare and/or
file any such patent application, it shall (i) provide the other Party with
written notice as soon as reasonably possible after making such election but in
any event no later than sixty (60) days before the other Party would be faced
with a possible loss of rights in a Major Country, (ii) give the other Party the
right, at the other Party's election and sole expense, to prepare and file the
priority application, and (iii) offer reasonable assistance to the other Party
in connection with such preparation and filing at no cost to the other Party
except for reimbursement of reasonable out-of-pocket expenses incurred by the
Party owning the Invention in rendering such assistance.

         The filing Party shall perform corresponding foreign filings at its own
cost, after having discussed the countries for foreign filings with the
non-filing Party within nine (9) months after the priority filing. Should the
Parties not agree on the countries for foreign filings, either Party will have
the right to file the subject of the priority application in the name of both
Parties in any country of its own choice at its own cost in any country where
the Parties do not agree as to filing.

                                      -61-
<PAGE>   67

         (ii) Joint Inventions. For Joint Inventions, the Parties shall consult
and agree upon (i) which Party shall have the first right of election to
prepare and file a priority patent application for the Joint Invention, in the
name of both Parties, and (ii) sharing of costs.

         The Party having the first right of election may elect to prepare and
file any such patent application at its own cost. Notwithstanding anything to
the contrary, if the Parties agreed to share costs, the non-filing Party shall
reimburse the filing Party in an amount equal to one-half of the reasonable
out-of-pocket expenses incurred by the filing Party in preparing and filing such
patent application, within thirty (30) days after receipt of an itemized invoice
from the filing Party.

         Should the Party having the first right of election elect not to
prepare and/or file any such patent application, it shall (i) provide the other
Party with written notice as soon as reasonably possible after making such
election but in any event no later than sixty (60) days before the other Party
would be faced with a possible loss of rights in a Major Country, (ii) give the
other Party the right, at the other Party's election and sole expense, to
prepare and file the priority application in the name of both Parties, and (iii)
offer reasonable assistance to the other Party in connection with such
preparation and filing at no cost to the other Party except for reimbursement of
reasonable out-of-pocket expenses incurred by the Party owning the Invention in
rendering such assistance.

         The filing Party shall perform corresponding foreign filings, at its
own cost and in the name of both Parties, after having discussed the countries
for foreign filings with the non-filing Party within nine (9) months after the
priority filing. Notwithstanding anything to the contrary, for corresponding
foreign filings filed in agreed upon countries, if the Parties agreed to share
costs, the non-filing Party shall reimburse the filing Party in an amount equal
to one-half of the reasonable out-of-pocket expenses incurred by the filing
Party in preparing and filing such corresponding foreign filings, within thirty
(30) days after receipt of an itemized invoice from the filing Party. Should the
Parties not agree on the countries for foreign filings, either Party will have
the right to file the subject of the priority application in the name of both
Parties in any country of its own choice at its own cost in any country where
the Parties do not agree as to filing.

         (c) Prosecution and Maintenance.

         (i) deCODE Inventions and Roche Inventions. The filing Party shall
prosecute and reasonably maintain applications filed under Section 10.2(b)(i)
and patents resulting therefrom at its own expense. On request of the filing
Party, the non-filing Party will cooperate in all reasonable ways in connection
with the prosecution and maintenance of such applications and patents resulting
therefrom, at the expense of the filing Party for all out-of-pocket expenses
incurred by the non-filing Party as a result of such cooperation. Upon written
request, the filing Party shall inform the non-filing Party

                                      -62-
<PAGE>   68

of the issuance of such patent application, initiation of an appeal of a
rejection of such patent application, or initiation of an interference involving
or an opposition to any such patent application or patent resulting therefrom.
The filing Party shall provide the non-filing Party, upon the non-filing Party's
written request, with copies of substantive communications to and from patent
offices regarding such patent applications and patents resulting therefrom in
sufficient time before the due date for response in order to give the non-filing
Party an opportunity to comment on the content thereof.

         Should the filing Party no longer wish to prosecute and/or maintain any
such patent application or patent resulting therefrom, the filing Party shall
(i) provide the non-filing Party with written notice of its wish no later than
sixty (60) days before the patent or patent application would otherwise become
abandoned, (ii) give the non-filing Party the right, at the non-filing Party's
election and sole expense (subject to the credit set forth below), to prosecute
and/or maintain such patent or patent application, and (iii) offer reasonable
assistance to the non-filing Party in connection with such prosecution and/or
maintenance at no cost to the non-filing Party except for reimbursement of the
filing Party's reasonable out-of-pocket expenses incurred by the filing Party in
rendering such assistance. The non-filing Party shall be entitled to recoup one
hundred percent (100%) of such Party's documented reasonable out-of-pocket
expenses incurred to prosecute and/or maintain such patents and/or patent
applications by taking a credit against any royalty payment otherwise due, as
shown on the Net Sales statement provided under Section 9.1, up to a maximum
credit, when combined with the credit provided pursuant to Section 10.2(c)(ii),
in any given calendar quarter equal to twenty-five percent (25%) of such royalty
payments otherwise due, until such amount has been fully credited.

         (ii) Joint Inventions. The filing Party shall prosecute and reasonably
maintain applications filed under Section 10.2(b)(ii) and patents resulting
therefrom.

         For a given patent application filed under Section 10.2(b)(ii), should
the non-filing Party have had an obligation under Section 10.2(b)(ii) to
reimburse the filing Party in an amount equal to one-half of the reasonable
out-of-pocket expenses incurred by the filing Party in preparing and filing such
patent application, then the non-filing Party shall reimburse the filing Party
in an amount equal to one-half of the reasonable out-of-pocket expenses incurred
by the filing Party in prosecuting and maintaining such application and patents
resulting therefrom, within thirty (30) days after receipt of an itemized
invoice from the filing Party. For a given patent application filed under
Section 10.2(b)(ii), should the non-filing Party have had no obligation under
Section 10.2(b)(ii) to reimburse the filing Party in an amount equal to one-half
of the reasonable out-of-pocket expenses incurred by the filing Party in
preparing and filing such patent application, then the filing Party shall
prosecute and reasonably maintain such application and patents resulting
therefrom at its own cost.

                                      -63-
<PAGE>   69

         On request of the filing Party, the non-filing Party will cooperate in
all reasonable ways in connection with the prosecution and maintenance of such
applications and patents resulting therefrom, at the expense of the filing Party
for all out-of-pocket expenses incurred by the non-filing Party as a result of
such cooperation. Upon written request, the filing Party shall inform the
non-filing Party of the issuance of such patent application, initiation of an
appeal of a rejection of such patent application, or initiation of an
interference involving or an opposition to any such patent application or patent
resulting therefrom. The filing Party shall provide the non-filing Party, upon
the non-filing Party's written request, with copies of substantive
communications to and from patent offices regarding such patent applications and
patents resulting therefrom in sufficient time before the due date for response
in order to give the non-filing Party an opportunity to comment on the content
thereof.

         Should the filing Party no longer wish to prosecute and/or maintain any
such patent application or patent resulting therefrom, the filing Party shall
(i) provide the non-filing Party with written notice of its wish no later than
sixty (60) days before the patent or patent application would otherwise become
abandoned, (ii) give the non-filing Party the right, at the non-filing Party's
election and sole expense (subject to the credit set forth below), to prosecute
and/or maintain such patent or patent application, and (iii) offer reasonable
assistance to the non-filing Party in connection with such prosecution and/or
maintenance at no cost to the non-filing Party except for reimbursement of the
filing Party's reasonable out-of-pocket expenses incurred by the filing Party in
rendering such assistance. The non-filing Party shall be entitled to recoup the
percentage of such Party's documented reasonable out-of-pocket expenses incurred
to prosecute and/or maintain such patents and/or patent applications as the
filing Party had agreed was its share of costs relating thereto pursuant to the
first paragraph of Section 10.2(b)(ii). Such amount shall be recouped by the
non-filing Party by taking a credit against any royalty payment otherwise due,
as shown on the Net Sales statement provided under Section 9.1, up to a maximum
credit, when combined with the credit provided pursuant to Section 10.2(c)(i),
in any given calendar quarter equal to twenty-five percent (25%) of such royalty
payments otherwise due, until such amount has been fully credited.

11.      PATENT ENFORCEMENT AND INFRINGEMENT.

         11.1 Patent Enforcement.

         (a) Notice. Each Party shall promptly provide written notice to the
other Party during the term of this Agreement of any (i) known infringement or
suspected infringement of a Program Patent, (ii) institution by a Third Party of
a proceeding for the purpose of revoking or holding unpatentable, invalid or
unenforceable a claim of a Program Patent, or (ii) unauthorized use or
misappropriation of any Program Know-How by a Third Party of which it becomes
aware.

                                      -64-
<PAGE>   70

         (b) Responsible Party. For Program Patents and Program Know-How solely
owned by a Party, the Party owning such Program Patent or Program Know-How shall
have the first right of election to (i) initiate an infringement suit or (ii)
take such appropriate action as is reasonably required to defend against such
potential revoking or holding unpatentable, invalid or unenforceable a claim of
a Program Patent, or (iii) take such other appropriate action as is required to
restrain or otherwise prevent such known or suspected infringement or
unauthorized use or misappropriation ("Responsible Party"). For Program Patents
and Program Know-How jointly owned by the Parties, within thirty (30) days after
written notice under Section 11.1(a), the Parties shall consult and agree upon
which Party shall be the Responsible Party.

         (c) Initiation of Suit or Action. Within a period of one hundred and
twenty (120) days after the Responsible Party provides or receives written
notice under Section 11.1(a), the Responsible Party, in its sole discretion,
shall decide whether or not to (i) initiate an infringement suit, (ii) take such
appropriate action as is reasonably required to defend against such potential
revoking or holding unpatentable, invalid or unenforceable a claim of a Program
Patent, or (iii) take such other appropriate action as is reasonably required to
restrain or otherwise prevent such known or suspected infringement or
unauthorized use or misappropriation ("Suit or Action", collectively).

         If, within the one hundred and twenty (120) day period, the Responsible
Party advises the other Party of a decision to initiate a Suit or Action, the
Responsible Party, at its own cost, shall promptly initiate such Suit or Action
and provide written notice to the other Party of such initiation.

         In the event that the Responsible Party does not advise the other Party
within the one hundred and twenty (120) day period a decision to initiate such
Suit or Action, or if the Responsible Party advises the other Party within the
one hundred and twenty (120) day period a decision not to initiate such Suit or
Action, the other Party shall thereafter have the right, at its own cost, to
initiate such Suit or Action.

         The Party initiating the Suit or Action ("Initiating Party") shall
provide written notice to the Responsible Party of such initiation. The
Initiating Party shall keep the other Party informed of the status of any such
Suit or Action and, upon the other Party's written request, shall provide the
other Party with copies of all substantive documents filed in, and all
substantive communications relating to such Suit or Action. If necessary, the
other Party shall join as a party to the Suit or Action but shall be under no
obligation to participate except to the extent such participation is required as
the result of being named party to the suit or proceeding. At the Initiating
Party's written request, the other Party shall offer reasonable assistance to
the Initiating Party at no charge except for reimbursement of reasonable
out-of-pocket expenses incurred by the other Party in rendering such assistance.
Reasonable assistance shall include, without limitation, the execution of such
legal papers as are reasonably necessary for the prosecution, settlement or
compromise of such Suit or Action.

                                      -65-
<PAGE>   71

         Each party shall have the right to be represented in any such Suit or
Action by counsel of its own choice at its own expense.

         (d) Recovery. Any recovery obtained by any Party as a result of any
Suit or Action shall be applied first to reimburse each Party for all costs and
expenses related to such Suit or Action, and if after such reimbursement any
funds shall remain from such recovery, such remaining funds shall be allocated
[CONFIDENTIAL TREATMENT REQUESTED] to the Party instituting such Suit or Action,
and [CONFIDENTIAL TREATMENT REQUESTED] to the other Party, but in no event shall
the other Party be entitled to receive more than the amount of royalties such
other Party would have received if the infringing Third Party's sales were
deemed to be Net Sales under this Agreement.

         (e) Settlement. Neither Party shall settle or compromise any such Suit
or Action in a manner which would restrict the scope or enforceability of any
Program Patent or Program Know-How jointly owned by the Parties without the
prior written consent of the other Party, which consent shall not be
unreasonably withheld.

         11.2 Notice of Certification. Notwithstanding anything to the contrary
in Section 11.1, for a Program Patent claiming the making, having made, using,
offering for sale, selling or importing of a Product, should either Party
receive a certification from a Third Party under the "Drug Price Competition and
Patent Term Restoration Act of 1984" (Public Law 98-417), as amended, or its
comparable law in a country other than the USA, then such Party shall
immediately give written notice to the other Party of such certification. The
Responsible Party shall have twenty-one (21) days from the date such Party
received the certification to initiate suit. In the event the twenty-one (21)
day period expires without the Responsible Party having initiated a suit, the
other Party shall have the right, but not the obligation, to immediately bring
suit against the Third Party that filed the certification. If either Party
initiates a suit within the forty-five (45) day period, it will immediately
notify the other Party.

         11.3 Infringement Actions by Third Parties. Each Party shall promptly
notify the other Party in the event that a Third Party at any time provides
written notice to, or commences an action, suit or proceeding against such Party
or such Party's Affiliates or sublicensees accusing infringement of patent
rights or unauthorized use or misappropriation of its technology owned or
controlled by such Third Party, based on an assertion or claim arising out of
(i) Roche's, its Affiliate's or its sublicensees making, having made, using,
offering for sale, selling or importing Roche Products in the Territory under
deCODE Know-How or deCODE Patents, including, without limitation, the making,
having made, or using of Candidate Genes or Validated Targets under deCODE
Patents or deCODE Know-How by Roche, its Affiliates or its Collaborators to
research and/or develop Roche Products; (ii) deCODE's, its Affiliate's or its
sublicensees making, having made, using, offering for sale, selling or importing
deCODE Products in the Territory under Roche Know-How or Roche Patents,
including, without limitation, the making, having made, or using of Candidate
Genes or Validated Targets under Roche Patents

                                      -66-
<PAGE>   72

or Roche Know-How by deCODE, its Affiliates or its Collaborators to research
and/or develop deCODE Products; (iii) either Party's fulfilling its obligations
under any and all Research Programs under this Agreement. The accused Party
shall defend, settle or compromise such action, suit or proceeding at its own
discretion and at its own cost; provided, however, that at the accused Party's
written request, the other Party shall offer reasonable assistance to the
accused Party at no charge except for reimbursement of reasonable out-of-pocket
expenses incurred by the other Party in rendering such assistance. Reasonable
assistance shall include, without limitation, the execution of such legal papers
as are reasonably necessary for the defense, settlement or compromise of such
action, suit or proceeding. Each party shall have the right to be represented in
any such action, suit or proceeding by counsel of its own choice at its own
expense.

12.      INDEMNIFICATION.

         12.1 Research Activities. Each Party agrees to indemnify, defend and
hold the other Party, its Affiliates and its sublicensees, if any, and their
respective directors, officers, employees and agents, harmless from and against
any and all liabilities, damages, losses, or reasonable costs and expenses
(including the reasonable fees of attorneys and other professionals)
(collectively "Claims") arising out of the activities of the indemnifying Party
in the conduct of any Research Program, except to the extent such Claims arose
out of or resulted from the negligence, recklessness or wrongful intentional
acts or omissions of the other Party, its Affiliates, or its sublicensees, if
any, and their respective directors, officers, employees and agents.

         12.2 Product Liability. Each Party shall indemnify, defend and hold the
other Party, its Affiliates and its sublicensees, if any, and their respective
directors, officers, employees and agents, harmless from and against any and all
Claims arising out of the manufacture, use, distribution or sale of any Product
by the indemnifying Party, its Affiliates or its sublicensees due to any
negligence, recklessness or wrongful intentional acts or omissions by, or strict
liability of, the indemnifying Party, its Affiliates or its sublicensees, if
any, and their respective directors, officers, employees and agents, except, in
each case, to the extent such Claims are due to the negligence, recklessness or
wrongful intentional acts or omissions of the other Party, its Affiliates or its
sublicensees, if any, and their respective directors, officers, employees and
agents.

         12.3 Notice. In the event that either Party is seeking indemnification
under Section 12.1 or 12.2, such Party shall inform the indemnifying Party of a
Claim as soon as reasonably practicable after it receives notice of the Claim,
shall permit the indemnifying Party to assume direction and control, at its
expense, of the defense of the Claim (including the sole right to settle the
claim at the sole discretion of the indemnifying Party, provided that such
settlement does not impose any material financial obligation on the indemnified
Party), and shall cooperate as requested (at the expense of the indemnifying
Party) in the defense of the Claim. The indemnified Party may, at

                                      -67-
<PAGE>   73

its option and expense, be represented in the defense of the Claim by counsel of
its own choice.

13.      PUBLICATION; NON-DISCLOSURE.

         13.1 Publication.

         (a) Manuscript. Both Parties recognize that each may wish to publish
the results of their scientific work relating to the Research Programs. However,
both Parties also recognize the importance of acquiring patent protection and of
maintaining Confidential Information as proprietary. Consequently, subject to
any applicable laws or regulations obligating either Party to do otherwise, any
proposed publication or oral presentation by either Party shall comply with this
Section 13.1. At least ninety (90) days before a manuscript is to be submitted
to a publisher, the publishing Party will provide the chairperson and secretary
of the Steering Committee with a copy of the manuscript]. If the publishing
Party wishes to make an oral presentation, it will provide the other Party
("Reviewing Party") with a copy of the abstract (if one is submitted) at least
forty (40) days before it is to be submitted. The publishing Party will also
provide to the Reviewing Party a copy of the text of the presentation, including
all slides, posters, and any other visual aids, at least forty (40) days before
the presentation is made.

         (b) Review of Manuscript. The Reviewing Party in good faith will review
the manuscript, abstract, text or any other material provided under Section
13.1(a) ("Proposed Publication") to determine whether the Proposed Publication
(i) contains an Invention for which the Reviewing Party desires patent
protection or (ii) could reasonably be expected to have a material adverse
effect on the commercial value of any Confidential Information that the
Reviewing Party reasonably wishes to have remain proprietary. The Reviewing
Party will notify (each, a "Withdrawal Notice") the publishing Party within
thirty (30) days of receipt of the Proposed Publication if the Reviewing Party,
in good faith, determines that the Proposed Publication (i) contains an
Invention for which the Reviewing Party desires patent protection or (ii) could
reasonably be expected to have a material adverse effect on the commercial value
of any Confidential Information that the Reviewing Party reasonably wishes to
have remain proprietary.

         (c) Delay or Withdrawal. If the Reviewing Party provides a Withdrawal
Notice that the Proposed Publication (i) contains an Invention for which the
Reviewing Party desires patent protection, the publishing Party shall delay its
publication or presentation for a period of ninety (90) days from the date of
such Withdrawal Notice, extendible upon mutual agreement, to allow for the
filing of a priority patent application claiming the Invention. If the Reviewing
Party provides a Withdrawal Notice that the Proposed Publication could
reasonably be expected to have a material adverse effect on the commercial value
of any Confidential Information that the Reviewing Party reasonably wishes to
have remain proprietary, the Reviewing Party shall recommend

                                      -68-
<PAGE>   74

changes it reasonably believes necessary to preserve the Confidential
Information as proprietary. If the Proposed Publication contains Confidential
Information that was disclosed by the Reviewing Party to the publishing Party
under this Agreement, the publishing Party shall incorporate such recommended
changes. For all other Confidential Information, the Parties will consult in
good faith and agree on mutually acceptable modifications to the Proposed
Publication to avoid disclosure of such Confidential Information.

         13.2 Non-Disclosure and Non-use; Exceptions. During the term of this
Agreement and for five (5) years thereafter, a Receiving Party shall (i) treat
Confidential Information provided by a Disclosing Party under this Agreement as
it would treat its own Confidential Information of a similar nature and take all
reasonable precautions not to disclose such Confidential Information to third
parties except Affiliates or potential sublicensees who agree to be bound by the
same terms and conditions as found in this Section 13, without the Disclosing
Party's prior written authorization and (ii) not use such Confidential
Information for other than fulfilling its obligations under this Agreement. The
provisions of this Section 13.2 shall not apply to such Confidential Information
which the Receiving Party can demonstrate by competent written proof:

         (a) was known or used by the Receiving Party or its Affiliates prior to
the date of disclosure to the Receiving Party or its Affiliates by the
Disclosing Party; or

         (b) either before or after the date of the disclosure to the Receiving
Party or its Affiliates, is lawfully disclosed to the Receiving Party or its
Affiliates by a third party rightfully in possession of such Confidential
Information and not under an obligation of confidentiality to the Disclosing
Party with respect to such Confidential Information; or

         (c) either before or after the date of the disclosure to the Receiving
Party or its Affiliates, becomes published or generally known to the public
through no fault or omission on the part of the Receiving Party or its
Affiliates, but such inapplicability applies only after such Confidential
Information is published or becomes generally known; or

         (d) is independently developed by the Receiving Party or its Affiliates
without reference to or reliance upon Confidential Information of the Disclosing
Party or its Affiliates; or

         (e) is required to be disclosed by the Receiving Party, its Affiliates
or its sublicensees to comply with applicable laws, to defend or prosecute
litigation or to comply with governmental regulations; provided, however, the
Receiving Party, its Affiliate or sublicensee provides prior written notice of
such disclosure to the Disclosing Party or its Affiliates and, to the extent
practicable, takes reasonable and lawful actions to avoid and/or minimize the
degree of such disclosure.

                                      -69-
<PAGE>   75

         13.3 Authorized Disclosure. The provisions of Section 13.2 shall not
prevent either Party from (i) preparing, filing, prosecuting or maintaining
patent applications or patents related to an Invention or a Product, or (ii)
disclosing Confidential Information to persons working on behalf of the
Receiving Party or to governmental agencies, to the extent the Receiving Party
reasonably believes it is required or desirable to secure government approval
for the development or marketing of a Product, or (iii) upon imminent
Registration of a Product in a country, disclosing Confidential Information to
the extent reasonably necessary to promote the use and sale of the Product in
the country.

         13.4 Injunctive Relief. The Parties acknowledge that monetary damages
alone may not adequately compensate the Disclosing Party in the event of a
breach by the Receiving Party of this Section 13, and that, in addition to all
other remedies available to the Disclosing Party at law or in equity, it may be
entitled to injunctive relief for the enforcement of its rights under this
Section 13 and to an accounting of profits made during the period of any breach
of the Receiving Party's obligations under this Section 13.

         13.5 Third Parties. Unless otherwise agreed to in writing, each Party
shall require all Third Parties, including consultants, Collaborators,
subcontractors, sublicensees or agents involved in fulfilling its obligations
under this Agreement, to be bound by the same terms and conditions as found in
this Section 13.

14.      TERM; TERMINATION.

         14.1 Term; Expiration. This Agreement shall commence as of the
Effective Date and, unless sooner - terminated as provided hereunder, shall
expire as follows:

         (a) As to each Roche Product in each country in the Territory, this
Agreement shall expire upon the expiration of the Royalty Term with respect to
such Roche Product in such country.

         (b) As to each deCODE Product in each country in the Territory, this
Agreement shall expire upon the expiration of the Royalty Term with respect to
such deCODE Product in such country.

         (c) This Agreement shall expire in its entirety upon the termination of
the Royalty Term with respect to all Roche Products and all deCODE Products
throughout the Territory.

                                      -70-
<PAGE>   76

         14.2 Effect of Expiration.

         (a) Following expiration of the term of this Agreement with respect to
a Roche Product in a country in the Territory pursuant to Section 14.1(a), Roche
shall have the fully-paid, royalty-free, perpetual right and license to continue
to make, have made, use, offer for sale, sell and import such Roche Product in
such country. Following expiration of the term of this Agreement in its entirety
with respect to all Roche Products pursuant to Section 14.1(c), Roche shall have
the fully-paid, worldwide, royalty-free, perpetual right and license to continue
to make, have made, use, offer for sale, sell and import all Roche Products in
the Territory.

         (b) Following expiration of the term of this Agreement with respect to
a deCODE Product in a country in the Territory pursuant to Section 14.1(b),
deCODE shall have the fully-paid, royalty-free, perpetual right and license to
continue to make, have made, use, offer for sale, sell and import such deCODE
Product in such country. Following expiration of the term of this Agreement in
its entirety with respect to all deCODE Products pursuant to Section 14.1(c),
deCODE shall have the fully-paid, worldwide, royalty-free, perpetual right and
license to continue to make, have made, use, offer for sale, sell and import all
deCODE Products in the Territory.

         14.3 Termination Without Cause. -

         (a) During the Research Term. During the Research Term, subject to
Sections 14.5, 14.6, 14.7 and 14.8, neither Party may terminate this Agreement
for any reason.

         (b) After the Research Term.

         (i) By Roche. Subject to Section 14.8, commencing at the end of the
Research Term, at any time during the term of this Agreement, Roche may, for any
reason, without affecting or altering Roche's other obligations under this
Agreement, terminate all rights and licenses by deCODE to Roche under this
Agreement by giving six (6) month's prior written notice to deCODE. In such
event deCODE shall be entitled to continue to exercise the rights granted to it
under this Agreement. The effective date of such termination shall be the date
six (6) months after Roche provides such written notice to deCODE. After the
effective date of such termination, in no event shall Roche, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any Roche
Product for any Disease.

         (ii) By deCODE. deCODE may, at any time and for any reason, without
affecting or altering deCODE's other obligations under this Agreement, terminate
all rights and licenses by Roche to deCODE under this Agreement with respect to
a Disease by giving six (6) month's prior written notice to Roche. In such event
Roche shall be entitled to continue to exercise the rights granted to it under
this Agreement.

                                      -71-
<PAGE>   77

The effective date of such termination shall be the date six (6) months after
deCODE provides such written notice to Roche. After the effective date of such
termination, in no event shall deCODE, its Affiliates or sublicensees make, have
made, use, offer for sale, sell or import any deCODE Product for any Disease.

         (c) Obligations. Termination of this Agreement by a terminating Party
under Section 14.3(b) shall not release the terminating Party, or its Affiliates
or sublicensees from any obligation to make payments or to pay royalties or the
percentage of Sublicensing Income to the other Party under this Agreement that
accrue prior to the effective date of such termination.

         (d) Inventory. In the event of termination by a Party under Section
14.3(b), the terminating Party, its Affiliates and sublicensees shall have the
right for one (1) year after the effective date of such termination to sell or
otherwise dispose of all Products then in its inventory, and shall pay royalties
and the percentage of Sublicensing Income thereon, in accordance with the
provisions of this Agreement, as though the Agreement had not terminated. After
the first anniversary of the effective date of a termination by a terminating
Party under Section 14.3(b), in no event shall the terminating Party, its
Affiliates or sublicensees sell or otherwise dispose of a Product.

         (e) Effect of Termination Without Cause. Following any such termination
of this Agreement by Roche pursuant to Section 14.3(b)(i): (i) all licenses
granted by deCODE to Roche under Section 7 and any other applicable Section of
this Agreement shall terminate; (ii) at deCODE's request, Roche shall transmit
to deCODE all reports, information and data in the possession or control of
Roche, its Affiliates or its sublicensees relating to Abandoned Products
(provided that Roche has the right to make available such information to deCODE)
within sixty (60) days after the date of such termination; and (iii) at deCODE's
request, Roche shall assign, and shall cause its Affiliates and sublicensees to
assign, to deCODE all regulatory filings and Registrations in the possession or
control of Roche, its Affiliates or its sublicensees as would enable deCODE to
carry on the development and/or marketing of Abandoned Products in the
Territory, within sixty (60) days of such termination.

         Following any such termination of this Agreement by deCODE pursuant to
Section 14.3(b)(ii), all licenses granted by Roche to deCODE under Section 7 and
any other applicable Section of this Agreement shall terminate.

         14.4 Effect of Abandonment.

         (a) Therapeutic Products for a Selected Disease.

         (i) Following a termination of this Agreement by Roche with respect to
all Therapeutic Products for a Selected Disease pursuant to Section 6.3(a)(i)
before obtaining a Validated Target for the Selected Disease, all licenses
granted by

                                      -72-
<PAGE>   78

deCODE to Roche under Section 7 and any other applicable Section of this
Agreement shall terminate with respect to Therapeutic Products for such Selected
Disease. At deCODE's request, within sixty (60) days after the date of such
termination, Roche shall [CONFIDENTIAL TREATMENT REQUESTED].

         (ii) Following a termination of this Agreement by Roche with respect to
all Therapeutic Products for a Selected Disease pursuant to Section 6.3(a)(i)
after obtaining a Validated Target for the Selected Disease and prior to the
first Registration in any Major Country of a Therapeutic Product for the
Selected Disease, all licenses granted by deCODE to Roche under Section 7 and
any other applicable Section of this Agreement shall terminate with respect to
Therapeutic Products for such Selected Disease. In addition, at deCODE's
request, within sixty (60) days after the date of such termination:
[CONFIDENTIAL TREATMENT REQUESTED].

         (iii) Following a termination of this Agreement by Roche with respect
to all Therapeutic Products for a Selected Disease in a given Major Country
pursuant to Section 6.3(a)(ii) after the first Registration in any Major Country
of a Therapeutic Product for the Selected Disease, all licenses granted by
deCODE to Roche under Section 7 and any other applicable Section of this
Agreement shall terminate with respect to Therapeutic Products for such Selected
Disease in the given Major Country. In addition, at deCODE's request, within
sixty (60) days after the date of such termination: [CONFIDENTIAL TREATMENT
REQUESTED].

                                      -73-
<PAGE>   79

         (b) Diagnostic Products for a Selected Disease.

         (i) Following a termination of this Agreement by Roche with respect to
all Diagnostic Products for a Selected Disease pursuant to Section 6.3(b)(i)
prior to the first Registration in any Major Country of a Diagnostic Product for
the Selected Disease, all licenses granted by deCODE to Roche under Section 7
and any other applicable Section of this Agreement shall terminate with respect
to such Diagnostic Products for such Selected Disease. In addition, at deCODE's
request, within sixty (60) days after the date of such termination:
[CONFIDENTIAL TREATMENT REQUESTED].

         (ii) Following a termination of this Agreement by Roche with respect to
all Diagnostic Products for a Selected Disease in a given Major Country pursuant
to Section 6.3(b)(ii) after the first Registration in any Major Country of a
Diagnostic Product for the Selected Disease, all licenses granted by deCODE to
Roche under Section 7 and any other applicable Section of this Agreement shall
terminate with respect to Diagnostic Products for such Selected Disease in the
given Major Country. In addition, at deCODE's request, within sixty (60) days
after the date of such termination: [CONFIDENTIAL TREATMENT REQUESTED].

         (c) Roche Product. Following a termination of this Agreement in a given
country by Roche with respect to a Roche Product pursuant to Section 6.4(c)
after such Roche Product was the subject of a Registration in the given country,
all licenses granted by deCODE to Roche under Section 7 and any other applicable
Section of this Agreement shall terminate with respect to the Roche Product in
the country. In addition, at deCODE's request, within sixty (60) days after the
date of such termination: [CONFIDENTIAL TREATMENT REQUESTED]

                                      -74-
<PAGE>   80

[CONFIDENTIAL TREATMENT REQUESTED]

         14.5 Breach by Roche Other than Under Section 6.2 or 6.4.

         (a) Procedure.

         (i) Failure by Roche to comply with any of its material obligations
contained in this Agreement, other than an obligation under Section 6.2 or 6.4,
shall entitle deCODE to give to Roche written notice ("Default Notice")
specifying the nature of the default and specifically stating that deCODE
intends to terminate this Agreement in the event Roche should fail to cure the
default.

         (ii) Roche shall have a period ("Cure Period") of thirty (30) days
after a Default Notice to cure such default in the case of a payment default,
and ninety (90) days after a Default Notice in the case of all other defaults.
Such ninety (90) day period shall be extended to end one hundred and twenty
(120) days after a Default Notice, or otherwise as the Parties may agree, if
Roche within sixty (60) days after such Default Notice in good faith commences
and diligently continue actions to cure such default.

         (iii) If, after a Cure Period, Roche does not cure the relevant
default, deCODE shall be entitled, without prejudice to any of its other rights
conferred on it by this Agreement, and in addition to any other remedies
available to it by law or in equity, to give a written notice either:

         (1) terminating this Agreement in its entirety; or

         (2) without affecting or altering Roche's other obligations under this
Agreement, terminating all rights licensed by deCODE to Roche under this
Agreement, in which event deCODE shall be entitled to continue to exercise the
rights granted to it under this Agreement.

         (iv) The effective date of any such termination shall be the date that
Roche receives such notice pursuant to the preceding clause.

                                      -75-
<PAGE>   81

         (b) Effect of Such Breach.

         (i) If deCODE terminates this Agreement in its entirety, after the
effective date of termination, in no event shall either Party, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any Product
for any Disease.

         (ii) If deCODE, without affecting or altering Roche's other obligations
under this Agreement, terminates all rights licensed by deCODE to Roche under
this Agreement (in which event deCODE shall be entitled to continue to exercise
the rights granted to it under this Agreement), then after the effective date of
such termination in no event shall Roche, its Affiliates or sublicensees make,
have made, use, offer for sale, sell or import any Roche Product for any
Disease. In addition, as to any Selected Disease for which a Validated Target
has been obtained, at deCODE's request, within sixty (60) days after the
effective date of such termination: [CONFIDENTIAL TREATMENT REQUESTED].

         14.6 Breach of Efforts Obligation by Roche.

         (a) Therapeutic Efforts for a Disease.

         (i) If it is agreed by the Parties, or if it is resolved in accordance
with Section 16.13, that Roche, within the Evidence Period provided for in
Section 6.2(a)(i), has not [CONFIDENTIAL TREATMENT REQUESTED].

         In addition, at deCODE's request, within sixty (60) days after the
effective date of such termination: [CONFIDENTIAL TREATMENT REQUESTED]

                                      -76-
<PAGE>   82

[CONFIDENTIAL TREATMENT REQUESTED]

         (ii) If it is agreed by the Parties, or if it is resolved in accordance
with Section 16.13, that Roche, within the Evidence Period provided for in
Section 6.2(a)(ii), has not [CONFIDENTIAL TREATMENT REQUESTED].

         In addition, at deCODE's request, within sixty (60) days after the
effective date of such termination: [CONFIDENTIAL TREATMENT REQUESTED].

         (b) Diagnostic Products for a Disease.

         (i) If it is agreed by the Parties, or if it is resolved in accordance
with Section 16.13, that Roche, within the Evidence Period provided for in
Section 6.2(b)(i), has not [CONFIDENTIAL TREATMENT REQUESTED]

                                      -77-
<PAGE>   83

[CONFIDENTIAL TREATMENT REQUESTED].

         In addition, at deCODE's request, within sixty (60) days after the
effective date of such termination: [CONFIDENTIAL TREATMENT REQUESTED]

         (ii) If it is agreed by the Parties, or if it is resolved in accordance
with Section 16.13, that Roche, within the Evidence Period provided for in
Section 6.2(b)(ii), has not [CONFIDENTIAL TREATMENT REQUESTED].

         In addition, at deCODE's request, within sixty (60) days after the
effective date of such termination: [CONFIDENTIAL TREATMENT REQUESTED]

                                      -78-
<PAGE>   84

         14.7 No Sales After Registration.

         (a) If it is agreed by the Parties, or if it is resolved in accordance
with Section 16.13, that Roche, within the Evidence Period provided for in
Section 6.4(b), has not [CONFIDENTIAL TREATMENT REQUESTED].

         (b) In addition, at deCODE's request, within sixty (60) days after the
date of such termination: [CONFIDENTIAL TREATMENT REQUESTED].

         14.8 Breach by deCODE.

         (a) Procedure.

         (i) Failure by deCODE to comply with any of its material obligations
contained in this Agreement, shall entitle Roche to give to deCODE written
notice ("Default Notice") specifying the nature of the default and specifically
stating that Roche intends to terminate this Agreement in the event deCODE
should fail to cure the default.

         (ii) deCODE shall have a period ("Cure Period") of thirty (30) days
after a Default Notice to cure such default in the case of a payment default,
and ninety (90) days after a Default Notice in the case of all other defaults.
Such ninety (90) day period shall be extended to end one hundred and twenty
(120) days after a Default Notice, or otherwise as the Parties may agree, if
deCODE within sixty (60) days after

                                      -79-
<PAGE>   85

such Default Notice in good faith commences and diligently continue actions to
cure such default.

         (iii) If, after a Cure Period, deCODE does not cure the relevant
default, Roche shall be entitled, without prejudice to any of its other rights
conferred on it by this Agreement, and in addition to any other remedies
available to it by law or in equity, to give a written notice either:

         (1) terminating this Agreement in its entirety; or

         (2) without affecting or altering deCODE's other obligations under this
Agreement, terminating all rights licensed by Roche to deCODE under this
Agreement in whole, in which event Roche shall be entitled to continue to
exercise the rights granted to it under this Agreement.

         (iv) The effective date of termination shall be the date that deCODE
receives such notice pursuant to the preceding clause.

         (b) Effect of Such Breach.

         (i) If Roche terminates this Agreement in its entirety, after the
effective date of termination, in no event shall either Party, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any Product
for any Disease.

         (ii) If Roche, without affecting or altering deCODE's other obligations
under this Agreement, terminates all rights licensed by Roche to deCODE under
this Agreement in whole (in which event Roche shall be entitled to continue to
exercise the rights granted to it under this Agreement), after the effective
date of such termination in no event shall deCODE, its Affiliates or
sublicensees make, have made, use, offer for sale, sell or import any deCODE
Product for any Disease.

         14.9 Obligations. In no event shall a termination under Section 5.2(d),
Section 6 or under this Section 14 release a Party or its Affiliates or
sublicensees from any obligation to make payments or to pay royalties or a
percentage of Sublicensing Income to the other Party under this Agreement that
accrued prior to the effective date of termination.

         14.10 Termination of Sublicenses. Upon any termination by Roche under
Section 5.2, 6.3(a), 6.3(b), 6.4(c) or 14.3(b)(i), or by deCODE under Section
14.6(a), 14.6(b), 14.7 or 14.5(a)(iii), all sublicenses granted by Roche under
this Agreement with respect to the rights and license being terminated shall
terminate simultaneously, subject, nevertheless, in the case of termination by
Roche under Section 14.3(b)(i), to Section 14.3(d). Upon any termination by
deCODE under Section 14.3(b)(ii) or by Roche under Section 14.8, all sublicenses
granted by deCODE under this Agreement with respect to

                                      -80-
<PAGE>   86

the rights and license being terminated shall terminate simultaneously, subject,
nevertheless, in the case of termination by deCODE under Section 14.3(b)(ii), to
Section 14.3(d).

         14.11 Surviving Obligations. Termination of this Agreement in its
entirety or expiration of this Agreement shall not terminate the Parties' rights
and obligations under Sections 5.6, 5.7(a)(v), 5.7(a)(vi), 5.8, 5.11(b), 9, 11
(only to the extent that a Suit or Action has been commenced prior to the date
of such termination or expiration), 12, 13.2, 13.3, 13.5, 14, 16.3, 16.4, 16.6,
16.12 and 16.13 which shall survive termination or expiration hereof, as well as
any other provision intended by the Parties to survive any such termination or
expiration hereof.

         14.12 No Waiver. The right of deCODE to terminate under Section 14.5,
Section 14.6 or Section 14.7 and of Roche to terminate under Section 14.8, shall
not be affected in any way by a waiver or failure to take action with respect to
any previous default. An election of remedy by a Party for a material breach of
this Agreement under this Section on one occasion shall not constitute a waiver
as to any other remedy that may be available to such Party under this Section 14
as to any material breach on another occasion.

         14.13 Dispute. And any dispute concerning whether a Party is in default
under the terms of this Agreement shall be referred for resolution in accordance
with Section 16.13. The effectiveness of any notice given pursuant to this
Section shall be tolled during and until such resolution of such dispute.

         15.  FORCE MAJEURE.

         15.1 Events of Force Majeure. Neither Party shall be held liable or
responsible to the other Party nor be deemed to be in default under or in breach
of any provision of this Agreement for failure or delay in fulfilling or
performing any obligation of this Agreement when such failure or delay is due to
force majeure, and without the fault or negligence of the Party so failing or
delaying. For purposes of this Agreement, force majeure is defined as causes
beyond the control of the Party, including, without limitation, acts of God;
acts, regulations, or laws of any government; war; civil commotion; destruction
of production facilities or materials by fire, flood, earthquake, explosion or
storm; labor disturbances; epidemic; and failure of public utilities or common
carriers. In such event Roche or deCODE, as the case may be, shall immediately
notify the other Party of such inability and of the period for which such
inability is expected to continue. The Party giving such notice shall thereupon
be excused from such of its obligations under this Agreement as it is thereby
disabled from performing for so long as it is so disabled and the thirty (30)
days thereafter. The disabled Party shall also give notice immediately upon the
termination of the force majeure. To the extent possible, each Party shall use
reasonable efforts to minimize the duration of any force majeure.

                                      -81-
<PAGE>   87

         16.  MISCELLANEOUS.

         16.1 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. Each Party's performance under this
Agreement is that of a separate entity.

         16.2 Assignment. Neither Party shall be entitled to assign its rights
hereunder without the express written consent of the other Party hereto, except
that both Roche and deCODE may otherwise assign their respective rights and
transfer their respective duties hereunder to any assignee of all or
substantially all of their respective businesses (or that portion thereof to
which this Agreement relates) or in the event of their respective merger or
consolidation or similar transaction. No assignment and transfer shall be valid
or effective unless and until the assignee/transferee shall agree in writing to
be bound by the provisions of this Agreement. Notwithstanding anything to the
contrary, during the Research Term, in no event shall deCODE be entitled to
assign its rights hereunder without the express written consent of Roche.
Notwithstanding anything to the contrary, without notice to the other Party,
either Party may at any time and for any reason assign all or certain rights and
obligations to its Affiliates who agree to be bound by the terms and conditions
of this Agreement; provided that such Party shall remain liable for all
obligations assigned to its Affiliates.

         16.3 Disclaimer of Warranties. THE PARTIES EXPRESSLY DISCLAIM ALL
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD
PARTY RIGHTS, UNLESS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT.

         16.4 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

         16.5 Notice. Any notice or request required or permitted to be given
under or in connection with this Agreement shall be deemed to have been
sufficiently given if in writing and personally delivered or sent by certified
mail (return receipt requested), or overnight express courier service (signature
required), prepaid, to the Party for which such notice is intended, at the
address set forth for such Party below:

                                      -82-
<PAGE>   88

                  (a)      In the case of Roche, to:

                           F.Hoffmann-La Roche Ltd
                           Grenzacherstrasse 124
                           CH-4070 Basel
                           Switzerland
                           Attention: Corporate Law

                           and to:

                           Hoffmann-La Roche Inc.
                           340 Kingsland Street
                           Nutley, New Jersey 07110
                           Attention:  Corporate Secretary

                  (b)      In the case of deCODE, to:

                           deCODE genetics, Inc.
                           Lynghalsi 1
                           IS-110 Reykjavik
                           ICELAND
                           Attention:  President

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. If delivered personally, the date of
delivery shall be deemed to be the date on which such notice or request was
given, unless otherwise set forth in this Agreement. If sent by overnight
express courier service, the date of delivery shall be deemed to be the next
business day after such notice or request was deposited with such service,
unless otherwise set forth in this Agreement. If sent by certified mail, the
date of delivery shall be deemed to be the third business day after such notice
or request was deposited with the U.S. Postal Service, or the foreign equivalent
thereto, unless otherwise set forth in this Agreement.

         16.6 Use of Name. Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party for any purpose, without the prior written consent of the other Party.

         16.7 Public Announcements.

         (a) Disclosure of Agreement and Press Release. Except as required by
law (including, without limitation, disclosure requirements of the U.S.
Securities and Exchange Commission, Nasdaq or any other stock exchange on which
securities issued

                                      -83-
<PAGE>   89

by deCODE are traded) and as permitted by Section 13.1, neither Party shall make
any public announcement concerning this Agreement, the Equity Agreement, or the
subject matter hereof or thereof, without the prior written consent of the other
Party, which shall not be unreasonably withheld. It shall not be unreasonable
for a Party to withhold consent with respect to any public announcement
containing any Confidential Information of such Party or the financial terms of
this Agreement. In the event of a required public announcement, the Party making
such announcement shall provide the other Party with a copy of the proposed text
prior to such announcement sufficiently in advance of the scheduled release of
such announcement to afford such other Party a reasonable opportunity to review
and comment upon the proposed text, which comment shall be incorporated unless
prohibited by law, as determined by counsel to the Party required to make such
public announcements. The Parties agree that each may make an initial public
announcement consistent with the form of announcement contained as Exhibit E.

         (b) Exceptions. Nothing in Section 13 or Section 16.7 shall prevent
deCODE in connection with efforts to secure financing at any time during the
term of this Agreement, from issuing statements as to achievements made or the
status of the work being done by the Parties under this Agreement
("Statements"), so long as such Statements do not jeopardize the ability to
obtain patent protection on Inventions or disclose Confidential Information;
provided (except in the case of a public offering) the recipients of such
Statements agree in writing to maintain such Statements in confidence.

         Nothing in Section 13 or Section 16.7 shall prevent deCODE from issuing
Statements necessary to comply with applicable law (including the disclosure
requirements of the U.S. Securities and Exchange Commission, Nasdaq or any other
stock exchange on which securities issued by deCODE are traded); provided that
deCODE shall provide Roche with a copy of the proposed text of such Statements
sufficiently in advance of the scheduled release thereof to afford Roche a
reasonable opportunity to review and comment upon the proposed text and discuss
any disagreements thereon.

         16.8 Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.

         16.9 Compliance with Law. Nothing in this Agreement shall be deemed to
permit a Party to export, reexport or otherwise transfer any Technical
Information or Product under this Agreement without compliance with applicable
laws.

         16.10 Severability. When possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any

                                      -84-
<PAGE>   90

provision of this Agreement is held to be prohibited by or invalid under
applicable law, such provision will be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement.

         16.11 Amendment. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

         16.12 Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of Delaware.

         16.13 Arbitration.

         (a) Escalation. In the event the Parties are unable to resolve any
dispute, controversy or claim arising out of this Agreement, or the breach,
termination or invalidity thereof ("Dispute"), the Parties shall refer such
Dispute for further review and resolution to the Executive Officers of each
Party. The Executive Officers of each Party shall use reasonable efforts to
resolve the matter within thirty (30) days after the matter is referred to them.

         (b) Binding Arbitration. If the Executive Officers cannot resolve the
Dispute within thirty (30) days, then such Dispute shall be settled by final and
binding arbitration pursuant to the then current commercial arbitration rules of
the American Arbitration Association ("AAA") as provided below:

         (i) The Arbitration Tribunal shall consist of three (3) arbitrators.
Each Party shall nominate in the request for arbitration and the answer thereto
one (1) arbitrator and the two (2) arbitrators so named will then jointly
appoint the third arbitrator as chairman of the Arbitration Tribunal. If one
Party fails to nominate its arbitrator or, if the Party's arbitrators cannot
agree on the person to be named as chairman within sixty (60) days, the AAA
shall make the necessary appointments of arbitrator or chairman.

         (ii) The place of arbitration shall be in New York, New York and the
arbitration proceedings shall be held in English.

         (iii) The award of the Arbitration Tribunal shall be final and judgment
upon such an award may be entered in any competent court or application may be
made to any competent court for juridical acceptance of such an award and order
of enforcement.

         (c) Injunctive Relief. Section 16.13(b) shall not prohibit a Party from
seeking - injunctive relief from a court of competent jurisdiction in the event
of a breach

                                      -85-
<PAGE>   91

or prospective breach of this Agreement by the other Party which would cause
irreparable harm to the first Party.

         16.14 Entire Agreement. This Agreement, together with the Exhibits,
which are attached hereto and made a part hereof, sets forth the entire
agreement and understanding between the Parties as to the subject matter hereof
and merges all prior discussions and negotiations between them, and neither of
the Parties shall be bound by any conditions, definitions, warranties,
understandings or representations with respect to such subject matter other than
as provided herein or as duly set forth on or subsequent to the date hereof in
writing and signed by a proper and duly authorized officer or representative of
the Party to be bound thereby.

         16.15    Parties in Interest and Bankruptcy.

         (a) All the terms and provisions of this Agreement shall be binding
upon, inure to the benefit of and be enforceable by the Parties hereto and their
respective permitted successors and assigns under Section 16.2.

         (b) Notwithstanding anything to the contrary, in the event that either
Party shall become insolvent, shall make an assignment to the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it
(which, in the case of an involuntary petition, is not dismissed or stayed
within sixty (60) days after such petition is filed) ("Bankrupt Party"), the
other Party shall have the right to terminate this entire Agreement immediately
upon written notice of such termination and the provisions of Section 14.5 or
Section 14.8, as the case may be, shall apply. All rights and licenses granted
by the Bankrupt Party under this Agreement are, and shall otherwise be deemed to
be, for purposes of Section 365(n) of Title 11, US Code (the "Bankruptcy Code"),
licenses of rights to "intellectual property" as defined under Section 101(60)
of the Bankruptcy Code. Unless the other Party elects to terminate this
Agreement under this Section 16.15(b), the Parties agree that the other Party,
as a licensee of such rights under this Agreement, shall retain and may fully
exercise all of its rights and elections under the Bankruptcy Code, subject to
the continued fulfillment of its obligations under this Agreement.

         16.16 Descriptive Headings. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

         16.17 Counterparts. This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of
more than one Party but all such counterparts taken together shall constitute
one and the same agreement.

                                      -86-
<PAGE>   92

         16.18 Interpretation. All defined terms used in this Agreement shall
have the meaning assigned to such term under this Agreement whether used in the
singular or plural.

                                      -87-
<PAGE>   93

IN WITNESS WHEREOF Hoffmann-La Roche Inc., F.Hoffmann-LaRoche Ltd, and deCODE
genetics, Inc. have caused this Agreement to be duly executed by their
authorized representatives on the dates written below.

HOFFMAN-LA ROCHE INC.
By: /s/ Dennis Y. Loh
Name: Dennis Y. Loh
Title: Vice President
Date: Jan. 23, 1998

F.HOFFMANN-LA ROCHE LTD
By:/s/ R. Schaffner                     By: /s/ Jonathan K.C. Knowles
Name: R. Schaffner                      Name: Jonathan K.C. Knowles
Title:Head of Pharma Licensing          Title: President of Global Research
Date: Jan. 23, 1998                     Date: Feb 2, 1998

DECODE GENETICS, INC.
By:/s/ Kari Stefansson
Name: Kari Stefansson
Title: President
Date:

                                      -88-
<PAGE>   94

                                    EXHIBIT A

                                PRIMARY DISEASES

                       [CONFIDENTIAL TREATMENT REQUESTED]

                                      -89-
<PAGE>   95

                                    EXHIBIT B

                               SECONDARY DISEASES

[CONFIDENTIAL TREATMENT REQUESTED]

                                      -90-
<PAGE>   96

                                    EXHIBIT C

              ENGLISH LANGUAGE TRANSLATION OF INFORMED CONSENT FORM

                                      -91-
<PAGE>   97

                             DECLARATION OF CONSENT

         TO PARTICIPATE IN A STUDY OF THE HEREDITY OF XXXXX

I, the undersigned, having agreed to participate in this study, have been
apprised of the following:

1. The study involves research into the heredity of XXXXX in Icelandic families
for the purpose of isolating and identifying the genetic factors that contribute
to the disorder. The study has been approved by the Data Protection Commission
and the Ethics Committee. I understand that I may unconditionally decline to
participate or withdraw from participation in this study at any time.

2. I agree to be interviewed and respond to questions regarding this disorder so
that the condition may be diagnosed as accurately as possible.

3. 50 ml of blood will be drawn from a vein in order to isolate its genetic
components (deoxyribonucleic acid, DNA). Apart from the minor discomfort
associated with normal blood tests, there is little risk of adverse effects
beyond the possibility of bleeding, bruising and infection at the site of the
puncture.

4. May name and identification number will be recorded in a computer and used to
investigate my relation to other individuals who have been diagnosed with XXXXX.
This study will be performed by comparing the data with computerized
genealogical records with the authorization of the Data Protection Commission.
The computer records will also be used in processing the data and results of the
study.

5. Examination of the genetic specimens or mislabeling of tubes may result in
indication of erroneous paternity. Any such specimens will be designated as
mislabeled tubes, and the parties responsible for the study declare that they
will not seek further information regarding the specimen.

6. Conclusions of studies may be published in medical journals. Such
publications will contain no references to individuals or persons, and will
refer exclusively to numerical and coded data.

7. The parties conducting the study have undertaken to hold in confidence any
information provided by me and will to the best of their ability endeavor to
limit the distribution of personal information. Thus, no personal identification
will be used on specimens or documents; instead, bar codes will be used which
can only be deciphered using a specific key and the required equipment. It will
not be possible to gain access to any information regarding conclusions on an
individual basis.

8. The study is conducted by and in co-operation between XXXXX and deCODE
genetics, which is a company specializing in the study of genetic disorders.

9. I consent to the biological material and data collected on me being preserved
in encoded form so that both may be used later for research on other disorders
than those specified above, provided that such research is conducted for the
purpose of discovering mechanisms which could lead to a cure or preventive
measures. All handling of specimens and information shall conform to all the
rules on security and handling of data laid out herein and all research is
subject to the approval of the Data Protection Commission and the Ethics
Committee, otherwise, the keys enabling the data or specimens to be traced to me
shall be destroyed and the Data Protection Commission informed of the
destruction.

                                      -92-

<PAGE>   98

10. Our participation in this study will contribute to increase knowledge of the
genetics of XXXXX and could be useful in treatment or prevention. Financial
costs and work contribution in the study are paid for by the parties involved in
the study, and the results of the study will be based on a group of participants
as whole and not on individuals. I therefore renounce all claims to any
potential profits or economic gain resulting from this research. In the event
that the results can be sold, benefits will accrue to further research of this
disorder. XXXXX, or other disorders where heredity is a contributing factor.

----------------------------------------        -------------------------------
Signature of participant/custodian, date        Signature of person responsible
                                                for the study, date.

                                      -93-
<PAGE>   99

                                    EXHIBIT D

                           INITIAL STEERING COMMITTEE

Initial Steering Committee Members from Roche:
[CONFIDENTIAL TREATMENT REQUESTED]

Initial Steering Committee Members from deCODE:
         Dr. Kari Stefansson
         Dr. Jeffrey Gulcher
         Dr. C. Augustine Kong

Initial Steering Committee Chairperson
         Dr. Kari Stefansson

Initial Steering Committee Secretary
         [CONFIDENTIAL TREATMENT REQUESTED]

                                      -94-

<PAGE>   100
                                    EXHIBIT E

                           FORM OF PUBLIC ANNOUNCEMENT

                                   (Omitted)

                                      -95-<PAGE>   1
                                                                   EXHIBIT 10.12

                              AMENDED AND RESTATED

                            INVESTOR RIGHTS AGREEMENT

                                       OF

                              DECODE GENETICS, INC.

              AS FURTHER AMENDED AND RESTATED THROUGH MARCH 1, 2000

<PAGE>   2

                                TABLE OF CONTENTS
<TABLE>
<CAPTION>
<S>                                                                                                              <C>

                                                                                                               Page
1.       DEFINITIONS..............................................................................................2

2.       RESTRICTIONS ON TRANSFER; REGISTRATION...................................................................4
         2.1         Restriction on Transfer......................................................................4
         2.2         Demand Registration..........................................................................5
         2.3         Piggyback Registrations......................................................................7
         2.4         Form S-3 Registration........................................................................8
         2.5         Series C Investor Registration Rights........................................................9
         2.6         Expenses of Registration....................................................................10
         2.7         Obligation of the Company...................................................................10
         2.8         Termination of Registration Rights..........................................................12
         2.9         Delay of Registration; Furnishing Information...............................................12
         2.10        Indemnification.............................................................................12
         2.11        Assignment of Registration Rights...........................................................14
         2.12        Acceptance of Registration Rights...........................................................14
         2.13        Limitation on Subsequent Registration Rights................................................15
         2.14        "Market Standoff" Agreement.................................................................15
         2.15        Rule 144 Reporting..........................................................................15

3.       COVENANTS OF THE COMPANY................................................................................16
         3.1         Basic Financial Information and Reporting...................................................16
         3.2         Inspection Rights...........................................................................17
         3.3         Confidentiality of Records..................................................................17
         3.4         Reservation of Common Stock.................................................................17
         3.5         Key Man Insurance...........................................................................17
         3.6         Visitation Observer Rights..................................................................17
         3.7         Proprietary Information and Inventions Agreement............................................18
         3.8         Directors' Liability and Indemnification....................................................18
         3.9         Real Property Holding Corporation...........................................................18
         3.10        Additional Major Investor...................................................................19
         3.11        Termination of Covenants....................................................................19

4.       RIGHTS OF FIRST REFUSAL.................................................................................19
         4.1         Roche Right of First Refusal................................................................19
         4.2         Investor Rights of First Refusal............................................................20
         4.3         Termination of Rights.......................................................................21
         4.4         Reserved....................................................................................21
         4.5         Excluded Securities.........................................................................21
         4.6         Reserved....................................................................................22
</TABLE>

                                       (i)
<PAGE>   3

<TABLE>
<CAPTION>
<S>                                                                                                             <C>
5.       MISCELLANEOUS...........................................................................................22
         5.1         Governing Law...............................................................................22
         5.2         Future Employees............................................................................22
         5.3         Survival....................................................................................22
         5.4         Successors and Assigns......................................................................22
         5.5         Severability................................................................................22
         5.6         Amendment and Waiver........................................................................23
         5.7         Delays or Omissions.........................................................................24
         5.8         Notices.....................................................................................24
         5.9         Titles and Subtitles........................................................................24
         5.10        Counterparts................................................................................24

</TABLE>
                                      (ii)
<PAGE>   4

                         TABLE OF CONTENTS (continued)

                                                                            Page
                                    EXHIBITS

EXHIBIT A                     Series A Investors

EXHIBIT B                     Series B Investors

EXHIBIT C                     Series C Investors

EXHIBIT D                     Investor Founders

EXHIBIT E                     Form of Director Indemnification Contract

                                     (iii)
<PAGE>   5

                              DECODE GENETICS, INC.

                 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

         THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this "Agreement")
dated as of February 2, 1998, by and among deCODE genetics, Inc., a Delaware
corporation with offices at Lynghalsi 1, IS-110 Reykjavik, Iceland (the
"Company"), the investors listed on Exhibit A attached, as amended from time to
time (the "Series A Investors"), the investors listed on Exhibit B attached, as
amended from time to time (the "Series B Investors"), the investor listed on
Exhibit C attached, as amended from time to time (the "Series C Investor"), and,
solely for those provisions specifically provided in this Agreement, Kari
Stefansson and Jeffrey Gulcher, as listed on Exhibit D attached (the "Investor
Founders"). The Series A Investors, the Series B Investors and the Series C
Investor are collectively referred to as the "Investors" and each individually
as an "Investor."

                             PRELIMINARY STATEMENTS

         A. Certain of the Series A Investors purchased 11,790,375 shares of
Series A Preferred Stock, $.001 par value per share, of the Company (the "Series
A Preferred Stock") and warrants (the "Series A Warrants") to purchase 1,137,814
shares of Series A Preferred Stock (the "Series A Warrant Shares") pursuant to
that certain Series A Preferred Stock and Warrant Purchase Agreement among the
Series A Investors and the Company dated as of August 23, 1996 (the "Series A
Purchase Agreement"). A certain other Series A Investor purchased 100,000 shares
of Series A Preferred Stock, and is obligated to acquire up to an additional
300,000 shares of Series A Preferred Stock, pursuant to that certain Settlement
Agreement between such Series A Investor and the Company dated as of December
31, 1997 (the "Settlement Agreement").

         B. The Company contemplates that it will issue and sell to the Series B
Investors, as initially determined at such time, up to 5,000,000 shares of
Series B Preferred Stock, $.001 par value per share, of the Company (the "Series
B Preferred Stock") pursuant to a Series B Preferred Stock Purchase Agreement
among the Series B Investors and the Company (the "Series B Purchase
Agreement"), on terms and conditions including the terms and conditions relating
to the Series B Preferred Stock contained in this Agreement.

         C. The Series C Investor has on this date: (i) purchased 2,500,000
shares of Series C Preferred Stock, $.001 par value per share, of the Company
(the "Series C Preferred Stock"), (ii) purchased warrants (the "Initial
Warrants") to purchase up to 250,000 shares of Series C Preferred Stock (the
"Initial Warrant Shares"), (iii) made a commitment to purchase an additional
1,111,111 shares of Series C Preferred Stock upon the achievement of certain
milestones, (iv) obtained a three-year option to purchase an additional 555,556
shares of Series C Preferred Stock, and (v) acquired the right to purchase
warrants (the "Subsequent Warrants") (the Initial Warrants and the Subsequent
Warrants collectively, the "Series C Warrants") to purchase an aggregate of
166,667 shares of Series C Preferred Stock (the "Subsequent Warrant Shares")
(the Initial Warrant Shares and the Subsequent Warrant Shares, the "Series C
Warrant Shares"), pursuant to that certain Series C Preferred Stock

<PAGE>   6

and Warrant Purchase Agreement of even date herewith between the Series C
Investor and the Company (the "Series C Purchase Agreement").

         D. The Series A Investors are parties to that certain Amended and
Restated Investor Rights Agreement dated as of January 20, 1998 with the Company
(the "Existing Investor Rights Agreement").

         E. In order to induce the Series C Investor to enter into and
consummate the transactions contemplated under the Series C Purchase Agreement,
the Company and the Series A Investors have agreed to amend and restate the
Existing Investor Rights Agreement to include the granting of certain rights to
the Series B Investors and the Series C Investor, as set forth in this
Agreement.

         NOW, THEREFORE, in consideration of foregoing statements and the mutual
covenants and agreements of the Parties contained in this Agreement, the Series
A Purchase Agreement, the Settlement Agreement and the Series C Purchase
Agreement, and to be contained in the Series B Purchase Agreement, the parties
mutually agree as follows:

1.       DEFINITIONS.

         As used in this Agreement the following terms shall have the following
respective meanings:

         1.1 "Common Stock" means the Common Stock, $.001 par value per share,
of the Company.

         1.2 "Equity Securities" shall mean (i) any Common Stock, Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or other
security of the Company, (ii) any security convertible, with or without
consideration, into any Common Stock, Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock or other security (including any
option to purchase such a convertible security), (iii) any security carrying any
warrant or right to subscribe to or purchase any Common Stock, Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or other
security or (iv) any such warrant or right (including, without limitation, the
Series A Warrants and the Series C Warrants).

         1.3 "Exchange Act" means the United States Securities Exchange Act of
1934, as amended.

         1.4 "Founders Shares" shall mean the Common Stock issued to the
Investor Founders from time to time.

         1.5 "Holder" means any person owning of record Shares or Registrable
Securities that have not been sold to the public or any assignee of record of
such Registrable Securities in accordance with Section 2.11.

         1.6 "Initial Offering" means the Company's first firm commitment
underwritten public offering of its Common Stock registered under the Securities
Act.

                                      -2-
<PAGE>   7

         1.7 "Major Investor" means any Investor (with its affiliates) who owns
not less than two percent (2%) of the Company's outstanding Common Stock
(treating all shares of Series A Preferred Stock, Series B Preferred Stock and
Series C Preferred Stock on an as-converted-to-Common Stock basis).

         1.8 "Register," "registered," and "registration" refer to a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act, and the declaration or ordering of
effectiveness of such registration statement or document.

         1.9 "Registrable Securities" means (i) Common Stock issued or issuable
upon conversion of the Shares; and (ii) any Common Stock issued as (or issuable
upon the conversion or exercise of any warrants, right or other security which
is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the Common Stock described in clause (i).
Notwithstanding the foregoing, Registrable Securities shall not include: (1) any
Common Stock not issued or issuable to Holders of Series A Preferred Stock,
Series B Preferred Stock and/or Series C Preferred Stock, except as specifically
provided in Section 2.3(d), or (2) any securities sold by a person to the public
either pursuant to a registration statement or Rule 144 promulgated under the
Securities Act or sold in a private transaction in which the transferror's
rights under Section 2 of this Agreement are not assigned.

         1.10 "Registrable Securities then outstanding" shall be the number of
shares determined by calculating the total number of shares of the Company's
Common Stock that are Registrable Securities and either (i) are then issued and
outstanding, or (ii) are issuable pursuant to then exercisable or convertible
securities.

         1.11 "Registration Expenses" shall mean all expenses incurred by the
Company in complying with Sections 2.2, 2.3, 2.4 and 2.5, including, without
limitation, all registration and filing fees, printing expenses, fees and
disbursements of counsel for the Company, reasonable fees and disbursements not
to exceed Fifteen Thousand Dollars ($15,000) of a single special counsel for the
Holders, blue sky fees and expenses and the expense of any special audits
incident to or required by any such registration (but excluding the compensation
of regular employees of the Company which shall be paid in any event by the
Company).

         1.12 "Securities Act" shall mean the United States Securities Act of
1933, as amended.

         1.13 "Selling Expenses" shall mean all underwriting discounts and
selling commissions applicable to the sale.

         1.14 "Shares" shall mean: (i) the Series A Preferred Stock issued
pursuant to the Series A Purchase Agreement, including the Series A Warrant
Shares issued upon exercise of the Series A Warrants issued pursuant to the
Series A Purchase Agreement, and the Series A Preferred Stock issued pursuant to
the Settlement Agreement; (ii) the Series B Preferred Stock issued pursuant to
the Series B Purchase Agreement; and (iii) the Series C Preferred Stock issued
pursuant to the Series C Purchase Agreement, including the Series C Warrant
Shares issued upon exercise of the Series C Warrants issued pursuant to, and
upon the exercise of the option granted under, the Series C Purchase Agreement.

                                      -3-
<PAGE>   8

         1.15 "Form S-3" means such form under the Securities Act as in effect
on the date hereof or any successor registration form under the Securities Act
subsequently adopted by the SEC which permits inclusion or incorporation of
substantial information by reference to other documents filed by the Company
with the SEC.

         1.16 "SEC" or "Commission" means the United States Securities and
Exchange Commission.

2.       RESTRICTIONS ON TRANSFER; REGISTRATION.

         2.1      Restriction on Transfer.

                  (a) Each Holder agrees not to make any disposition of all or
any portion of the Shares or Registrable Securities unless and until:

                      (i) There is then in effect a registration statement under
the Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement; or

                      (ii) (A) The transferee has agreed in writing to be bound
by the terms of this Agreement, (B) such Holder shall have notified the Company
of the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and (C) if
reasonably requested by the Company, such Holder shall have furnished the
Company with an opinion of counsel, reasonably satisfactory to the Company, that
such disposition will not require registration of such shares under the
Securities Act. It is agreed that the Company will not require opinions of
counsel for transactions made pursuant to Rule 144 except when the Company
reasonably believes, in unusual circumstances and after consultation with
counsel, that Rule 144 may not be available with respect to a proposed transfer.

                      (iii) Notwithstanding the provisions of Sections 2.1(a)(i)
and (ii), no such registration statement or opinion of counsel shall be
necessary for a transfer by a Holder in which no consideration is given and
which is (A) a partnership to its partners or former partners in accordance with
partnership interests, (B) a corporation to an affiliate or to its stockholders
in accordance with their interest in the corporation, (C) a limited liability
company to its members or former members in accordance with their interest in
the limited liability company, or (D) to the Holder's family member or trust for
the benefit of an individual Holder; provided, that the transferee will be
subject to the terms of this Agreement to the same extent as if he or she were
an original Holder under this Agreement.

                  (b) Each certificate representing Shares or Registrable
Securities shall (unless otherwise permitted by the provisions of this
Agreement) be stamped or otherwise imprinted with a legend substantially similar
to the following (in addition to any legend required under applicable United
States federal or state securities laws or as provided elsewhere in this
Agreement):

                                      -4-
<PAGE>   9

                  THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
                  UNDER THE SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE
                  OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR
                  HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR
                  UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
                  SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH
                  REGISTRATION IS NOT REQUIRED.

                  (c) The Company shall be obligated to reissue promptly
unlegended certificates at the request of any holder thereof if the holder shall
have obtained an opinion of counsel (which counsel may be counsel to the
Company) reasonably acceptable to the Company to the effect that the securities
proposed to be disposed of may lawfully be so disposed of without registration,
qualification or legend.

                  (d) Any legend endorsed on an instrument pursuant to
applicable United States state securities laws and the stop-transfer instruction
with respect to such securities shall be removed upon receipt by the Company of
an order of the appropriate blue sky authority authorizing such removal.

         2.2      Demand Registration.

                  (a) Subject to the conditions of this Section 2.2, if the
Company shall receive a written request from the Holders of more than fifty
percent (50%) of the Registrable Securities then outstanding (the "Initiating
Holders") that the Company file a registration statement under the Securities
Act covering the registration of Registrable Securities having an aggregate
offering price to the public of not less than $5,000,000 (a "Qualified Public
Offering"), then the Company shall, within thirty (30) days of the receipt
thereof, give written notice of such request to all Holders, and subject to the
limitations of this Section 2.2, use its best efforts to effect, as soon as
practicable, the registration under the Securities Act of all Registrable
Securities that the Holders request to be registered. Notwithstanding the
foregoing, in the event that Form S-3 (or any successor or similar form) is not
available for offerings by the Company on, or at any time after, the date
fifteen (15) months after the Initial Offering, then the Initiating Holders
shall be deemed to be Holders of more than thirty percent (30%) of the
Registrable Securities then outstanding, and a Qualified Public Offering shall
be deemed to be Registrable Securities having an aggregate offering price to the
public of not less than $2,000,000.

                  (b) If the Initiating Holders intend to distribute the
Registrable Securities covered by their request by means of an underwriting,
they shall so advise the Company as a part of their request made pursuant to
this Section 2.2 and the Company shall include such information in the written
notice referred to in Section 2.2(a). In such event, the right of any Holder to
include its Registrable Securities in such registration shall be conditioned
upon such Holder's participation in such underwriting and the inclusion of such
Holder's Registrable Securities in the underwriting (unless otherwise mutually
agreed by a majority in interest of the Initiating Holders and such Holder) to
the extent provided herein. All Holders proposing to distribute their securities
through such

                                      -5-
<PAGE>   10

underwriting shall enter into an underwriting agreement in customary form with
the underwriter or underwriters selected for such underwriting by a majority in
interest of the Initiating Holders (which underwriter or underwriters shall be
reasonably acceptable to the Company). Notwithstanding any other provision of
this Section 2.2, if the underwriter advises the Company that marketing factors
require a limitation of the number of securities to be underwritten (including
Registrable Securities), then the Company shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities on a pro rata basis
based on the number of Registrable Securities held by all such Holders
(including the Initiating Holders). Any Registrable Securities excluded or
withdrawn from such underwriting shall be withdrawn from the registration.

                  (c) The Company shall not be required to effect a registration
pursuant to this Section 2.2:

                      (i)   prior to August 23, 2000; or

                      (ii)  after the Company has effected two (2) registrations
pursuant to this Section 2.2, and such registrations have been declared or
ordered effective; or

                      (iii) during the period starting with the date of
filing, and ending on the date one hundred eighty (180) days following the
effective date, of the registration statement pertaining to the Initial
Offering; provided that the Company makes reasonable good faith efforts to cause
such registration statement to become effective;

                      (iv)  if within thirty (30) days of receipt of a written
request from Initiating Holders pursuant to Section 2.2(a), the Company gives
notice to the Holders of the Company's intention to make its Initial Offering
within ninety (90) days;

                      (v) if the Company shall furnish to Holders requesting a
registration statement pursuant to this Section 2.2, a certificate signed by the
Chairman of the Board stating that in the good faith judgment of the Board of
Directors of the Company, it would be seriously detrimental to the Company and
its stockholders for such registration statement to be effected at such time, in
which event the Company shall have the right to defer such filing for a period
of not more than ninety (90) days after receipt of the request of the Initiating
Holders; provided that such right to delay a request shall be exercised by the
Company not more than once in any twelve (12) month period; or

                      (vi) if, after allocation in accordance with Section
2.2(b), the Registrable Securities to be registered in such registration
constitute (A) fifty percent (50%) or less of the Registrable Securities then
outstanding or have an aggregate offering price to the public of less than
$5,000,000; or (B) thirty percent (30%) or less of the Registrable Securities
then outstanding or have an aggregate offering price to the public of less than
$2,000,000, as applicable under Section 2.2(a).

                                      -6-
<PAGE>   11

         2.3      Piggyback Registrations.

                  (a) The Company  shall  notify all Holders of  Registrable
Securities in writing at least thirty (30) days prior to the filing of any
registration statement under the Securities Act for purposes of a public
offering of securities of the Company (including, but not limited to,
registration statements relating to secondary offerings of securities of the
Company, but excluding registration statements relating to employee benefit
plans or with respect to corporate reorganizations or other transactions under
Rule 145 of the Securities Act), and will afford each such Holder an opportunity
to include in such registration statement all or part of such Registrable
Securities held by such Holder. Each Holder desiring to include in any such
registration statement all or any part of the Registrable Securities held by it
shall, within fifteen (15) days after the above-described notice from the
Company, so notify the Company in writing. Such notice shall state the intended
method of disposition of the Registrable Securities by such Holder. If a Holder
decides not to include all of its Registrable Securities in any registration
statement thereafter filed by the Company, such Holder shall nevertheless
continue to have the right to include any Registrable Securities in any
subsequent registration statement or registration statements as may be filed by
the Company with respect to offerings of its securities, all upon the terms and
conditions set forth in this Section 2.3.

                  (b) If the  registration  statement  under which the Company
gives notice under this Section 2.3 is for an underwritten offering, the Company
shall so advise the Holders of Registrable Securities. In such event, the right
of any such Holder to be included in a registration pursuant to this Section 2.3
shall be conditioned upon such Holder's participation in such underwriting and
the inclusion of such Holder's Registrable Securities in the underwriting to the
extent provided in this Section 2.3(b). All Holders proposing to distribute
their Registrable Securities through such underwriting shall enter into an
underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting by the Company. Notwithstanding any other
provision of the Agreement, but subject to the immediately following sentence,
if the underwriter determines in good faith that marketing factors require a
limitation of the number of shares to be underwritten, the number of shares that
may be included in the underwriting shall be allocated, first, to the Company
(or to Roche in the case of a registration pursuant to Section 2.5); second, to
the Holders on a pro rata basis based on the total number of Registrable
Securities held by the Holders; and third, to any stockholder of the Company
(other than a Holder) on a pro rata basis. Notwithstanding the foregoing, in no
event shall the amount of securities of the selling Holders included in the
registration be reduced below twenty-five percent (25%) of the total amount of
securities included in such registration, unless such offering is the Initial
Offering and such registration does not include shares of any other selling
stockholders (other than Excess Shares pursuant to Section 2.5), in which event
any or all of the Registrable Securities of the Holders may be excluded in
accordance with the immediately preceding sentence. In no event will shares of
any other selling stockholder (other than Excess Shares pursuant to Section 2.5)
be included in such registration which would reduce the number of shares which
may be included by Holders without the written consent of Holders of not less
than seventy-five (75%) of the Registrable Securities proposed to be sold in the
offering.

                  (c) The Company  shall have the right to terminate or withdraw
any registration initiated by it under this Section 2.3 prior to the
effectiveness of such registration, whether or not any

                                      -7-
<PAGE>   12

Holder has elected to include securities in such registration. The Registration
Expenses of such withdrawn registration shall be borne by the Company in
accordance with Section 2.6.

                  (d) For purposes of this Section 2.3 only, all of the parties
to this Agreement agree that Kari Stefansson shall have the rights and
obligations of a Holder pursuant to this Section 2.3, and any shares of Common
Stock of the Company held by Dr. Stefansson shall be deemed Registrable
Securities for purposes of this Section 2.3.

         2.4      Form S-3 Registration. In case the Company shall receive from
any Holder or Holders of Registrable Securities a written request or requests
that the Company effect a registration on Form S-3 (or any successor to Form
S-3) or any similar short-form registration statement and any related
qualification or compliance with respect to all or a part of the Registrable
Securities owned by such Holder or Holders, the Company will:

                  (a) promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders of Registrable
Securities; and

                  (b) as soon as practicable,  effect such registration and all
such qualifications and compliances as may be so requested and as would permit
or facilitate the sale and distribution of all or such portion of such Holder's
or Holders' Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given
within fifteen (15) days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such
registration, qualification or compliance pursuant to this Section 2.4:

                      (i)    if Form S-3 (or any successor or similar form) is
not available for such offering by the Holders, or

                      (ii)   if the Holders, together with the holders of any
other securities of the Company entitled to inclusion in such registration,
propose to sell Registrable Securities and such other securities (if any) at an
aggregate price to the public of less than $500,000 (following underwriter's
cut-backs, if any), or

                      (iii)  if the Company shall furnish to the Holders a
certificate signed by the Chairman of the Board of Directors of the Company
stating that in the good faith judgment of the Board of Directors of the
Company, it would be seriously detrimental to the Company and its stockholders
for such Form S-3 Registration to be effected at such time, in which event the
Company shall have the right to defer the filing of the Form S-3 registration
statement for a period of not more than ninety (90) days after receipt of the
request of the Holder or Holders under this Section 2.4; provided, that such
right to delay a request shall be exercised by the Company not more than once in
any twelve (12) month period, or

                      (iv)   if the Company has already effected two (2)
registrations on Form S-3 for the Holders pursuant to this Section 2.4, or

                                      -8-
<PAGE>   13

                      (v)    in any particular jurisdiction in which the Company
would be required to qualify to do business or to execute a general consent to
service of process in effecting such registration, qualification or compliance.

                  (c) Subject to the foregoing, the Company shall file a
Form S-3 registration statement covering the Registrable Securities and other
securities to be requested to be registered as soon as practicable after receipt
of the request or requests of the Holders. All such Registration Expenses
incurred in connection with registrations requested pursuant to this Section 2.4
after the first two (2) registrations shall be paid by the selling Holders pro
rata in proportion to the number of shares sold by each.

         2.5      Series C Investor Registration Rights.

                  (a) Subject to the  conditions  of this Section 2.5, in the
event that the initial Series C Investor, Roche Finance Ltd, or any of its
affiliates (collectively, "Roche") shall be the beneficial owner (within the
meaning of Rule 13d-3(d) promulgated under the Exchange Act, as interpreted by
independent counsel selected by Roche and reasonably acceptable to the Company)
of Registrable Securities in excess of 9.9% of the Common Stock immediately
after the close of the Company's Initial Offering (such Registrable Securities,
the "Excess Shares"), Roche shall have the right to require the Company to
include such Excess Shares in the registration statement filed under the
Securities Act pertaining to the Initial Offering. The Company shall notify
Roche in writing at least thirty (30) days prior to the filing of any
registration statement under the Securities Act pertaining to the Initial
Offering. If Roche desires to include in such registration statement all or any
part of the Excess Shares held by it, Roche shall, within fifteen (15) days
after the above-described notice from the Company, so notify the Company in
writing. Such notice shall state the intended method of disposition of the
Excess Shares by Roche. Notwithstanding the foregoing, the Company shall not be
obligated to include any Excess Shares in such registration statement pursuant
to this Section 2.5 without the approval of the lead underwriter. If the lead
underwriter does not consent to inclusion of the Excess Shares sought to be
included by Roche in the registration statement pertaining to the Initial
Offering or if the number of Excess Shares is cut back pursuant to Section
2.5(b), then the Company shall use its best efforts to effect registration of
the Excess Shares:

                      (i)    if Roche requests inclusion of Excess Shares that
are not included in the registration statement pertaining to the Initial
Offering which have an aggregate price to the public of at least $2,000,000,
within one hundred eighty (180) days after the effective date of the
registration statement filed by the Company in connection with the Initial
Offering; or

                      (ii)   if Roche  requests  inclusion  of Excess  Shares
that are not included in the registration statement pertaining to the Initial
Offering which have an aggregate price to the public of less than $2,000,000,
within one (1) year after the effective date of the registration statement filed
by the Company in connection with the Initial Offering.

                  (b) The right of Roche to have Excess Shares included in a
registration pertaining to the Company's Initial Offering pursuant to this
Section 2.5 shall be conditioned upon Roche's participation in the underwriting
and the inclusion of the Excess Shares in the underwriting to the extent
provided in this Section 2.5. If Roche proposes to distribute the Excess Shares
through

                                      -9-
<PAGE>   14

such underwriting, Roche shall enter into an underwriting agreement in customary
form with the underwriter or underwriters selected for such underwriting by the
Company. Notwithstanding any other provision of this Agreement, if the
underwriter determines in good faith that marketing factors require a limitation
of the number of shares to be underwritten, the number of shares that may be
included in the underwriting shall be allocated, first, to the Company; second,
to Roche for the Excess Shares; third, to the Holders (under any other right
provided to the Holders in this Section 2); and fourth, to any stockholder of
the Company (other than a Holder) on a pro rata basis. No such reduction shall
reduce the securities being offered by the Company for its own account to be
included in the registration and underwriting. In no event will shares of any
other selling stockholder be included in such registration which would reduce
the number of Excess Shares which may be included by Roche without the written
consent of Roche.

                  (c) The Company  shall have the right to terminate or withdraw
any registration pertaining to the Company's Initial Offering initiated by it
under this Section 2.5 prior to the effectiveness of such registration, whether
or not Roche has elected to include securities in such registration. The
Registration Expenses of such withdrawn registration shall be borne by the
Company in accordance with Section 2.6.

                  (d) The Company shall not be required to effect a registration
pursuant to Section 2.5(a)(i) or (ii) if the Company shall furnish to Roche a
certificate signed by the Chairman of the Board stating that, in the good faith
judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such registration statement
to be effected at such time, in which event the Company shall have the right to
defer such filing for a period of not more than ninety (90) days after the date
any such registration would otherwise be required to be effective pursuant to
Section 2.5(a)(i) or (ii).

         2.6      Expenses of Registration. Except as specifically provided in
this Agreement, all Registration Expenses incurred in connection with any
registration, qualification or compliance pursuant to Section 2.2, or any
registration under Section 2.3, 2.4 or Section 2.5, shall be borne by the
Company. All Selling Expenses incurred in connection with any registrations
under this Agreement shall be borne by the holders of the securities so
registered, pro rata on the basis of the number of shares so registered. The
Company shall not, however, be required to pay for expenses of any registration
proceeding begun pursuant to Section 2.2 or 2.4, the request of which has been
subsequently withdrawn by the Initiating Holders unless: (a) the withdrawal is
based upon material adverse information concerning the Company of which the
Initiating Holders were not aware of the time of such request, or (b) the
Holders of a majority of Registrable Securities agree to forfeit their rights to
one requested registration pursuant to Section 2.2 or Section 2.4, as
applicable, (in which event such right shall be forfeited by all Holders). If
the Holders are required to pay the Registration Expenses, such expenses shall
be borne by the holders of securities (including Registrable Securities)
requesting such registration in proportion to the number of shares for which
registration was requested. If the Company is required to pay the Registration
Expenses of a withdrawn offering pursuant to clause (a) of this Section 2.6,
then the Holders shall not forfeit their rights pursuant to Section 2.2 or
Section 2.4 to a demand registration.

         2.7      Obligation of the Company. Whenever required to effect the
registration of any Registrable Securities, the Company shall, as expeditiously
as reasonably possible:

                                      -10-
<PAGE>   15

                  (a) Prepare and file with the SEC a registration statement
with respect to such Registrable Securities and use all reasonable efforts to
cause such registration statement to become effective, and, upon the request of
the Holders of a majority of the Registrable Securities registered thereunder,
keep such registration statement effective for up to ninety (90) days or, if
earlier, until the Holder or Holders have completed the distribution related
thereto.

                  (b) Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement.

                  (c) Furnish to the Holders such number of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them.

                  (d) Use all reasonable efforts to register and qualify the
securities covered by such registration statement under such other United States
federal or state securities or blue sky laws of such jurisdictions as shall be
reasonably requested by the Holders, provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states
or jurisdictions.

                  (e) In the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.

                  (f) Notify each Holder or Registrable Securities covered by
such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing.

                  (g) Furnish, at the request of a majority of the Holders
participating in the registration, on the date that such Registrable Securities
are delivered to the underwriters for sale, if such securities are being sold
through underwriters, or, if such securities are not being sold through
underwriters, on the date that the registration statement with respect to such
securities becomes effective, (i) an opinion, dated as of such date, of the
counsel representing the Company for the purposes of such registration, in form
and substance as is customarily given to underwriters in an underwritten public
offering and reasonably satisfactory to a majority in interest of the Holders
requesting registration, addressed to the underwriters, if any, and to the
Holders requesting registration of Registrable Securities, and (ii) a letter
dated as of such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified
public accountants of the Company to underwriters in an underwritten public

                                      -11-
<PAGE>   16

offering and reasonably satisfactory to a majority in interest of the Holders
requesting registration, addressed to the underwriters, if any, and if permitted
by applicable accounting standards, to the Holders requesting registration of
Registrable Securities.

         2.8      Termination of Registration Rights. All registration rights
granted under this Section 2 shall terminate and be of no further force and
effect five (5) years after the date of the Company's Initial Offering. In
addition, a Holder's registration rights shall expire if (i) the Company has
completed its Initial Offering and is subject to the provisions of the Exchange
Act, (ii) such Holder (together with its affiliates, partners and former
partners) holds less than one percent (1%) of the Company's outstanding Common
Stock (treating all shares of Series A Preferred Stock, Series B Preferred Stock
and Series C Preferred Stock on an as-converted-to-Common Stock basis), and
(iii) all Registrable Securities held by and issuable to such Holder may be sold
under Rule 144 during any ninety (90) day period.

         2.9      Delay of Registration; Furnishing Information.

                  (a) No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result
of any controversy that might arise with respect to the interpretation or
implementation of this Section 2.

                  (b) It shall be a condition precedent to the obligations of
the Company to take any action pursuant to Section 2.2, 2.3, 2.4 or 2.5 that the
selling Holders shall furnish to the Company such information regarding
themselves, the Registrable Securities held by them and the intended method of
disposition of such securities as shall be required to effect the registration
of their Registrable Securities.

         2.10     Indemnification. In the event any Registrable Securities
are included in a registration statement under Section 2.2, 2.3, 2.4 or 2.5:

                  (a) To the extent permitted by United States federal or State
of Delaware law, the Company will indemnify and hold harmless each Holder, the
partners, officers, directors and legal counsel of each Holder, any underwriter
(as defined in the Securities Act) for such Holder and each person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or
the Exchange Act, against any losses, claims, damages, or liabilities (joint or
several) to which they may become subject under the Securities Act, the Exchange
Act or other United States federal or state law, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any of the following statements, omissions or violations (collectively a
"Violation") by the Company: (i) any untrue statement or alleged untrue
statement of a material fact contained in such registration statement, including
any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any United
States state securities law or any rule or registration promulgated under the
Securities Act, the Exchange Act or any United States state securities law in
connection with the offering covered by such registration statement; and the
Company will reimburse each such Holder, partner, officer or director,
underwriter or controlling person for any

                                      -12-
<PAGE>   17

legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action;
provided, however, that the indemnity agreement contained in this Section
2.10(a) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability or action if such settlement is effected without the consent
of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that is arises out of or is based upon a Violation which
occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration by such Holder, partner,
officer, director, underwriter or controlling person of such Holder.

                  (b) To the extent permitted by United States federal or state
law, each Holder will, if Registrable Securities held by such Holder are
included in the securities as to which such registration, qualification or
compliance is being effected, indemnify and hold harmless the Company, each of
its directors, its officers, and legal counsel and each person, if any, who
controls the Company within the meaning of the Securities Act, any underwriter
and any other Holder selling securities under such registration statement or any
of such other Holder's partners, directors or officers or any person who
controls such Holder, against any losses, claims, damages or liabilities (joint
or several) to which the Company or any such director, officer, controlling
person, underwriter or other such Holder, or partner, director, officer or
controlling person of such other Holder may become subject under the Securities
Act, the Exchange Act or other United States federal or state law, insofar as
such losses, claims, damages or liabilities (or actions in respect thereto)
arise out of or are based upon any Violation, in each case to the extent (and
only to the extent) that such Violation occurs in reliance upon and in
conformity with written information furnished by such Holder under an instrument
duly executed by such Holder and stated to be specifically for use in connection
with such registration; and each such Holder will reimburse any legal or other
expenses reasonably incurred by the Company or any such director, officer,
controlling person, underwriter or other Holder, or partner, officer, director
or controlling person of such other Holder in connection with investigating or
defending any such loss, claim, damage, liability or action if it is judicially
determined that there was such a Violation; provided, however, that the
indemnity agreement contained in this Section 2.10(b) shall not apply to amounts
paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder, which consent shall
not be unreasonably withheld; provided further, that in no event shall any
indemnity under this Section 2.10 exceed the net proceeds from the offering
received by such Holder.

                  (c) Promptly after receipt by an indemnified party under this
Section 2.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 2.10, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other
party represented by such counsel in such proceeding. The failure to deliver
written

                                      -13-
<PAGE>   18

notice to the indemnifying party within a reasonable time of the commencement of
any such action, if materially prejudicial to its ability to defend such action,
shall relieve such indemnifying party of any liability to the indemnified party
under this Section 2.10, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 2.10.

                  (d) If the indemnification provided for in this Section 2.10
is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any losses, claims, damages or liabilities referred to in
this Section 2.10, the indemnifying party, in lieu of indemnifying such
indemnified party thereunder, shall to the extent permitted by applicable United
States federal or State of Delaware law contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim , damage or liability
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in
connection with the Violation(s) that resulted in such loss, claim, damage or
liability, as well as any other relevant equitable considerations. The relative
fault of the indemnifying party and of the indemnified party shall be determined
by a court of law by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party of by the
indemnified party and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission;
provided, that in no event shall any contribution by a Holder hereunder exceed
the proceeds from the offering received by such Holder.

                  (e) The obligations of the Company and Holders under this
Section 2.10 shall survive completion of any offering of Registrable Securities
in a registration statement. No Indemnifying Party, in the defense of any claim
or litigation, shall, except with the consent of each Indemnified Party, consent
to entry of any judgment or enter into any settlement which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or
litigation.

         2.11     Assignment of Registration Rights. The rights to cause the
Company to register Registrable Securities pursuant to this Section 2 may be
assigned by a Holder to a transferee or assignee of Registrable Securities which
(i) is a partner, general partner, limited partner or retired partner of a
Holder that is a partnership, (ii) is an affiliate of a Holder that is a
corporation or to the stockholders of such a Holder in accordance with their
interest in such Holder, (ii) is a Holder's family member or trust for the
benefit of an individual Holder, or (iii) acquires at least one percent (1%) of
the Company's outstanding Common Stock (treating all shares of Series A
Preferred Stock, Series B Preferred Stock and Series C Preferred Stock on an
as-converted-to-Common Stock basis); provided, however, (A) the transferor
shall, within ten (10) days after such transfer, furnish to the Company written
notice of the name and address of such transferee or assignee and the securities
with respect to which such registration are being assigned and (B) such
transferee shall agree to be subject to all restrictions set forth in this
Agreement.

         2.12     Acceptance of  Registration  Rights.  By acceptance of any
benefits under this Section 2, Holders of Registrable Securities hereby agree to
be bound by the provisions hereunder.

                                      -14-
<PAGE>   19

         2.13     Limitation on Subsequent Registration Rights. After the date
of this Agreement, the Company shall not, without the prior written consent of
the Holders of seventy-five percent (75%) of the Registrable Securities, enter
into any agreement with any holder or prospective holder of any securities of
the Company that would grant such holder registration rights senior to those
granted to the Holders hereunder or that would reduce the number of shares
includable by the Holders in the event of a registration pursuant to Section
2.3.

         2.14     "Market Stand-Off" Agreement. If requested by the Company or
the representative of the underwriters of Common Stock (or other securities) of
the Company, each Holder shall not sell or otherwise transfer or dispose of any
Common Stock (or other securities) of the Company held by such Holder (other
than those included in the registration) for a period specified by the
representative of the underwriters not to exceed one hundred eighty (180) days
following the effective date of a registration statement of the Company filed
under the Securities Act, provided that:

                  (a) such agreement shall apply only to the Company's Initial
Offering; and

                  (b) all officers and directors of the Company and holders of
at least one percent (1%) of the Company's voting securities enter into similar
agreements.

         The obligations described in this Section 2.14 shall not apply to a
registration relating solely to employee benefit plans on Form S-1 or Form S-8
or similar forms that may be promulgated in the future, or a registration
relating solely to a Commission Rule 145 transaction on Form S-4 or similar
forms that may be promulgated in the future. The Company may impose
stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one
hundred eighty (180) day period.

         2.15     Rule 144 Reporting. With a view to making available to the
Holders the benefits of certain rules and regulations of the SEC which may
permit the sale of the Registrable Securities to the public without
registration, the Company agrees to use its best efforts to:

                  (a) Make and keep public information available, as those terms
are understood and deemed in Rule 144 or any similar or analogous rule
promulgated under the Securities Act, at all times after the effective date of
the first registration filed by the Company for an offering of its securities to
the general public;

                  (b) File with the SEC, in a timely manner, all reports and
other documents required of the Company under the Exchange Act;

                  (c) So long as a Holder owns any Registrable Securities,
furnish to such Holder forthwith upon request: a written statement by the
Company as to its compliance with the reporting requirements of Rule 144, and of
the Exchange Act (at any time after it has become subject to such reporting
requirements); a copy of the most recent annual or quarterly report of the
Company; and such other reports and documents as a Holder may reasonably request
in availing itself of any rule or regulation of the SEC allowing it to sell any
such securities without registration.

                                      -15-
<PAGE>   20

         2.16     Applicability. The provisions of Section 2 shall apply to the
holders of the Company's Series B Preferred Stock originally issued pursuant to
the Stock Purchase Agreement dated as of June 30,1999. For purposes of this
Section 2 only and notwithstanding anything to the contrary contained in this
Agreement, the shares of Series B Preferred Stock so issued shall be deemed to
be Shares, as defined in Section 1.14 of this Agreement so that the shares of
(i) Common Stock issued or issuable upon conversion of such Shares and (ii) any
Common Stock issued as (or issuable upon the conversion or exercise of any
warrants, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the
Common Stock described in clause (i) shall be Registrable Securities and the
holders thereof shall have all of the rights and obligations of Holders for
purposes of Section 2.

3.       COVENANTS OF THE COMPANY.

         3.1      Basic Financial Information and Reporting.

                  (a) The Company will maintain true books and records of
account in which full and correct entries will be made of all its business
transactions pursuant to a system of accounting established and administered in
accordance with generally accepted accounting principles consistently applied,
and will set aside on its books all such proper accruals and reserves as shall
be required under generally accepted accounting principles consistently applied.

                  (b) As soon as practicable after the end of each fiscal year
of the Company, and in any event within one hundred twenty (120) days
thereafter, the Company will furnish each Investor a consolidated balance sheet
of the Company, as at the end of such fiscal year, and a consolidated statement
of income and a consolidated statement of cash flows of the Company, for such
year, all prepared in accordance with generally accepted accounting principles
consistently applied and setting forth in each case in comparative form the
figures for the previous fiscal year, all in reasonable detail. Such financial
statements shall be accompanied by a report and opinion thereon by independent
public accountants of national standing selected by the Company's Board of
Directors.

                  (c) The Company will furnish each Series A Investor and the
Series C Investor, as soon as practicable after the end of the first, second and
third quarterly accounting periods in each fiscal year of the Company, and in
any event within forty-five (45) days thereafter, a consolidated balance sheet
of the Company as of the end of each such quarterly period, and a consolidated
statement of income and a consolidated statement of cash flows of the Company
for such period and for the current fiscal year to date, prepared in accordance
with generally accepted accounting principles, with the exception that no notes
need be attached to such statements and year-end audit adjustments may not have
been made.

                                      -16-
<PAGE>   21

         3.2      Inspection Rights.

                  (a) Each Series A Investor who is a Major Investor (each, a
"Major Series A Investor," and, collectively, the "Major Series A Investors")
shall be entitled to consult with and advise management of the Company on
significant business issues, including management's proposed annual operating
plans. Each Major Series A Investor shall be entitled to discuss the affairs,
finances and accounts of the Company or any of its subsidiaries with its
officers. Management will meet with each Major Series A Investor regularly
during each year at the Company's facilities, upon request by such Major Series
A Investor, at mutually agreeable times for such consultation and advice and to
review progress in achieving said plans.

                  (b) Each Major Series A Investor may examine the books and
records of the Company and visit and inspect the facilities and properties of
the Company and any of its subsidiaries, and may request information at
reasonable times and intervals concerning the general status of the Company's
financial condition and operations; provided, however, that the Company shall
not be obligated under this Section 3.2 with respect to a competitor of the
Company or with respect to information which the Board of Directors determines
in good faith is confidential and should not, therefore, be disclosed.

         3.3      Confidentiality of Records. Each Investor agrees to use, and
to use its best efforts to insure that its authorized representatives use, the
same degree of care as such Investor uses to protect its own confidential
information to keep confidential any information furnished to it which the
Company identifies as being confidential or proprietary (so long as such
information is not in the public domain), except that such Investor may disclose
such proprietary or confidential information to any partner, subsidiary or
parent of such Investor for the purpose of evaluating its investment in the
Company as long as such partner, subsidiary or parent is advised of the
confidentiality provisions of this Section 3.3.

         3.4      Reservation of Common Stock. The Company will at all time
reserve and keep available, solely for issuance and delivery upon the conversion
of the Series A Preferred Stock, the Series B Preferred Stock and Series C
Preferred Stock, all Common Stock issuable from time to time upon such
conversion.

         3.5      Key Man Insurance. Subject to the approval of the Board of
Directors, the Company will use its best efforts to obtain and maintain in full
force and effect term life insurance in the amount of one million dollars
($1,000,000) on the life of Kari Stefansson, M.D., naming the Company as
beneficiary.

         3.6      Visitation Observer Rights. If a Major Investor is a Series A
Investor or a Series C Investor and is not represented on the Company's Board of
Directors, the Company shall: (i) invite a representative of such Major Investor
to attend all meetings of its Board of Directors ("Board Meetings") in a
non-voting observer capacity, and in this respect shall give such representative
(with a copy, if so requested, to another person as may be designated by such
Major Investor from time to time) copies of all notices, minutes, consents, and
other material that it provides to its directors, which shall include fiscal
budgets and projections of the Company provided annually at least thirty

                                      -17-
<PAGE>   22

(30) days prior to the beginning of each fiscal year of the Company, and (ii)
give a representative of such Major Investor the right to meet with the
President of the Company at the Company's facilities, at mutually agreeable
times, to consult with and discuss the affairs, finances and accounts of the
Company; provided, however, that the Company reserves the right to exclude such
representative from access to any material or meeting or portion thereof if the
Company believes upon advice of counsel that such exclusion is reasonably
necessary to preserve the attorney-client privilege, to protect highly
confidential proprietary information or for other similar reasons; and provided,
further, that in no event shall the Series C Investor be entitled, as a result
of or in connection with any such materials, visit and/or discussion, to any
scientific, technical, financial and other information concerning, relating to
or used in connection with any strategic alliance, joint venture, sponsored
research program, licensing arrangement, or any other kind of agreement,
relationship or arrangement entered into, or proposed to be entered into, by the
Company with any third party for the purpose of gene discovery or the discovery,
development, manufacture or commercialization of drugs. The Company will
reimburse such representatives, except for such representatives of the Series C
Investor, for expenses incurred in connection with their attendance at Board
Meetings in accordance with its policy for reimbursing directors for attendance
at Board Meetings. Such expenses of such representatives of the Series C
Investor shall be borne by the Series C Investor. Such representative may
participate in discussions of matters brought to the Board. Except as otherwise
provided in Section 3.11(b), the rights granted under this Section 3.6 shall be
nonassignable, and shall terminate and be of no further effect with respect to
any Series A Investor or Series C Investor who is no longer a Major Investor.

         3.7      Proprietary  Information  and Inventions  Agreement.  The
Company shall require all employees and consultants to execute and deliver a
Proprietary Information and Inventions Agreement in the form attached as Exhibit
C.

         3.8      Directors' Liability and Indemnification. The Company's
Certificate of Incorporation and Bylaws shall provide: (i) for elimination of
the liability of directors to the maximum extent permitted by Delaware, USA law,
and (ii) for indemnification of directors for acts on behalf of the Company to
the maximum extent permitted by Delaware, USA law. In addition, the Company
shall enter into and use its best efforts to at all times maintain
indemnification contracts substantially in the form attached as Exhibit E with
each of its directors to indemnify such directors to the maximum extent
permissible under Delaware, USA law. The Company will use its reasonable efforts
to limit the liability, to the maximum extent permissible under Delaware, USA
law, of any Investor represented by or affiliated with a Director of the
Company.

         3.9      Real Property Holding Corporation. The Company covenants that
it will operate in a manner such that it will not become a "United States real
property holding corporation" (a "USRPHC") as that term is defined in Section
897(c)(2) of the Internal Revenue Code of 1986, as amended, and the regulations
thereunder. The Company agrees to make determinations as to its status as a
USRPHC, and will file statements concerning those determinations with the
Internal Revenue Service, in the manner and at the times required under Reg.
Section 1.897-2(h), or any supplementary or successor provision thereto. Within
thirty (30) days of a request from an Investor or any of its partners, the
Company will inform the requesting party, in the manner set forth in Reg.
Section 1.897-2(h)(1)(iv) or any supplementary or successor provision thereto,
whether that party's interest in the Company constitutes a United States real
property interest (within the meaning of Internal

                                      -18-
<PAGE>   23

Revenue Code Section 897(c)(1) and the regulations thereunder) and whether the
Company has provided to the Internal Revenue Service all required notices as to
its USRPHC status.

         3.10     Additional Major Investor.

                  (a) The parties hereto agree that Kari Stefansson shall have
the rights and obligations of a Major Investor provided in Sections 3.1, 3.2,
3.3 and 3.6 hereof for so long as Dr. Stefansson continues to hold at least
250,000 shares of the Company's Common Stock or until the effective date of the
registration statement pertaining to the Initial Offering.

                  (b) The parties hereto further agree that Beth Israel
Deaconess Medical Center, Inc. ("Beth Israel Deaconess") shall have the rights
and obligations of a Major Investor provided for in Sections 3.1 and 3.2(b)
hereof for as long as Beth Israel Deaconess continues to hold at least 100,000
Shares. The Company shall send relevant information to the representative
appointed by Beth Israel Deaconess from time to time, upon notice to the
Company. Beth Israel Deaconess agrees that members of its finance department
shall be the sole persons to utilize and/or review the information that Beth
Israel Deaconess receives pursuant to Sections 3.1 and 3.2(b).

         3.11     Termination of Covenants.

                  (a) Except as otherwise provided in Section 3.11(b), all
covenants of the Company contained in this Section 3 shall expire and terminate
as to each Investor on the effective date of the registration statement
pertaining to the Initial Offering, except that the covenants contained in
Section 3.1(b) and (c) of this Agreement shall continue after such effective
date with respect to each Major Investor given such right in such Section.

                  (b) The covenants contained in Section 3.6 with respect to
Roche shall continue for so long as Roche continues to hold at least fifty
percent (50%) in interest of the issued and outstanding Shares defined in
Section 1.14(iii) (including shares of Common Stock into which any such Shares
may have been converted), or until the end of the Research Term (as such term is
defined in that certain Research Collaboration and License Agreement dated of
even date herewith between the Company and Roche), whichever is later.

4.       RIGHTS OF FIRST REFUSAL.

         4.1      Roche Right of First Refusal.

                  (a) Roche shall have a right of first refusal to purchase up
to that number of the Equity Securities that the Company may, from time to time,
propose to sell and issue after the date of this Agreement, other than the
Equity Securities excluded by Section 4.5, which, when added to the Shares and
the shares of Common Stock held by Roche as of the date of exercise of such
right of first refusal, would make Roche the beneficial owner (within the
meaning of Rule 13d-3(d) promulgated under the Exchange Act, as interpreted by
independent counsel selected by Roche and reasonably acceptable to the Company)
of 9.9% of the Company's Common Stock (calculated on an as-converted-to-Common
Stock basis).

                                      -19-
<PAGE>   24

                  (b) If the Company proposes to issue any Equity Securities,
other than the Equity Securities excluded by Section 4.5, it shall give each
Roche written notice of its intention, describing such Equity Securities, the
price and the terms and conditions upon which the Company proposes to issue the
same. Roche shall have ten (10) business days from the giving of such notice to
agree to purchase up to the maximum number of the Equity Securities that it is
entitled to purchase under this Section 4.1 for the price and upon the terms and
conditions specified in the notice by giving written notice to the Company and
stating therein the quantity of Equity Securities to be purchased.
Notwithstanding the foregoing, the Company shall not be required to offer or
sell such Equity Securities to Roche if such offer or sale would cause the
Company to be in violation of applicable United States federal securities laws
by virtue of such offer or sale.

                  (c) If Roche fails to exercise in full its right of first
refusal under this Section 4.1, the Company shall have seventy (70) days
thereafter to sell the Equity Securities in respect of which Roche's right was
not exercised, at a price and upon general terms and conditions materially no
more favorable to the purchasers thereof (including, without limitation,
Investor Founders) than specified in the Company's notice to Roche pursuant to
Section 4.1(b). If the Company has not sold such Equity Securities within
seventy (70) days of the notice provided pursuant to Section 4.1(b), the Company
shall not thereafter issue or sell any Equity Securities, without first offering
such securities to Roche in the manner provided above.

         4.2      Investor Rights of First Refusal.

                  (a) Subject to the rights of Roche under Section 4.1, each
Investor Founder shall have a right of first refusal to purchase his pro rata
share of all Equity Securities that the Company may, from time to time, propose
to sell and issue after the date of this Agreement, other than the Equity
Securities excluded by Section 4.5. Each Investor Founder's pro rata share shall
be equal to the ratio of (A) the number of shares of the Company's Common Stock
(including all shares of Common Stock issued or issuable upon conversion of the
Shares) which such Investor Founder is deemed to be a holder of immediately
prior to the issuance of such Equity Securities, to (B) the total number of
shares of the Company's outstanding Common Stock (including all shares of Common
Stock issued or issuable upon conversion of the Shares or upon the exercise of
any outstanding warrants or options) immediately prior to the issuance of the
Equity Securities.

                  (b) If the Company proposes to issue any Equity Securities,
other than the Equity Securities excluded by Section 4.5, and Roche shall not
have purchased all of such Equity Securities pursuant to Section 4.1, the
Company shall give each Investor Founder written notice of its intention,
describing such Equity Securities, the price and the terms and conditions upon
which the Company proposes to issue the same. Each Investor Founder shall have
seven (7) days from the giving of such notice to agree to purchase his pro rata
share of the Equity Securities for the price and upon the terms and conditions
specified in the notice by giving written notice to the Company and stating
therein the quantity of Equity Securities to be purchased. Notwithstanding the
foregoing, the Company shall not be required to offer or sell such Equity
Securities to any Investor Founder who would cause the Company to be in
violation of applicable United States federal securities laws by virtue of such
offer or sale.

                                      -20-
<PAGE>   25

                  (c) If not all of the Investor Founders elect to purchase
their pro rata share of the Equity Securities, then the Company shall promptly
notify in writing such Investor Founders who do so elect and shall offer such
Investor Founders the right to acquire such unsubscribed shares. Such Investor
Founders shall have five (5) days after receipt of such notice to notify the
Company of their election to purchase all or a portion thereof of the
unsubscribed shares. If the Investor Founders fail to exercise in full the
rights of first refusal, the Company shall have sixty (60) days thereafter to
sell the Equity Securities in respect of which such Investor Founders' rights
were not exercised, at a price and upon general terms and conditions materially
no more favorable to the purchasers thereof than specified in the Company's
notice pursuant to Section 4.2(b). If the Company has not sold such Equity
Securities within sixty (60) days of the notice provided pursuant to Section
4.2(b), the Company shall not thereafter issue or sell any Equity Securities,
without first offering such securities to the Investor Founders in the manner
provided above.

         4.3      Termination of Rights. The rights of first refusal established
by this Section 4 shall not apply to, and shall terminate upon the effective
date of, the registration statement pertaining to the Company's Initial
Offering.

         4.4      Reserved.

         4.5      Excluded Securities. The rights of first refusal established
by this Section 4 shall have no application to any of the following Equity
Securities:

                  (a) up to an aggregate amount of 5,000,000 shares of Common
Stock (and/or options, warrants or other Common Stock purchase rights issued
pursuant to such options, warrants or other rights) issued or to be issued to
employees, officers or directors of, or consultants or advisors to the Company
(including members of the Company's Scientific Advisory Board) or any
subsidiary, pursuant to stock purchase or stock option plans or other
arrangements that are approved by the Board of Directors;

                  (b) stock issued pursuant to any rights or agreements
outstanding as of the date of this Agreement, options and warrants outstanding
as of the date of this Agreement; and stock issued pursuant to any such rights
or agreements granted after the date of this Agreement, provided that the rights
of first refusal and co-investment established by this Section 4 applied with
respect to the initial sale or grant by the Company of such rights or
agreements; provided, however, that such right shall not apply to the issuance
of the Series C Preferred Stock or the Series C Warrants being issued pursuant
to the Series C Purchase Agreement simultaneously herewith, or the issuance of
the Series C Warrant Shares upon the exercise of the Series C Warrants; and
provided further, however, that such right shall not apply to the issuance of
the Series B Preferred Stock to be issued pursuant to the Series B Purchase
Agreement as contemplated hereunder;

                  (c) any Equity Securities issued for consideration other than
cash pursuant to a merger, consolidation, acquisition or similar business
combination;

                  (d) shares of Common Stock issued in connection with any stock
split, stock dividend or recapitalization by the Company;

                                      -21-
<PAGE>   26

                  (e) shares of Common Stock issued upon conversion of the
Shares;

                  (f) any Equity Securities issued pursuant to any equipment
leasing arrangement, or debt financing from a bank or similar financial
institution;

                  (g) any Equity Securities that are issued by the Company
pursuant to a registration statement filed under the Securities Act; and

                  (h) any Equity Securities issued in connection with corporate
partnering transactions, if such issuance is approved by the Board of Directors.

         4.6      Reserved.

5.       MISCELLANEOUS.

         5.1      Governing Law. This Agreement shall be governed by and
construed under the laws of the State of Delaware, USA as applied to agreements
among Delaware, USA residents entered into and to be performed entirely within
Delaware, USA.

         5.2      Future Employees. The parties hereto agree that, in the event
that shares of Common Stock held as of the date hereof by the Investor Founders
are repurchased by the Company as a result of the termination of any Investor
Founder's employment by or consulting relationship with the Company, it is the
Company's policy that these shares be used to recruit future employees whose
employment will be in the best interest of the Company. To the extent not
inconsistent with such policy, it is also the Company's policy to seek to
allocate the reissuance of such shares to residents or citizens of Iceland.

         5.3      Survival. The representations, warranties, covenants, and
agreements made herein shall survive any investigation made by any Holder and
the closing of the transactions contemplated hereby. All statements as to
factual matters contained in any certificate or other instrument delivered by or
on behalf of the Company pursuant hereto in connection with the transactions
contemplated hereby shall be deemed to be representations and warranties by the
Company hereunder solely as of the date of such certificate or instrument.

         5.4      Successors and Assigns. Except as otherwise expressly provided
in this Agreement, the provisions of this Agreement shall inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors, and
administrators of the parties hereto and shall inure to the benefit of and be
enforceable by each person who shall be a holder of Registrable Securities from
time to time; provided, however, that prior to the receipt by the Company of
adequate written notice of the transfer of any Registrable Securities specifying
the full name and address of the transferee, the Company may deem and treat the
person listed as the holder of such shares in its records as the absolute owner
and holder of such shares for all purposes, including the payment of dividends
or any redemption price.

         5.5      Severability.  In case any provision of the Agreement shall be
invalid, illegal, or unenforceable, the validity, legality, and enforceability
of the remaining provisions shall not in any

                                      -22-
<PAGE>   27

way be affected or impaired thereby.

         5.6      Amendment and Waiver.

                  (a) Except as otherwise expressly provided, neither this
Agreement nor any provision herein may be amended or waived except by a written
agreement signed by the parties hereto; provided, however, that:

                      (i)   any of the provisions of Section 2 may be amended or
waived by the written consent of the Company and the Holders of at least
sixty-seven percent (67%) of the Registrable Securities then outstanding; except
that any amendment or waiver relating to (1) Section 2.5 shall require the
written consent of the Company and Roche; and (2) Section 2.3(d) shall require
the written consent of the Company and Kari Stefansson; and except that the
provisions of Section 2 may be granted, pari passu, to additional purchasers of
equity securities of the Company by the written consent of the Company and
Holders of at least fifty percent (50%) of the Registrable Securities then
outstanding;

                      (ii)  any of the  provisions  of Section 3 may be amended
or waived by the written consent of the Company and Investors holding at least
sixty-seven percent (67%) in interest of the then issued and outstanding Shares
(including shares of Common Stock into which any such Shares may have been
converted); except that any amendment or waiver relating to: (1) Section 3.2
shall require the written consent of the Company and Series A Investors holding
at least fifty percent (50%) in interest of the then issued and outstanding
Shares defined in Section 1.14(i) (including shares of Common Stock into which
any such Shares may have been converted); (2) the rights of the Series A
Investors under Section 3.6 shall require the written consent of the Company and
Series A Investors holding at least fifty percent (50%) in interest of the then
issued and outstanding Shares defined in Section 1.14(i) (including shares of
Common Stock into which any such Shares may have been converted); (3) the rights
of the Series C Investor under Section 3.6 and Section 3.11(b) shall require the
written consent of the Company and the Series C Investors holding at least fifty
percent (50%) in interest of the then issued and outstanding Shares defined in
Section 1.14(iii) (including shares of Common Stock into which any such Shares
may have been converted); (4) Section 3.10(a) shall require the written consent
of the Company and Kari Stefansson; and (5) Section 3.10(b) shall require the
written consent of the Company and Beth Israel Deaconess;

                      (iii) any of the  provisions  of Section 4 may be amended
or waived by the written consent of the Company and Series C Investors and
Investor Founders holding at least sixty-seven percent (67%) in interest of the
then issued and outstanding Series C Preferred Stock issued pursuant to the
Series C Purchase Agreement, including the Series C Warrant Shares issued upon
exercise of the Series C Warrants issued pursuant to, and upon the exercise of
the option granted under, the Series C Purchase Agreement and the Founders
Shares (including shares of Common Stock into which any such Shares may have
been converted); except that any amendment or waiver relating to: (1) Section
4.1 shall require the written consent of the Company and Roche; and (2) the
rights of the Investor Founders under Section 4.2 shall require the written
consent of the Company and the Investor Founders holding at least sixty-seven
percent (67%) in interest of the then issued and outstanding Founders Shares;
and

                                      -23-
<PAGE>   28

                      (iv)  any of the provisions of Section 5 may be amended
or waived by the written consent of the Company and Investors holding at least
sixty-seven percent (67%) in interest of the then issued and outstanding Shares
(excluding shares of Common Stock into which any such Shares may have been
converted).

                  (b) Notwithstanding the foregoing, this Agreement may be
amended with only the written consent of the Company to include additional
purchasers of Shares as "Investors," "Holders" and parties hereto.

         5.7      Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power, or remedy accruing to any Holder, upon any breach,
default or noncompliance of the Company under this Agreement shall impair any
such right, power, or remedy, nor shall it be construed to be a waiver of any
such breach, default or noncompliance, or any acquiescence therein, or of any
similar breach, default or noncompliance thereafter occurring. It is further
agreed that any waiver, permit, consent, or approval of any kind or character on
any Holder's part of any breach, default or noncompliance under the Agreement or
any waiver on such Holder's part of any provisions or conditions of this
Agreement must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this
Agreement, by law, or otherwise afforded to Holders, shall be cumulative and not
alternative.

         5.8      Notices. All notices required or permitted hereunder shall be
in writing and shall be deemed effectively given: (i) upon personal delivery to
the party to be notified, (ii) when sent by confirmed telex or facsimile if sent
during normal business hours of the recipient; if not, then on the next business
day, (iii) five (5) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (iv) one (1) day after deposit
with a nationally or internationally (as the case may be) recognized overnight
courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent, if to the Company, to the address set forth in the
introductory paragraph to this Agreement, and if to the Investors, to the
address as set forth on Exhibit A, Exhibit B, Exhibit C or Exhibit D, as
applicable, or at such other address as such party may designate by ten (10)
days advance written notice to the other parties hereto.

         5.9      Titles and  Subtitles.  The titles of the sections and
subsections of this Agreement are for convenience of reference only and are not
to be considered in construing this Agreement.

         5.10     Counterparts.  This Agreement may be executed in any number of
counterparts each of which shall be an original, but all of which together shall
constitute one instrument.

                                      -24-
<PAGE>   29

         IN WITNESS WHEREOF, the parties hereto have executed this Investor
Rights Agreement, or have caused this Investor Rights Agreement to be executed
by its duly authorized officer, as of the date first above written.

                                             deCODE genetics, Inc.

                                             By: /s/ Kari Stefansson
                                                 ---------------------------
                                                 Kari Stefansson
                                                 President

<PAGE>   30

                (MULTIPLE SIGNATURE PAGES AND EXHIBITS OMITTED)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]